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Shigellosis (bacillary dysentery) is a severe inflammatory diarrhoeal disease in humans caused 
by the Gram-negative bacteria belonging to the Shigella species. Despite over 60 years of 
vaccine research, no licensed vaccine to prevent shigellosis is commercially available. 
Bioconjugate vaccines based on the O-antigen against various Shigella serotypes are under 
development. Shigella sonnei and Shigella flexneri 2a are the most prevalent serotypes in 
industrialised and developed countries respectively and is the subject of this study.  
 
This project involves the design and evaluation of alternative synthetic routes to derivatives of 
2-acetamido-4-amino-2,4,6-trideoxy-β-D-galactopyranose (FucNAc4N/AAT) and 2-acetamido-
2-deoxy-α-L-altruronic acid (AltNAcA), the two unusual monosaccharides found in the repeating 
unit of the Shigella sonnei O-antigen. Since these sugars are not commercially available, 
synthetic derivatives are required as authentic standards for the analysis of the bioconjugate.  
 
Various routes to the FucNAc4N derivative were investigated and evaluated. Routes proceeding 
either through 1,6-anhydro-D-glucose or cyclohexyl-2-acetamido-1-thioglucoside were shown 
to have potential, but ultimately both were rejected on the basis of inefficient conversions in the 
early stages of the synthetic sequence. However, important insights were gained into the crucial 
challenge of differentiating O-3 and O-4, common to any approach involving starting materials 
with the D-gluco configuration. This led to preparation in good yield of phenyl 2-amino-2-N,3-O-
carbonyl-2-deoxy-1-thio-β-D-glucopyranoside as a key oxazolidinone-protected intermediate,   
which allowed for successful preparation of a FucNAc4N derivative in the form of a 4-azido-β-
thioglycoside. This was achieved in 10 steps from the commercially available 2-acetamido-
1,3,4,6-tetra-O-acetyl-β-D-glucopyranose in an overall yield of 17%.  
 
Synthesis of an AltNAcA derivative was initially investigated via a sequence starting from a 
glucofuranurono-3,6-lactone. This involved initial inversion at C-5 followed by opening of the 
lactone and migration of the substituent at O-5 to O-3, to form an idofuranuronate which, 
however, could not be readily converted to the required pyranose form. A more successful route 
utilized a 6-iodo-2,3-oxazolidinone derivative of D-glucose, prepared as a key intermediate in 
the synthesis of FucNAc4N. The crucial epimerization at C-5 was attempted through initial 
formation of the 5-ene, followed by a hydroboration/oxidation, but this led exclusively to the D- 
rather than the L-sugar. Computer modelling and literature precedent suggested that the 
anomeric configuration strongly influenced the face selectivity of the hydroboration step. An α-
analogue of the 6-iodo-2,3-oxazolidinone derivative was therefore prepared via an efficient 




mediated elimination to the corresponding 5-enopyranoside were not successful, giving rise 
instead to a product in which the oxazolidinone had been cleaved followed by intramolecular 
substitution of the 6-iodide to form a 3,6-anhydro derivative. On the basis of these results and 
observations, an alternative synthetic route to AltNAcA has been proposed, which incorporates 
early formation of an α-glycoside and removal of the useful 2,3-oxazolidinone protecting group, 
thus setting the substrate up for effective elimination followed by selective hydroboration from 
the less hindered β-face to give the L-sugar.   
 
This study also incorporates a spectroscopic analysis of Shigella flexneri 2a glycoconjugate and 
glycopeptide samples.  A full set of nuclear magnetic resonance (NMR) spectra were recorded 
and analysed, resulting in the unambiguous determination of the structure and integrity of the 
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Ac  acetyl 
ACCN  1,1′-azobis(cyclohexanecarbonitrile) 
ACN acetonitrile 
ADH adipic acid dihydrazide 
AltNAcA 2-acetamido-2-deoxy-α-L-altruronic acid 
An anisoyl 
aq.  aqueous 
Ar  aryl 
BIAB [bis(acetoxy)iodo] benzene 
Bn  benzyl 
BnBr  benzyl bromide 
Boc  tert-butoxycarbonyl 
bs broad singlet 
bt broad triplet 
Bz  benzoyl 
Cbz carboxybenzyl  
CD circular dichroism 
COSY correlation spectroscopy 
CPS capsular polysaccharide 
CSA  10-camphorsulfonic acid 
Cycl cyclohexyl 
d doublet 
DBU  1,8-diazabicyclo[5.4.0]undec-7-ene 
DCM dichloromethane 
dd doublet of doublets 
ddd doublet of doublet of doublets 
DEPT distortionless enhancement by polarization  transfer 
DIAD  diisopropyl azodicarboxylate 
DIBAL diisobutylaluminium hydride 
DMAP  4-dimethylaminopyridine 
DMF  N,N-dimethylformamide 
DMSO  dimethylsulfoxide 
DT diphtheria toxoid 
E1 unimolecular elimination 
E2 bimolecular elimination 
EE enteric enteropathy 
ELISA enzyme linked immunosorbent assay 




ESI  electrospray ionisation 




GalNAc N-acetyl galactosamine 
Glc glucose 
GlcNAc N-acetyl glucosamine 
HIV/AIDS human immunodeficiency virus/acquired immune deficiency syndrome 
HMBC heteronuclear multiple bond correlation 
HPAEC high performance anion exchange chromatography 
HPLC high performance liquid chromatography 
HPSEC high performance size exclusion chromatography 
HRMS high resolution mass spectrometry 
HSQC heteronuclear single quantum correlation 
Hz hertz 
IgG immunoglobulin G  
IR  infrared spectroscopy 
J  coupling constant 
LAH lithium aluminium hydride 




M molarity (moles per cubic decimeter) 
M+ molecular ion 
MALLS multi angle laser light scattering 
Me methyl 
mg milligrams 
MHz mega hertz 
min minute(s) 
mL  millilitre(s) 
mmol millimole(s) 
mp melting point  
PMP p-methoxyphenyl 
Ms   mesyl 
NBS  N-bromosuccinimide 
NCS N-chlorosuccinimide 
NIS  N-iodosuccinimide 
NMR nuclear magnetic resonance 






PAD pulsed-amperometric detection 
PG  protecting group 
Ph phenyl 
Phth phthaloyl 
Piv  pivaloyl 
ppm parts per million 
PTFACI N-phenyltrifluoroacetimidoyl chloride 
q quartet 
r.t. room temperature  
rEPA recombinant genetically detoxified exotoxin A from Pseudomonas aeruginosa 
RI refractive index 
rxn reaction 
s singlet  
SM starting material 
SN2  bimolecular nucleophilic substitution 
SNAc nucleophilic acyl substitution 
t triplet 
TBAF  tetra-n-butylammonium fluoride 
TBAI  tetra-n-butylammonium iodide 
TBDPS tert-butyldiphenylsilyl 
TEMPO 2,2,6,6-tetramethylpiperidine-1-oxy 
tert tertiary  
TES  triethylsilyl 
TFA  trifluoroacetic acid 
THF  tetrahydrofuran 
TLC thin layer chromatography 
TIPS triisopropylsilyl ether 
TMS  trimethylsilyl 
Ts  p-toluenesulfonyl (tosyl) 
TT tetanus toxoid 
UV ultraviolet 
WHO World Health Organization 
wt weight 
ZPS zwitterionic polysaccharide 
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1.1  Enteric diseases 
Enteric diseases are a major cause of death worldwide.1 Diarrhoea is defined as the passing of 
loose or watery stool more than three times per day and if left untreated, leads to dehydration 
and can eventually result in death.2 Dysentery is characterised by the addition of abdominal 
cramps, blood in the stool and fever, and is associated with a higher mortality rate than 
diarrhoea.3,4 Diarrhoea and dysentery are caused by bacterial, viral or protozoan pathogens and 
of these Rotavirus causes the most cases, with other major pathogens including Vibrio cholera, a 
variety of Salmonella enterica serotypes, Campylobacter (especially Campylobacter jejuni), a 
variety of enteropathogenic Escherichia coli serotypes, and Shigella, which accounts for 5 – 15% 
of all cases.5,6  
 
1.1.1 Shigellosis 
Shigellosis (bacillary dysentery) is a severe inflammatory diarrhoeal disease in humans 
confined to the lower intestine and is caused by the Gram-negative, non-motile, rod-shaped, 
anaerobic bacteria belonging to the Shigella species.4,7,8 For the infected person, this results in 
further developmental problems, including stunted growth and fitness, and cognitive 
impairments.9–13  
 
Infection occurs after the ingestion of contaminated food or water, which may be a result of 
transmission through the common housefly, or passed from human-to-human via the oral-faecal 
route or through personal contact.3,14–16 It is a low-inoculum contagion requiring between 10-
1000 microorganisms to cause infection in adults.15,17 Shigellosis is common in confined 
populations, especially where there are poor hygiene practises and a lack of  sanitation.14,15,18 
The most effective methods for controlling shigellosis are the promotion of good hygiene 
practices, provision of ample and safe drinking water, and effective faeces disposal.2 But in the 
developing world, these public health measures are unfortunately still long term goals. Although 
oral rehydration therapy has hugely reduced the number of deaths from diarrhoeal dehydration 
in developing countries since their introduction in the 1970’s,6,19–22 it has been less effective 
against the mucosally invasive Shigella.23 Antibiotic treatment of diarrhoeal diseases has been 
successful, however, in the era of multi-drug resistance, various Shigella strains have become 
impervious to treatment with fluoroquinolones (ciprofloxacin), sulfonamides, tetracyclines, 
ampicillin, and the trimethoprim/sulfamethoxazole combination, which were successful as first 
line therapies in the past.6,24–28 Shigella poses a huge problem for current and future treatment, 




The greatest group at risk of shigellosis infection are children under the age of five where the 
symptoms are far more severe compared to adults.32 In addition, travelers, people in areas of 
political upheaval, areas affected by natural disaster and deployed military personnel are also at 
risk.6,33–38 A multitude of studies have shown that people infected with HIV/AIDS or other 
immunosuppressed states are also at higher risk,39–48 and may develop persistent or recurrent 
Shigella infections.6,46 People suffering from malnutrition, diabetes and malignancy have also 
been found to be at an increased risk of infection.2,29,41,42,47,49,50 Furthermore, in both developing 
and industrialised countries, shigellosis persists in places where there is communal living or 
where personal hygiene can be sub-optimal, such as daycare centres, old age homes and among 
institutionalised patients.51–54 
 
In 1999 the World Health Organisation (WHO) reviewed the literature published on Shigella 
infection between 1966 and 1997 and estimated the total number of Shigella episodes 
worldwide to be 164.7 million each year with 1.5 million cases in industrialised countries and 
163.2 million cases in developing countries, resulting in an estimated 5 million hospitalisations 
and 1.1 million deaths. Of the total 163.2 million cases of shigellosis in developing countries 
approximately 113.2 million of these cases occur in children under the age 5 (69% of all 
episodes).6 Although more recent reviews estimate the number of episodes and mortalities to 
be lower.55 
 
There are four main serogroups of Shigella which have been grouped according to their 
“distinctive” antigens and are currently further subdivided into various serotypes: Serogroup A 
(S. dysenteriae, 15 serotypes); Serogroup B (S. flexneri, 17 serotypes); Serogroup C (S. boydii, 20 
serotypes); and Serogroup D (S. sonnei, 1 serotype).6,55–57  Serogrouping is based on the 
production of antibodies, generally in animals, when challenged with a particular antigen.58,59 
Antigenic structures within the same serogroup generally have a similar repeating unit.58,59 The 
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Figure 1.1: Repeating units of the 5 most prevalent Shigella serotypes. L-Rha = L-rhamnose, D-GlcNAc = N-
acetyl-D-glucosamine, D-GalA = D-galacturonic acid, L-AltNAcA = 2-acetamido-2-deoxy-α-L-altruronic acid, 
FucNAc4N = 2-acetamido-4-amino-2,4,6-trideoxy-β-D-galactopyranose. 
 
 
Of these five serotypes, S. sonnei is composed of the two uncommon sugars – the 2-acetamido-2-
deoxy-α-L-altruronic acid (AltNAcA) and 2-acetamido-4-amino-2,4,6-trideoxy-β-D-
galactopyranose  (FucNAc4N) both of which are not commercially available. The AltNAcA unit is 
found only in the S. sonnei repeating unit,61 while FucNAc4N (also referred to as AAT) is found in 
the capsular polysaccharides (CPS) of Streptococcus pneumoniae type 1,62 and Bacteroides 
fragilis,63,64 Streptococcus mitis,65 expressed by the organism Plesiomonas shigelloides type 
17,66,67 as well as in the O-specific polysaccharide (O-PS) of Providencia alcalifaciens O8,68 
Providencia alcalifaciens O2269 and Proteus vulgaris strain TG 276-1.70   
 
Figure 1.2 shows that S. flexneri is the most prevalent in developing countries, while S. sonnei is 
the most prevalent in industrialised countries and is a common cause of traveler’s diarrhoea.35 
Shigellosis due to S. boydii is uncommon and exists only on the Indian sub-continent, while 






Figure 1.2: WHO estimates of Shigella serogroup isolates.6 
 
 
From these statistics it is clear that shigellosis is endemic throughout the world, causing many 
cases of morbidity and mortality. With this knowledge, the WHO has placed the development of 
a safe, affordable and efficacious vaccine as a global health priority.6 
 
1.2  Bacterial surface polysaccharides 
The bacterial cell envelope of Gram-negative bacteria comprises an inner membrane or 
cytoplasmic membrane and an outer membrane separated by the periplasmic space. This 
mainly contains peptidoglycans and other smaller molecules like mono- and oligosaccharides, 
amino acids and peptides. The outer membrane may be covered by a capsular polysaccharide 
(CPS) or a lipopolysaccharide (LPS) as seen in Figure 1.3. The CPS is found in both Gram-
negative and Gram-positive bacteria, while only Gram-negative bacteria are covered by LPS. 
This is also the component of the bacterial cell envelope that is virulent (in the case of toxic 
bacteria) to a eukaryotic host and is hence also known as the endotoxin.72 The LPS is composed 
of three structurally distinct regions – the toxic lipid A, the core polysaccharide region and the 
external O-specific polysaccharide (O-PS) which is the highly antigenic structure and is 
therefore also known as the O-antigen.72 The LPS can either be smooth (S-) LPS or rough (R-) 
LPS. S-LPS is a higher molecular mass and is normally found in wild-type strains, while R-LPS is 








Figure 1.3: Schematic depicting the cell envelope of the Gram-negative bacteria.72 
 
 
The lipid A anchors the LPS to the outer membrane and represents the endotoxically active 
moiety of toxic LPS.  The toxicity is highly dependent on the structural properties, and it should 
be noted that not all LPSs are toxic molecules. The core region is covalently linked to lipid A and 
comprises an oligosaccharide of up to 15 sugars. The O-PS is covalently linked to the core region 
and is mostly composed of repeating units containing 2–8 monosaccharide residues. The core 
region and O-PS can act as receptors for bacteriophages, thereby contributing indirectly to the 
destruction of the bacterial cell.72 The O-PS is an essential virulence factor, and it is this portion 
of the bacteria that certain vaccines are based on.73  
 
1.3  Vaccination 
Vaccines are an efficient and cost effective way of preventing human diseases. The advent of 
antibiotics overshadowed the need for vaccine development,74 but with the large increase in 
antibiotic resistant strains of various pathogens in recent years, the need for vaccine 
development has never been greater.74,75 Edward Jenner’s studies of what we now call 
vaccination against cowpox in 1796 was a landmark discovery.76 Jenner essentially showed that 
by exposing the immune system of a human to a pathogen, in this case the smallpox virus, an 
immune response can be induced. These studies were successfully carried out without any 




advance in scientific knowledge and a more thorough understanding of the human immune 
system,  the development of successful vaccines against polio, rabies, smallpox, meningococcus, 
pneumococcus, Haemophilus influenzae type b, hepatitis, rubella, measles and mumps, has 
reduced the burden of most of these diseases.77 However, despite these advances, various 
diseases such as cancer, HIV/AIDS, tuberculosis and dysentery still remain unpreventable 
through vaccination.75,78 Achieving effective results against enteric infections is particularly 
problematic, as inducing immunity against pathogens that mainly colonise the gut is difficult 
through traditional vaccine methods.1,79  
 
The majority of vaccines developed to date can be broadly divided into three categories, 
depending on whether they contain live attenuated microorganisms, inactivated whole 
microorganisms, or subunit vaccines, which contain purified components of  the 
microorganism.80 Vaccines developed using the live attenuated approach involve the weakening 
of the microorganism through deleting or modifying genes.80 The advantage of this method is 
that no thorough understanding of their attenuation was needed. Today, vaccines developed 
using this method would be difficult to license.80 However, successful vaccines against 
tuberculosis (BCG vaccine),81,82 polio (the Sabin approach),83 measles, mumps, rubella,84 and 
varicella80,85,86 have all been licensed using this method. On the other hand, inactivated whole 
cell vaccines are treated with either heat or chemicals (formalin or glycerine phenol)77 and an 
advantage of this method is that all antigens are present, so there is no need to know which is 
responsible for the immune response. Conversely, other antigens present may be responsible 
for side effects or may be toxic.80 Successful vaccines against pertussis,87 polio (the Salk 
approach),88 influenza,89 rabies90 and tick-borne encephalitis91 have been licensed using this 
method. Subunit vaccines consist of one or more antigens which are purified from the 
microorganism or produced by recombinant DNA technology and can consist of proteins, 
polysaccharides conjugated to proteins (glycoconjugate vaccines) or virus-like particles (VLP). 
Current licensed subunit vaccines using this method include the tetanus and diphtheria 
vaccine,92 pertussis,93 Neisseria meningitidis;94  Streptococcus pneumoniae,95,96 H. influenzae type 
b,94,97 and Salmonella typhi.80  
 
1.4  Glycoconjugate vaccines 
The studies in 1929 by Avery and Goedel98 paved the way for glycoconjugate vaccine 
development. Their studies showed that conjugation of the polysaccharide to a carrier protein 
induced an enhanced immunogenicity in rabbits compared to that of the polysaccharide only 
vaccine. Today, glycoconjugate vaccines have superseded their polysaccharide only 




covalently linked to an immunogenic protein carrier and are classed as subunit vaccines.80,99 
The advantage of this method is that only well-defined antigens are present. However, the exact 
protective antigens need to be identified and production and purification on a large scale needs 
to be efficient.80 Glycoconjugates induce a narrower range of immune responses characterized 
mainly by the production of serum IgG to the O-antigen, while live attenuated oral vaccines 
confer a wider immune response.30 
 
1.5 Immune response  
The common principle behind these vaccines is the exposure of a particular epitope that exists 
on an invading microorganism to the human immune system. This in turn elicits an immune 
response which can be activated through two different systems: the innate immune system and 
the adaptive or acquired immune system, both of which involve humoral and cell mediated 
immunity.100 The innate immune system involves the immediate recognition of antigenic 
structures and is generally short lived.100,101 The adaptive immune response is longer lasting 
and is made up of B and T lymphocytes which have receptors on them that are unique for 
various microbial antigens and are only created through a complex cellular cascade upon 
exposure to a pathogen.100 It is these antigen-specific cells that are responsible for producing 
antibodies and therefore immunity when re-exposed to a microbial antigen, and is thus the 
principle behind vaccination.100  
 
Different microbial antigens elicit different immune responses. For example, capsular 
polysaccharides (CPS) elicit B-cell responses, and are therefore termed T-cell independent 
responses.101 The production of antibodies in this case is rapid (days), but does not elicit long-
lasting antibody memory (months).100,101 CPS vaccines like the H. influenza type b vaccine97 
make them poor vaccines for infants and young children, the elderly and immunocompromised 
patients.74,102 Any memory responses elicited by CPS vaccines are due to the high tendency of an 
antibody to bind to a specific epitope at the surface of an antigen.74,101  
 
On the other hand, glycoconjugate vaccines elicit a T-cell dependent immune response. This is 
due to the presence of the protein carrier of the glycoconjugate which the immune system 
recognizes.100,101  In addition to glycoconjugate vaccines, zwitterionic polysaccharides (ZPS), 
which are rare and contain both a negative (e.g. phosphate or carboxylate) and a positive (e.g. 
free amine) charge within the repeating unit are also capable of eliciting T-cell dependent 
immune responses.103 T-cell dependent immune responses are generally slow (weeks) to 
activate antibody production, but elicit long-lasting (years) immune memory due to the 




lasting antibody production in children under the age of 2, the elderly and 
immunocompromised patients.104,105 
 
1.6 The production and control of glycoconjugate vaccines 
The production and control of glycoconjugate vaccines is complex and expensive. The purity 
and structure of all of the intermediates involved in the process of making the final formulated 
glycoconjugate vaccine needs to be controlled and characterized at each step as seen in Figure 
1.4.  
 
The process and testing is performed following the regulatory guidelines and good 
manufacturing practices (GMP) established by the WHO and pharmacopoeia to ensure 








1.6.1  Preparation and characterization of the polysaccharide and protein carrier 
Traditionally, the CPS and protein carrier have to be purified from fermented bacteria in several 
steps. Glycoconjugate vaccines produced from LPS require an extra step in order to cleave the 
Lipid A from the O-antigen and must be achieved without any effect on the O-antigen structure. 
The polysaccharide is purified using various techniques depending on the nature of the 
repeating unit and can include selective precipitation, filtration, various types of 
chromatography (e.g. size exclusion or hydrophobic chromatography), and enzyme 
treatment.75,99,113 After purification, the polysaccharide identity and structure need to be 
determined, which can be achieved through the application of various physicochemical 
techniques.75,110–112,114,115 Of these, nuclear magnetic resonance (NMR) spectroscopy (see Ch. 6 




also gives an indication of purity, as well as the degree of O- and N-acetylation, which can be 
quantified using an internal standard.121 Immunological identity methods can be used to 
distinguish between closely related polysaccharide antigens.106,122 Composition and quantitation 
of the polysaccharide then needs to be determined and can be achieved through the use of 
colorimetric assays123 and various chromatography techniques. For example, gas 
chromatography coupled to a mass spectrometer (GC-MS) can be used after derivatisation 
(methanolysis followed by re-N-acetylation and trimethylsilylation),124 and high performance 
anion exchange chromatography with pulsed amperometric detection (HPAEC-PAD) can be 
used after the hydrolysis of the polysaccharide and can be compared to a commercially available 
standard.125–129 However, hydrolysis of certain glycosidic linkages often leads to the degradation 
of certain labile monomers and is therefore product-specific and may not be quantitative for all 
components. In addition, HPAEC connected to a conductivity detector (HPAEC-CD) can be used 
to identify charged components such as uronic acids, phosphates and acetates, which can 
likewise be detected using colorimetric assays or capillary ion electrophoresis.130,131 
 
Once the structure and composition of the polysaccharide have been identified, the 
polysaccharide molecular size distribution needs to be determined. This is an important factor 
as it ensures manufacturing consistency between batches. In the case of polysaccharide 
vaccines, the molecular size is a correlate of vaccine potency.75,106,132,133 Various studies highlight 
the importance of the length of the saccharide chain as it has a direct effect on the 
immunogenicity of the vaccine, but is of course, dependent on the antigen.134–138 Again, 
chromatography techniques such as high performance size exclusion chromatography coupled 
to either a refractive index or multi-angle laser light scattering  detector (HPSEC-RI/MALLS) can 
be used to determine this.118,139,140 
  
The protein carrier must be safe in humans and is responsible for eliciting a T-cell-dependent 
immune response. Common protein carriers used in licensed vaccines include tetanus toxoid 
(TT), diphtheria toxoid (DT) or the genetically toxoided, single amino acid variant of diphtheria 
toxin (CRM197).  Other less common protein carriers include recombinant genetically detoxified 
exotoxin A from Pseudomonas aeruginosa (rEPA);141–145 protein D; a designed recombinant 
protein, N19; keyhole limpet hemocyanin and virus-like particle Qβ, with the latter three mainly 
being used in vaccines against non-infectious dieases.146–150  Likewise with the polysaccharide, 
the purity and identity of the carrier protein needs to be characterized for licensure and can be 






1.6.2  Conjugation and characterization of the conjugate vaccine 
Coupling of the protein carrier to the polysaccharide is through chemical activation of certain 
functional groups and needs to be achieved without any modification of immunological integrity 
of the O-antigen.75,145,151 Activation of the polysaccharide is generally random and can be 
achieved through a variety of different strategies depending on the functional group. For 
example, periodate oxidation of vicinal hydroxyl groups to aldehydes can be conjugated to the 
protein through reductive amination75,102,152,153 or through oxime formation.154 On the other 
hand, hydroxyl groups can be selectively activated through cyanogen bromide.155 Carboxylic 
acids can be coupled through carbodiimide-mediated condensation156 or various thio/thiol 
chemistry can be employed to obtain the conjugate.135,157–160 Alternatively, the reducing end of a 
short polysaccharide (where size reduction has been carried out), which is a masked carbonyl 
group, can be coupled directly through reductive amination.161–164 Conjugation can also be 
formed directly through the use of spacer groups, such as adipic acid dihydrazide (ADH),165 or 
alkyl type maleimido spacers.138,157 Spacer groups can also be used to reduce steric hindrance 
between the antigen and protein carrier.99,102,104,166  
 
Once conjugation has been achieved and proved through the use of SDS-PAGE, size exclusion 
chromatography or capillary electrophoresis,122 the structure, composition and molecular size 
of the conjugate needs to be determined using various physicochemical techniques already 
mentioned. These tests are critical for assuring batch consistency. In addition, the 
saccharide:protein ratio  must be determined, as well as the free saccharide content and amount 
of unconjugated protein carrier.138,167,168 Unreacted functional groups as a result of the coupling 
chemistry employed need to be capped in order to prevent further reactions in vivo and any 
residual reagents determined. Finally, stability testing of the conjugate must be carried out and 
this can be achieved, for example, through the use of HPAEC-PAD and SEC-HPLC-RI/UV/MALLS 
and NMR spectroscopy.75,117,169 
 
1.7 Vaccines against Shigella  
Efforts to develop a vaccine against Shigella have been ongoing for over half a century with 
several vaccine candidates making it to various stages of clinical trials (summarised in Table 









Table 1.1: Summary of vaccine candidates against shigellosis. 1,3,5,23,30,170–173 
Vaccine candidate 







Serial passage in 
vitro 
Phase III Oral 
Mel et al.174  
Mel et al.175  
Mel et al.176 
S. flexneri T32-Istrati 
Serial passage in 
vitro  
Phase III - IV Oral Meitert et al.177  
S. flexneri 2a E. coli K12, aroD Phase II Oral Cohen et al.178  
S. flexneri 2a SC602 virG, iuc Phase I–II Oral 
Sansonetti et al.179  
Coster et al.180  
Katz et al.181 
Rahman et al.182  
S. sonnei WRSs1 virG Phase I-II Oral 
Kotloff et al.183  
Orr et al.184 
S. flexneri 2a CVD 1204 
and CVD1208 
guaBA Phase I Oral Kotloff et al.185  
S. dysenteriae 1WRSd1 virG, stxAB Phase I Oral 
Venkatesan et al.186  
McKenzie et al.187  
S. flexneri 2a CVD 1208S guaBA, set, sen Phase II Oral Kotloff et al.188 
S. flexneri 2a 
WRSf2G11, 12, 15 
virG, senA, senB, 
msbB2 
Preclinical Oral 
Ranallo et al.189  
Ranallo et al.190  
Ranallo et al.191  
S. sonnei WRSs2, 3 
virG, senA, senB, 
msbB2 
Preclinical NHP Oral 
Collins et al.192  
Barnoy et al.193  
Bedford et al.194  
Barnoy et al.195  
S. dysenteriae 1 CVD 
1256 
guaBA, sen, stxA, 
virG 
Preclinical Oral Wu et al.196 




Preclinical Oral McKenzie et al.197 







Osorio et al.198 
Subunit vaccines 
S. sonnei Ribosome-LPS Preclinical Intranasal Levenson et al.199 
S. flexneri 2a Ribosome-LPS Preclinical Intranasal Shim et al.200 
S. flexneri 2a Proteosome-LPS Phase II Intranasal Fries et al.201 
S. flexneri 2a, S. sonnei 
Invaplex (LPS plus 
IpaB, IpaC and IpaD) 
Phase I Intranasal 
Oaks et al.202  
Tribble et al.203  
Riddle et al.204 
S. flexneri 2a IcsP, SigA Preclinical Mucosal Czerkinsky et al.205 
S. sonnei GMMA vesicles Preclinical Intranasal Berlanda Scorza et al.206 
S. flexneri 2a, S. sonnei IpaB, IpaD Preclinical Intranasal 
Martinez-Becerra et al.207  






Table 1.1 continued 
Vaccine candidate 





Subunit vaccines - Glycoconjugates 
S. dysenteriae 1 LPS-rEPA Chemical conjugate Preclinical Parenteral Chu et al.209 
S. flexneri 2a LPS-rEPA,  







Cohen et al.210 
Cohen et al.211 
Cohen et al.212  
Ashkenazi et al.213  
Passwell et al.214 
S. flexneri 2a LPS-rEPA , S. 
sonnei LPS-CRM9 
Chemical conjugate Phase I–III Parenteral Passwell et al.215 





Preclinical Parenteral Pozsgay et al.216 





Phalipon et al.138 
Theillet et al.217 
S. dysenteriae 1 O-PS-rEPA Bioconjugate Phase I Parenteral Dro et al.218 
 
 
Of the vaccines developed, the majority of the live attenuated and glycoconjugate vaccines, as 
well as the proteosome vaccines have shown efficacy in field trials, while the nuclear protein–
ribosomal parenteral vaccine, the Invaplex vaccine and the inactivated S. sonnei administered 
orally are still in preclinical testing (see Table 1.1). The live attenuated vaccine approach has 
had the greatest amount of research invested and has achieved the greatest success by making it 
to Phase IV clinical trials. Unfortunately, the vaccine developed by Mel et al. encountered scale-
up and process control problems.219 Nevertheless, this vaccine paved the way for future 
development as it showed that a multivalent Shigella vaccine is possible and that serotype 
specific protection can be induced.174,220 On the other hand, glycoconjugate vaccines have also 
successfully made it to Phase III clinical trials.214 
 
1.7.1  Enteric enteropathy 
An overall challenge for live attenuated vaccines has been in achieving the correct balance of 
safety and immunogenicity.23 Another major concern, which is poorly understood, has been the 
ability of an oral live attenuated vaccine to induce immunogenicity in both developed and 
developing nation populations.221,222 This has been seen with the S. flexneri 2a SC602 vaccine 
which was immunogenic in a North American population, but failed to induce an immune 
response in Bangladeshi adults.181,182 Similar complications with oral live attenuated vaccines 
against polio, rotavirus and cholera have also been observed.223–228 This phenomenon is referred 
to as enteric enteropathy (EE) and is a condition thought to be caused by the continual exposure 




malnutrition, genetic factors and interference by maternal antibodies are also thought to affect 
the vaccine’s efficacy. This results in an increase in intestinal permeability, impaired gut 
immune function and ultimately efficacy problems with oral live attenuated vaccines.221,222 Since 
EE is not yet well understood and the link between oral live attenuated vaccines unclear, the use 
of glycoconjugate vaccines may provide the ideal alternative. This is because they are 
administered parenterally and are thus not subjected to the intestinal barrier. This, along with  
the implications of enteric enteropathy and vaccine efficacy need to be fully investigated. 
 
1.7.2  Additional challenges for Shigella vaccine development 
As well as the complicated and poorly understood effects of EE, there have been additional 
hurdles encountered for producing a licensed Shigella vaccine. These include:23  
 An unsatisfactory animal model that accurately represents shigellosis. Non-human 
primates offer a reasonable model, however, are costly and present additional 
challenges;229–231  
 An inadequate understanding of the pathogenesis and effect on immunity; 
 Insufficient funding and low profit gains for pharmaceutical companies;79 
 Manufacturing limitations (as with synthetic vaccines); 
 Views that good hygiene and sanitation practises, and safe drinking water are easier 
to attain; 
 Concerns for the ability to provide broad coverage of many serotypes, despite this 
being shown in various studies.23,30,60 
 
Despite all of the above challenges, a novel method for vaccine development is currently being 
investigated by the biotech company, GlycoVaxyn.    
 
1.8 GlycoVaxyn technology 
GlycoVaxyn’s novel technology for the production of glycoconjugate vaccines uses recombinant, 
non-toxic Escherichia coli to synthesis the glycoconjugate in vivo. 
 
The biosynthesis of the glycoconjugate is achieved through the transfer of the general N-linked 
protein glycosylation system found in Campylobacter jejuni to E. coli.232 This glycosylation 
machinery is encoded by 12 genes in a single gene cluster called pgl (protein glycosylation),233 
and is responsible for the synthesis of lipid-linked oligosaccharides and flipping these into the 
periplasmic space.234 The mechanism by which the glycoconjugate is assembled is shown in 
Figure 1.5. It involves the biosynthesis and assembly of the O-antigen, which is possible via two 




pathway,235 both of which can be initiated in E. coli.236 The Wzy-dependent mechanism 
synthesizes repeating units on the undecaprenyl-pyrophosphate (Und-PP) lipid carrier at the 
cytoplasmic side of the inner membrane and flips these across the cytoplasmic membrane, 
where Wzy polymerase polymerizes the repeating units of the O-antigen in the periplasmic 
space, and transfers this to the lipid A core by the WaaL ligase. Similarly, the ABC transporter-
dependent pathway forms the O-antigen by reactions occurring at the cytosolic face of the 
cytoplasmic membrane. An ATP-binding cassette transporter then moves the O-antigen across 
the inner membrane, where it is then attached to the Lipid A core.237 The integral membrane 
protein, PglB, is the key enzyme (oligosaccharyltransferase (OST)) in the C. jejuni N-
glycosylation system and is responsible for the glycosylation of a range of proteins.233,238 In C. 
jejuni, the pgl enzymes synthesize a heptasaccharide, GalNAc-a1,4-GalNAc-a1,4-(Glc-b1,3)-
GalNAc-a1,4-GalNAc-a1,4-GalNAc-a1,3-Bac, where Bac is 2,4-diacetamido-2,4,6-trideoxy-D-Glc 
on an Und-PP lipid carrier where it is transferred to an asparagine side chain present on a 
protein carrier.233,234 When PglB is expressed in a waaL mutant strain of E. coli, it can efficiently 
accept a diverse range of Und-PP-linked glycans in a similar manner.234 This allows for the 
transfer of the O-antigen on the Und-PP lipid carrier to the side chain of site-specific asparagine 
residues in the consensus sequence N-X-S/T (where X can be any amino acid except proline) on 
the periplasmic carrier proteins, which is either AcrA from C. jejuni or a genetic toxoid form of 
Pseudomonas aeruginosa exotoxin type A (rEPA).141,234,239,240 
 
 
Figure 1.5: Schematic depicting the in vivo biosynthesis of a glycoconjugate.239 The polysaccharide is 
assembled on the Und-PP lipid carrier and conjugated to a side chain of site-specific asparagine 





The relaxed specificity of PglB means that a variety of glycan structures can be used241 and since 
the prerequisite for transfer of a polysaccharide by PglB is the presence of a consensus 
sequence on the carrier protein and a N-acetylhexosamine residue at the reducing end of the 
sugar,239 this should be possible for various Shigella serotypes. rEPA was chosen as the protein 
carrier for the Shigella bioconjugates due to its safety and efficacy as shown in previous clinical 
trials.67,242 There are five potential sites of N-glycosylation sites in rEPA that follow the N-X-S/T 
sequence, but only two of these have been glycosylated. The first site of glycosylation is 
DQNRTK and the second is DNNNST. 
 
This method of developing glycoconjugates is obviously advantageous. It requires no culturing 
of pathogenic or slow growing bacteria; no chemical treatments, such as removal of endotoxin;  
no modification or derivatisation of the polysaccharide and protein in order to achieve 
conjugation.234 In addition the polysaccharide chain length is controlled in vivo yielding 
reproducible results. Furthermore, this method allows for the production of acid-labile  
conjugates which cannot be produced by traditional methods.234 
 
1.8.1  GlycoVaxyn purification and derivatisation for analysis of bioconjugates 
GlycoVaxyn performs various purification and analysis of intermediates and final bioconjugates 
which are in accordance with regulatory recommendations set out by the WHO and 
pharmacopoeia, this information is confidential, but will be briefly outlined below.  
 
Intermediate analysis of the polysaccharide linked to the Und-PP lipid carrier is carried out to 
ensure the correct O-antigen is being synthesised and the methodology has been specially 
adapted by GlycoVaxyn for this purpose. This is of relevance for this project, as it will give an 
indication of the ideal form that the S. sonnei disaccharide should be in (see subsequent 
sections). Mild acid hydrolysis of the sugar from the lipid carrier is carried out as reported by 
Glover et al.243 followed by C-18 Sep-Pak purification, and fluorescent labelling of the 
polysaccharide at the reducing end by reductive amination using 2-aminobenzamide.244 The 
labelled polysaccharide can be separated by HPLC and analysed by MALDIMS/MS, which will 
confirm if the correct O-antigen has been synthesised.   
 
Once the bioconjugate has been synthesised in vivo, it is extracted from the E. coli cells by 
osmotic shock and then purified by various types of chromatography. Monosaccharide analysis, 
HPLC, total protein mass spectrometry and NMR analysis are carried out on glycoconjugate 
samples in order to determine structure, composition and molecular size of the conjugate, as 




protein carrier. For analytical purposes, a portion of the glycoconjugate is treated with pronase, 
yielding a glycopeptide. The glycopeptide sample is purified using C-18 Sep-Pak, followed by 
SEC chromatography and analysed as above. This makes analysis simpler, especially in the case 
of NMR spectroscopy. 
 
1.8.2 Development of S. flexneri 2a and S. sonnei glycoconjugates using GlycoVaxyn 
technology 
GlycoVaxyn has embarked on developing a multivalent glycoconjugate vaccine against Shigella 
using their technology. The consensus is that an effective vaccine need only cover the 5 most 
prevalent strains in order to prevent or significantly reduce several important and clinically 
relevant types of Shigella disease.6,30,57,60 As mentioned, these are S. flexneri 2a, 3a and 6, S. 
dysenteriae type 1 and S. sonnei.  To date, GlycoVaxyn has developed a S. dysenteriae O1 
conjugate vaccine which has been successfully tested in Phase I of human clinical trials. At the 
start of this project the S. flexneri 2a and S. sonnei strains were the next targets, with the S. 
flexneri 2a glycoconjugate currently being tested in human subjects at the time of writing.    
 
The S. sonnei serotype presents specific challenges owing to the nature of the unusual 
monosaccharides in the repeating unit (Figure 1.6) which consists of two unusual sugars: 2-
acetamido-2-deoxy-α-L-altruronic acid (AltNAcA)61 and 2-acetamido-4-amino-2,4,6-trideoxy-β-
D-galactopyranose  (FucNAc4N or AAT) which is labile.68,70,245,246 In addition to this, the 
zwitterionic nature of the disaccharide repeating unit complicates not only biosynthesis, but 




Figure 1.6: The zwitterionic repeating unit of S. sonnei comprises two unusual sugars:  
2-acetamido-2-deoxy-α-L-altruronic acid (AltNAcA)61 and 2-acetamido-4-amino-2,4,6-trideoxy-β-D-
galactopyranose  (FucNAc4N or AAT), both of which preferentially adopt the 4C1 conformation.247 
 
 
The development and licensure of glycoconjugate vaccines relies on a combination of biological 
testing and the detailed physicochemical characterization at various stages of vaccine 
development to evaluate manufacturing consistency and vaccine integrity. In order to carry out 
this testing, monosaccharide standards are required. The monosaccharides found in the 




(D-glucose, D-galactose, D-glucosamine and L-rhamnose). However, AltNAcA and FucNAc4N are 
not, and will need to be chemically synthesised. Owing to the charged nature and lability of each 
of these sugars,68,70,245–247 they will need to be synthesised in a suitable form.  
 
1.9 Chemical synthesis of carbohydrates 
Oligosaccharides can be obtained in reasonable quantities either through isolation from natural 
products,248 through enzymatic synthesis249,250 or through chemical synthesis. The latter 
remains the most efficient method to obtaining well defined fragments of the desired 
saccharide.251 However, even chemical synthesis presents an array of challenges, despite the 
years of research in the field. Synthesis of the required carbohydrate building blocks is 
complicated by the presence of the many hydroxyl groups in the monosaccharide,252 where the 
reactivity/nucleophilicity varies according to the location and stereochemistry.253 These 
hydroxyls require orthogonal functionalisation and various regioselective protecting group 
manipulations, which are often difficult to achieve despite the considerable advances in 
methodology.253,254 However, it is also possible to differentiate between groups of similar 
reactivity by exploiting subtle differences in chemical environment, with various authors 
reporting these seemingly straightforward transformations.255–257,‡ 
 
The assembly of complex oligosaccharides is also complicated by the formation of glycosidic 
linkages.258 Here, the desired stereochemistry in the product, whether a 1,2-trans or 1,2-cis 
linkage, needs to be investigated prior to glycosylation, as the effect of the various protecting 
groups in the donor and acceptor pair often affects not only the stereoselectivity, but the 
reactivity as well.258 In addition, the most suitable promoter system and reaction conditions for 
this step requires careful consideration, as this can also affect the desired stereochemistry.258–260 
Furthermore, the protecting groups can either enhance or reduce the overall reactivity of the 
monosaccharide building block, and a prominent example of this has been the advances in 
reactivity tuning by using armed and disarmed approaches, which have greatly improved 
synthetic efficiency.251,261–263 Along with these aspects of reactivity tuning, a significant number 
of programmable one-pot glycosylation strategies have also been published,264,265 making the 
reactivity of certain glycosyl donor and acceptor pairs fairly predictable.  
 
A further aspect that hampers carbohydrate synthesis is the effect of the substituent 
configuration on the overall reactivity of the monosaccharide, not only in glycosylation 
reactions but also in modifications of the carbohydrate skeleton itself. Here, for example,  gluco- 
                                                 
‡ See Ch. 2 for various examples of references which include a list of methods using additional reagents or 




vs. galacto-configurations are known to affect reactivity, but such effects cannot always be 
predicted.253,266 The configuration of substituents clearly influences the possible conformations 
of the monosaccharide building block, which in turn influences overall reactivity and 
selectivity.263,267 
 
Despite all of the advances in chemical synthesis, the overall effect of various protecting groups 
and/or differentially functionalized positions of the monosaccharide is still difficult to predict. 
These effects are generally poorly understood and an empirical approach remains the only way 
to unambiguously determine whether the desired outcome is possible.  
 
1.10  Published FucNAc4N (AAT) syntheses 
As a result of its occurrence in numerous naturally occurring polysaccharides,62–66,68–70,268  the 
synthesis of FucNAc4N derivatives has been the focus of many attempts over the years.269–282  
 
The earliest report of a FucNAc4N synthesis is by Sharon et al.269 where the protected 2-





Scheme 1.1: Sharon’s (1978)269 synthesis of the protected sugar 1.2. 
This was synthesised in 13 steps from D-glucosamine. 
 
 
Lönn and Lönngren270 then published their method, where the di-mesylate 1.3 was selectively 
reduced to yield the 6-deoxy sugar, after which the 4-position was inverted with NaN3 and the 




Scheme 1.2: Lönn and Lönngren’s (1984)270 synthesis of the glycosyl acceptor 1.4. 





In 1997, Pozsgay et al.273 published their synthesis of the protected FucNAc4N glycosyl donor 
via the 4,6-O-di-tosylate intermediate 1.5 (Scheme 1.3). This was selectively reduced to the 6-
deoxy sugar and inversion of the 4-position was achieved by displacement of the 4-O-tosylate 




Scheme 1.3: Pozsgay’s (1997)273 synthesis of the protected glycosyl acceptor 1.6. 
This was synthesised in 12 steps from D-glucosamine in an overall yield of 8%. 
 
 
The key step in the synthesis reported by Liang and Grindley was the regioselective 
benzoylation at O-3 using 1.1 eq. of BzCl in pyridine at -35°C for 2 hours, giving the 6-deoxy 
intermediate 1.7, which was then converted to the 4-azido sugar 1.8 via a Mitsunobu-type 




Scheme 1.4: Liang & Grindley’s (2004)274 synthesis of the protected glycosyl acceptor 1.8. 
This was synthesised in 7 steps from D-glucosamine in an overall yield of 39%. 
 
 
Bundle’s approach is one of the shortest and most efficient for obtaining the FucNAc4N glycosyl 
acceptor (Scheme 1.5). The 3-O-benzyl protected oxazoline 1.9 was easily converted to the 6-
deoxy sugar 1.10 and then the 4-amino methyl glycoside 1.11.#  
 
 
                                                 
‡ The trehalose-dimer was also obtained. 
∗ The gluco-configured 4-azido diastereomer is also obtained in a 18% yield. 
# Treatment with of 1.10 with excess Tf2O followed by NaN3 resulted in the formation of tetrazole 






Scheme 1.5: Bundle’s (2009)276 approach to the glycosyl acceptor 1.11. 
This was obtained in 6 steps from oxazoline 1.9  in an overall yield of 22%. 
 
 
In 2010, Schmidt and co-workers published two papers277,278 that used a similar approach to 
obtain 1.12 which was converted to various differentially protected glycosyl donors and 
acceptors  (Scheme 1.6). As with Liang and Grindley, the key step in the synthesis was the 
regioselective benzoylation  at O-3. Conversion and inversion to the protected 4-amino sugar 





Scheme 1.6: Schmidt’s (2010)277 synthesis of the protected sugar 1.13. 
This was obtained in 10 steps from D-glucosamine in an overall yield of 25%. 
 
  
In a similar approach to previous methods reported by the group,275 van der Marel’s Cbz 
protected imidate donor 1.16 was obtained from 1.14 via the regioselective 3-O-
trichloroacetimidate formation, triflation at O-4, and intramolecular substitution (to give 1.15) 




Scheme 1.7: van der Marel’s (2007 & 2012)275,281 synthesis of the imidate donor 1.16. 
This was obtained over 14 steps from D-glucosamine in an overall yield of 15%. 
 
 
                                                 




Methods for obtaining FucNAc4N derivatives from other starting materials have also been 
developed. Starting from a mannose derivative, van Boom271 synthesised the 1,6-anhydro sugar 
1.17 through a stepwise introduction of the two azido groups (Scheme 1.8), implying that one 
azide could be selectively modified before addition of the other azide. Acetolysis followed by a 
Barton-McCombie radical deoxygenation reaction gave the 6-deoxy sugar 1.18. This would 





Scheme 1.8: van Boom’s (1987)271 synthesis of the protected FucNAc4N derivative 1.18. This is obtained 
over 12 steps starting from the 1,6-anhydro-2,3-O-(4-methoxybenzylidene)-β-D-mannose.284 An = anisoyl. 
 
 
The Kulkarni282,285 group synthesised the D-rhamnosyl diol 1.19 from D-mannose (Scheme 1.9). 
Here C-6 deoxygenation was achieved by regioselective tosylation followed by reduction with 
LiAlH4. Their one-pot triflation and highly regioselective SN2 displacement with TBAN3 (at C-2) 
and then potassium phthalimide (at C-4) gave 1.20. This is also one of the most efficient routes 




Scheme 1.9: Emmandi and Kulkarni’s (2014)285 highly regioselective synthesis of the FucNAc4N glycosyl 




The method developed by van Boom and co-workers, is by far the longest, but makes use of 
some interesting chemistry (Scheme 1.10). The oxime 1.21 is synthesised from D-mannose and 
upon reduction with NaCNBH3 and TiCl3, a 4-amino talo-derivative is obtained.‡ N-Cbz 
                                                 




protection, acid hydrolysis, bromination and treatment with zinc dust gave the D-galactal 




Scheme 1.10: van Boom’s (1992)272 synthesis of the free sugar 1.23. 
This was obtained over 13 steps from D-mannose. 
 
 
In 2010, Bundle’s group published another route which began with commercially available tri-
O-acetyl-D-glucal (Scheme 1.11).279 The benzylcarbamate 1.25 was obtained from the 
regioselectively 3-O-silylated sugar 1.24. Azidonitration of the glucal, deprotection and 




Scheme 1.11: Bundle’s (2010)279 synthesis of the donor 1.26. 
This was obtained over 13 steps from tri-O-acetyl-D-glucal in an overall yield of 24%. 
 
 
And lastly, Seeberger’s de novo synthesis of the FucNAc4N derivative 1.29 (Scheme 1.12) is by 
far one of the most elegant. Beginning with the O-acetate of the N-Cbz-L-threonine methyl ester, 
the enone 1.27 was obtained via a Dieckmann cyclization followed by methylation of the 
intermediate β-keto-ester. From there an initial 1,2-reduction of the lactone using DIBAL, 
followed by acid work-up gave the 1-en-3-one, which upon Luche reduction and acetylation 
gave galactal derivative 1.28. Azidonitration followed by anomeric deprotection and treatment 
with trichloroacetonitrile gave the donor 1.29.  
 
 
                                                 






Scheme 1.12: Seeberger’s (2010)280 synthesis of the donor 1.29. 
This was obtained over 10 steps from N-Cbz-L-threonine in an overall yield of 22%. 
 
 
The majority of these approaches obtain the 6-deoxy sugar by conversion to a 6-iodo derivative 
via a 6-O-tosylate,273,277,279,281,286 followed by conversion of 4-hydroxy group to a leaving group 
and SN2 inversion with NaN3 or potassium phthalimide to get the 4-amino functionality in the 
galacto-configuration.271,273,276,277,282,286 C-3 and C-4 are generally differentiated by a seemingly 
straightforward regioselective protection.274,277,279,281,282,286  These conversions seem the easiest, 
most efficient and robust way of obtaining the 4-amino-6-deoxy sugar. In many of these routes 
the 2-position remains masked as an azide and requires further manipulation in order to obtain 
the 2-acetamido group or other N-protecting groups which are capable of anchimeric assistance.  
Many research groups synthesized the glycosyl acceptor only, with immediate installation of the 
acceptor group. Further manipulation of this position is difficult, but not impossible.273,274,276,286 
The key steps in some of the more efficient and original routes suffer from diastereoselectivity 
issues, where the desired compound is obtained in a less than ideal yield.  
 
1.11  Published S. sonnei disaccharide synthesis 
Despite the years of interest in the two unusual sugars found in S. sonnei and the need for a well-
defined fragment of the repeating unit, there has only been one report for the synthesis of the 
protected form of the S. sonnei di- and tri-saccharides, which was published recently by Pfister 
and Mulard.286 Prior to this, Pozsgay and co-workers published the synthesis of the methyl 
glycoside derivatives of both FucNAc4N and AltNAcA,273 and later reported glycosylations using 
a derived FucNAc4N glycosyl donor and acceptor with readily available analogues of AltNAcA.287   
 
Pfister and Mulard’s approach for the FucNAc4N glycosides (Scheme 1.13) began from the allyl 
glycoside 1.30 of D-glucosamine, where the amine is protected as the trichloroacetate. Since 
both FucNAc4N and AltNAcA are β-linked, the N-acyl group would be required for anchimeric 
assistance in the glycosylation reactions.288–290 De-O-acetylation of 1.30, regioselective 
tosylation and O-acetylation, C-6 halogen substitution followed by reductive elimination with 
NaCNBH3 and de-O-acetylation yielded the diol 1.31. Regioselective acetylation at O-3 was 




followed by SN2 inversion with NaN3 provided the fully protected 4-azido precursor 1.32. 
Selective acetate removal yielded the acceptor 1.33 in 9 steps from the allyl glycoside 1.30, 
while deallylation and treatment of the hemiacetal with N-phenyltrifluoroacetimidoyl chloride 








Synthesis of the AltNAcA glycosyl acceptor and donor was based on methods published 
previously by Pozsgay et al.273 and Walvoort et al.291 (Scheme 1.14) The expensive 
commercially available L-glucose was chosen as the starting material for the synthesis as it 
contains the desired configuration at C-4 and C-5. The epoxide 1.35 was obtained by conversion 
of L-glucose to the allyl glycoside, followed by 4,6-O-benzylidene protection and 2,3-di-O-
mesylation.‡ Treatment of 1.35 with NaN3 yielded the trans-di-axial C-2 amino altropyranoside 
precursor 1.36.§ Benzylation, selective reduction of the azide and conversion to the 
trichloroacetamide# gave 1.37.  From here acetal acidolysis and selective TEMPO/BAIB 
oxidation292 of C-6 and subsequent benzyl esterification gave the acceptor 1.38 in 11 steps, 
while the donor 1.39 was obtained in 10 steps as described above for the conversion of 1.33 to 
1.34.  
 
                                                 
‡ Medgyes et al.273 synthesised the methyl 2,3-anhydro-4,6-O-benzylidene-α-L-allopyranoside via the 2,3-
di-O-tosyl intermediate instead.  
§ Partial trans-diequatorial opening of the epoxide ring into allyl 3-azido-4,6-O-benzylidene-3-deoxy-α-L- 
glucopyranoside could not be avoided. 






Scheme 1.14: Pfiste and Mulard’s synthesis of the AltNAcA glycosyl acceptor 1.38 and donor 1.39.286 
 
 
The partially protected disaccharide 1.40 was then synthesised from FucNAc4N acceptor 1.33 
and AltNAcA donor 1.39, after which global deprotection yielded the disaccharide 1.41 
(Scheme 1.15). Chain elongation of the disaccharide 1.40 was then evaluated. Protection and 
conversion of 1.40 to the N-phenyltrifluoroacetimidate donor, followed by TMSOTf-mediated 
coupling with 1.38 and global deprotection yielded the trisaccharide 1.42, while in a similar 
manner, acceptor 1.40 was coupled with donor 1.34 and deprotected to yield 1.43. The NMR 
data for the disaccharide 1.41 and trisaccharides 1.42 and 1.43 suggests that the AltNAcA 




Scheme 1.15: Synthesis of the disaccharide 1.41 and trisaccharides 1.42 and 1.43 which show that chain 





This route is the first and only synthesis of the S. sonnei disaccharide, which also shows that 
chain elongation at both ends is possible.   
 
1.12  Methods for synthesising L-sugars  
Pozsgay and Mulard’s approaches to synthesizing the AltNAcA derivative both begin with the 
commercially available, yet very expensive L-glucose.273,286 This seemed an unfeasible starting 
point for our synthesis and so an alternative was explored. Beginning with a different L-sugar 
also seemed impractical as only L-arabinose, L-fucose and L-rhamnose are commercially 
available in reasonable quantities. These are still expensive and suffer from the obvious 
drawback of requiring extensive manipulations to obtain an AltNAcA derivative.  Since isolation 
and purification of L-sugars that are useful in this synthesis are almost impossible from natural 
sources, chemical synthesis remains the only viable route to obtaining sufficient and well 
defined amounts of an AltNAcA derivative.293 
 
To this end, a review of the literature reveals an extensive array of L-sugar syntheses. These 
methods include a de novo approach,294–296 where key steps involve enantioselective 
dihydroxylation297–299 or a selective aldol reaction;300,301 synthesis of L-sugars from chiral 
building blocks,302–305 or ascorbic acid;306,307 or through the use of enzymes;308–310 and from 
various D-carbohydrate starting materials.311–313 In the latter case, the L-sugar has been obtained 
through a radical tandem decarboxylation-cyclization reaction,314  or via a stereocontrolled 
cyanohydrin reaction,315 or via inversion at C-5 through various strategies to give the required 
R-configuration which is present in the L-sugar.  
 
Many of the above methods for L-sugar synthesis exploit the use of non-carbohydrate starting 
materials, and were not considered for this synthesis of an AltNAcA derivative given our intent 
to use a readily available carbohydrate material. As there are a multitude of publications 
describing the synthesis of L-altruronic acid and L-iduronic acid, these were explored as 
potential starting points, noting that these would both require subsequent introduction of the 
amino group at C-2, and, in the case of the L-iduronic acid, an inversion of configuration at C-4. 
The published approaches to these L-sugars generally start from a form of D-glucose and can 
broadly be divided into 2 categories: those proceeding through the formation of 4-
deoxypentenosides 316,317 and those proceeding through epimerization of C-5. The methods in 







 SN2 Inversion at C-5 of a glucopentose derivative:  
Synthesis of an L-iduronic acid derivative via SN2 inversion was carried out by Seeberger et al.318 
(Scheme 1.16A) and Ojeda et al.319 (Scheme 1.16B) on different substrates, both of which were 
obtained from D-glucose. Triflation of 1.44 or 1.46 followed by SN2 inversion with NaOLev or 




Scheme 1.16: The SN2 inversion of C-5 as published by Seeberger et al.318 and Ojeda et al.319   
 
 
 Inversion at C-5 via hydroboration/oxidation of an exocyclic olefin in 5-enopyranosides320–322 
An example of this is seen in Scheme 1.17 where Rochepeau-Jobron and co-workers320 
achieved inversion through hydroboration of the 5-enopyranoside 1.48 with 9-BBN followed by 




Scheme 1.17: Inversion of C-5 via hydroboration/oxidation.320 
 
 
 Inversion via bromination, rearrangement, elimination and hydroboration/oxidation.  
The synthesis of the 1,6-anhydro sugar 1.52, an L-idose precursor described by Hung and co-
workers is summarized in Scheme 1.18.323,324 Starting with diacetone-α-D-glucose, one-pot SN2 
NBS-mediated bromination and rearrangement gave 1.50, which was subjected to E2 
elimination and hydroboration/oxidation to yield the 1,2:3,5-di-O-isopropylidene-β-L-









Scheme 1.18: Inversion via bromination, rearrangement, elimination and hydroboration/oxidation 
which after acid hydrolysis yields the L-idose derivative 1.52.323,324 
 
 
 Inversion via free radical bromination at C-5 of a D-glucuronic acid derivative, followed by 
reduction.  
Wong and co-workers325 described the epimerization of C-5 via the free radical bromination of 
1.53 yielding 1.54, which after isomerization and free radical reduction yielded the D-gluco and 




Scheme 1.19: Epimerization of C-5 via the free radical bromination, isomerization and reduction.325 
 
 
 Inversion via δ-hydroxybenzyloxamate.  
The synthesis of an L-ido derivative published by Takahashi et al.326,327 was obtainable from the 
6-silylated lactone 1.56 via the alkoxyamidation to give the δ-hydroxyalkoxamate 1.57. 












1.13  Synthetic challenges and strategy 
From the strategies for synthesizing FucNAc4N and AltNAcA (or other L-sugars) outlined above, 
it was decided that a cheap and readily available D-sugar would be a good starting point. The 
challenges beginning with, for example, a D-glucosamine precursor for the synthesis of these 
two unusual sugars are highlighted in Figures 1.7A and 1.7B. The choice of D-galactosamine 
was considered, but thought to be unsuitable due to the unfavorable orientation of O-4 in 




Figure 1.7: Synthetic challenges faced when synthesising the two monosaccharides, FucNAc4N and AltNAcA 
from an inexpensive and commercially available starting material such as D-glucosamine. 
 
 
Retrosynthetic analysis of the two monosaccharides (Scheme 1.21) linked either in an AB or 
BA fashion reveals that both can be synthesised from the FucNA4N derivatives designated A’ 







Scheme 1.21: Retrosynthetic analysis for the synthesis of the S. sonnei disaccharide in a suitably protected 
form. The disaccharides AB or BA can be obtained from the differentially protected monosaccharides A’, A’’, 
B’ and B’’. The AltNAcA derivatives B’ and B’’ should adopt the 4C1 conformation as reported by Pozsgay273 
and Mulard286 who noted this conformation in their 2-acetamido derivatives. This is also the case in the S. 
sonnei di- and tri-saccharides synthesised by Pfiste and Mulard.286 
 
 
For the synthesis of the A’, A’’, B’ and B’’ sugars, the anomeric position (designated as X) needs 
to be suitably or differentially protected and easily converted to the free sugar post-
glycosylation. From a  literature survey of the vast array of strategies for simultaneously 
protecting the anomeric position and selectively priming it for activation, the alkyl or aryl 
thioglycosides seemed to be a suitable and versatile class of donors and acceptors.258,328,329 Not 
only is their preparation generally straightforward, with the Lewis acid-mediated thiolysis of 
peracetylated sugars being the most direct method,329,‡ but they act as anomeric protecting 
                                                 




groups which can be selectively activated by soft electrophiles and can be used directly in 
glycosylation reactions, or indirectly through the selective transformation to an alternative 
donor group.329 For example, a thioglycoside can be converted to a trichloroacetimidate donor 
via the hemiacetal,329–332 which is obtained using N-bromosuccinimide (NBS) or N-
iodosuccinimide (NIS) in wet acetone.329,333–337 Alternatively, the so called ‘two-step strategy’ 
can be used to selectively transform a thioglycoside to the glycosyl halide which permits 
glycosylation in association with a variety of possible promoters.329,338–342 An active-latent 
strategy can also be employed, which involves a modification of the donor group instead of its 
substitution. For example, an alkyl or aryl thioglycoside can be oxidized to yield a sulfoxide 
donor which can be selectively activated with Tf2O.343–347 Alternatively, a pre-activation strategy 
could be employed, This involves pre-activation of the thioglycoside donor and coupling this 
with a glycosyl acceptor incorporating the thioglycoside in an un-activated form.329,348 In 
addition, these can also act as a glycosyl acceptor.329,338,349–352 All of these transformations occur 
under different reaction conditions, thereby allowing for the chemoselective glycosylation to 
give either the A’B’ or B’’A’’ disaccharide. Furthermore, the reactivity of the thioglycosyl donor 
can be “tuned” by taking various factors into account – solvent, activating/deactivating 
protecting groups, C-2 neighboring group participation and activator systems, all of which can 
be investigated at the time of glycosylation.329  This strategy will also allow for the possibility of 
chain elongation at each end.  
 
Next, the 2-position must be suitably protected for glycosylation reactions in order to achieve 
the correct reactivity and selective formation of the 1,2-trans glycosidic linkage as desired in the 
AB and BA products (Scheme 1.21). The 2-acetamido functionality is present in both AltNAcA 
and FucNAc4N monosaccharides and is of particular concern as its presence in glycosyl donors 
and acceptors is known to reduce their reactivity.353–360 For example, in the case of the donor, 
under glycosylation conditions, the oxocarbenium ion can rearrange to form the cyclic (2-
methyl)oxazoline intermediate, which can be unreactive under harsh Lewis acid conditions.360 
In the case of glycosyl acceptors, the reactivity of the 4-hydroxyl group in N-acetyl glucosamine 
derivatives is generally low due to the suspected intermolecular hydrogen bonding from the N-
H of the amide.355,357–359 Although there is evidence for poorer reactivity of 2-acetamido 
derivatives, there are various reports that they can be used without manipulation in 
glycosylation reactions.361–364 The advantage of starting with a 2-acetamido precursor is that no 
manipulations pre- and post-glycosylation are required, and this warrants an investigation in 
this study. Alternatively, the N,N-diacetyl or N-acetyl-N-benzyl derivatives could also be 
synthesised.359 Most commonly however, N-trichloroacetyl or N-phthaloyl protecting groups 




groups are capable of anchimeric assistance, via the more reactive oxazoline, which is made 
more reactive by the electron withdrawing chlorine atoms,‡ and the oxazolinium intermediate 
respectively.288,289,365–369 These can be installed if necessary.360 
 
In the case of the FucNAc4N monosaccharides A’ and A’’, the 4-position can be masked as an 
azide, which is compatible with almost all conditions and can be installed via a Mitsunobu-type 
reaction or by esterification at O-4 with triflic anhydride, followed by SN2 substitution with 
NaN3 to give the correct galacto-configuration if starting with a gluco-derivative. Alternatively, 
the azide can be reduced and protected as the N-Boc derivative, which is easily removed under 
acidic conditions. The 3-position of the A’ unit can be protected with an ether or ester group (R2 
= Bn or Bz). The benefit of a benzyl ester protecting group is that it is removed during the 
reduction of the 4-azido group.  
 
In the case of the AltNAcA monosaccharides B’ and B’’, the carboxylic acid moiety at C-6 can be 
protected as a methyl ester, and since discrimination between the O-3 and O-4 positions is 
required for the alternate coupling patterns, these will be protected with different groups, 
selected from esters, ethers or silyl ethers.  
 















                                                 
‡ Various authors report that this derivative makes excellent glycosyl donor intermediates,288,365–368 while 





1.14  Aims of the project:  
The aims of the project are twofold and involve:   
 The synthesis of the two unusual sugars found in S. sonnei, 2-acetamido-4-amino-2,4,6-
trideoxy-β-D-galactopyranose  (FucNAc4N/AAT) and  2-acetamido-2-deoxy-α-L-altruronic 
acid  (AltNAcA) in the suitably protected form of A’, A’’, B’, B’’. These will then be coupled to 
form the required disaccharides AB and BA which can be used as standards for the 
physicochemical characterization of the S. sonnei glycoconjugate vaccine being developed 
by GlycoVaxyn. 
 The analysis of glycoconjugate and glycopeptide samples derived from S. flexneri 2a 
obtained from GlycoVaxyn using NMR spectroscopy. Detailed 1D and 2D NMR spectroscopy 
will be used to determine the structural identity and integrity of the conjugated 
carbohydrate antigen. 
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Chapter 2: Design and evaluation of alternative synthetic routes to 
derivatives of 2-acetamido-4-amino-2,4,6-trideoxy-β-D-





2. 1  Proposed synthesis of the protected FucNAc4N derivative via the 1,6-anhydro 
sugar route 
On the basis of considerations discussed in Ch 1.13, and the challenge of pursuing some 
alternative routes towards a versatile, robust synthesis, a survey of the literature revealed the 
1,6-anhydro-2-azido-2-deoxy-4-O-tosyl-β-D-glucopyranose 2.3 synthesised by Karban et al.1 to 
be a suitable starting point (Scheme 2.1). This would serve as an ideal intermediate as the 2-
azido group can be reduced and protected as any acylamino functionality, for later conversion 
to the 2-acetamido group, while the tosyl group at O-4 can later be substituted to give the 4-
azido D-galacto-derivative 2.5. In addition, the 1,6-anhydro bridge provides effective temporary 
protection of the anomeric position, which can later be converted to a suitable glycosyl donor or  
the free sugar. 
 
A plausible route, based on literature precedent, is outlined in Scheme 2.1. The key 
intermediate 2.3  can be obtained in two steps from D-glucal via the Ćerný epoxide 2.1.2–5 
Selective nucleophilic opening of the epoxide with NaN3 should then give the diol 2.2,6 which 
has the 2,3-trans-diaxial substituent geometry in place, and regioselective tosylation at the less 
hindered hydroxyl group would give access to the key intermediate 2.3.1 Reduction of the azide 
and protection with phthalic anhydride should yield 2.4. Cleavage of the anhydro ring with 
TMSSPh7 should then afford the thioglycoside, while C-4 azide substitution should then yield 
2.5, with the desired galacto-configuration as required in the FucNAc4N derivative. From here, 
conversion to the 6-deoxy sugar could be achieved by the Barton-McCombie radical 
deoxygenation method8–10 yielding 2.6 (A’’), which after benzylation at O-3 can give the 











2.2 Towards the synthesis of the protected FucNAc4N derivative via the 1,6-anhydro 
sugar 
The synthesis began with the commercially available 3,4,6-tri-O-acetyl-D-glucal (Scheme 2.2). 
Deacetylation followed by treatment with bis(tributyltin)oxide and iodine in ACN gave the 2-







The formation of 2.8 is thought to proceed via the tin-mediated 1,6-iodocyclization of the D-
glucal (Scheme 2.3) as postulated by Czernecki and co-workers.11 The D-glucal forms the cyclic 
iodonium cation intermediate A which probably adopts the 5H4 conformation due to 
intramolecular chelation of the pseudo-axial O-3 and the tin atom at O-6, with additional 
stabilization by the co-ordination of the stannylene complex to acetonitrile. The iodonium 
cation forms  exclusively on the bottom face of the molecule, and upon nucleophilic substitution 




Scheme 2.3: Proposed mechanism for the formation of the 1,6-anhydro-2-deoxy-2-iodo-β-D-
glucopyranose (2.8) via the tin-mediated 1,6-iodocyclization of D-glucal.11 
 
 
The Ćerný epoxide 2.1 was then obtained via the SN2 displacement of the iodine.5 However, 
subsequent nucleophilic addition of an azide to form the 1,6-anhydro-2-azido-2-deoxy-β-D-
glucopyranose (2.2) was not achieved, despite attempts under various conditions.6 However, as 
 
 
Scheme 2.2: Towards the synthesis of a protected FucNAc4N derivative via the 1,6-anhydro sugar route. 
Reagents & conditions: (i) MeOH/H2O/Et3N (10:10:1), r.t., 30 mins (ii) a.) (Bu3Sn)2O, CH3CN,  reflux, 3 hrs 
b.)  I2, r.t., 2 hrs, 85% over 2 steps (iii) NaHCO3, DMF/H2O (10:3), 120°C, 4 hrs, 85% (iv) NaN3, NH4Cl, 
MeOH/H2O, reflux, overnight (v) NaN3, DMF/H2O, 80°C, 9 hrs (vi) Ac2O, pyridine, r.t., overnight, 84% (vii) 
NaN3, DMF/H2O (9:1), 110°C, 9 hrs, 66% (viii) p-TsCl, pyridine, r.t., 48 hrs (ix) p-TsCl, Et3N, DCM, 0°C to 





an alternative, it was found that acetylation‡ of 2.1 at O-4 to form acetate 2.9 followed by 
treatment with NaN3 at a slightly higher temperature yielded the desired 2-azido sugar 2.2,5 
which had evidently also undergone de-O-acetylation, possibly due to the basicity of 
NaN3.1213,14The next step required regioselective tosylation at O-4. Treatment of  2.2 with 1.1 eq. of 
freshly recrystallized p-TsCl in pyridine in an attempt to form the mono-tosylate 2.3 as 
described by Karban et al.,1 yielded no result, while use of p-TsCl in DCM containing Et3N gave 
2.3 in a low yield (19%), with evidence for trace amounts of the di-tosylated product. In an 
attempt to optimize the yield and maintain regioselectivity, 2.2 was treated with dibutyltinoxide 
in refluxing toluene, followed by azeotropic removal of the toluene and treatment with p-TsCl 
and DMAP.15 After 27 hours the yield of 2.3 was only increased to 25%. The limited success of 
this reaction was surprising in view of the literature precedent as well as the reported 
regioselective benzylation at O-4 of 2.2.6,16  
 
At this point, an increase in temperature of the tosylation reaction was contemplated, but it was 
anticipated that this could lead to the formation of the 1,6:3,4-di-anhydro sugar 2.10 as shown 
in Scheme 2.4. Triflation of the 4-O-position would most likely have led to the same result 
(Scheme 2.4).17 Similarly, it was anticipated that tosylation at O-4 of the Ćerný epoxide 2.1  
(Scheme 2.5) giving 2.12, followed by treatment with NaN3 could yield the desired 4-O-tosylate 
2.3, but could also form the 1,6:3,4-di-anhydro sugar (2.10) under the high temperatures 
required for azide substitution, and in fact this was found to be the case.18 Alternatively, the di-




Scheme 2.4: Potential formation of the 2-azido-1,6:3,4-dianhydro sugar 2.10, either from 2.3 or from 4-





                                                          







Scheme 2.5: Potential side products (2.10 and 2.13) that could be formed from attempting to synthesis 




In view of the difficulties encountered with the formation of the key 4-O-tosyl derivative 2.3, 
this overall route to the FucNAc4N derivative was abandoned at this point. With hindsight, an 
alternative worth exploring would be to convert diol 2.2 to the di-benzyl ether 2.14 (Scheme 
2.6) with a view to carrying out a regioselective de-O-benzylation using a Lewis acid as 
described by Hori et al.,19 where the 3-O-benzyl ether 2.15 was obtained in an excellent yield. 









2.3 Proposed synthesis of the protected FucNAc4N derivative via a sugar thiazoline  
An alternative route to the FucNAc4N derivative was then considered, based on work published 
by Knapp and co-workers and involving the synthesis of the thiazoline 2.17 and its conversion 
to thioglycoside 2.18 (Scheme 2.7) for further elaboration.20–24 As demonstrated by Knapp et al. 
the commercially available 2-acetamido-1,3,4,6-tetra-O-acetyl-β-D-glucose can be readily 
converted to the thiazoline 2.17 using Lawesson’s reagent. Acid hydrolysis of 2.17, followed by 
radical addition to cyclohexene and transesterification will yield the thioglycoside 2.18 in 







Scheme 2.7: Proposed synthesis of the triol 2.18.20–24 
 
 
At this point, various strategies could be employed to provide access to the regioselectively 
protected 6-deoxy sugars (2.20) and (2.22) (Scheme 2.8), with three options selected for 
further exploration.  The first alternative (option 1) would involve halogenation at C-6 followed 
by reduction to yield the diol 2.19. Then using the same approach as Liang and Grindley,25 
regioselective protection of O-3 should then give the benzoyl ester 2.20. A second approach 
(option 2) would involve the synthesis of the 4,6-O-benzylidene acetal, followed by benzylation  
at O-3 to yield 2.21. Acetal hydrolysis and regioselective halogenation, followed by reduction 
would then give 2.22. The third option would utilize the 4,6-O-benzylidene acetal 2.23 which 
when subjected to the Hanessian-Hullar radical-mediated acetal fragmentation reaction 
conditions, could directly give the 6-bromo-4-O-benzoyl derivative 2.24. Protection at O-3 and 
deprotection of O-4, followed by C-6 reduction could then yield the 6-deoxy sugar 2.22. This last 












The final steps (Scheme 2.9) would involve initial introduction of an azide at C-4 of 2.20 or 
2.22 with inversion of configuration,  either under Mitsunobu-type conditions or via a 
triflation/azide displacement sequence to yield 2.25 or 2.26 both in the required A’ form, which 
after deprotection could yield 2.27 (A’’). At this point, the conversion of the 2-acetamido group 
to an alternative acylamino functionality could also be investigated, yielding the alternative 
















Scheme 2.9: Proposed synthesis of the differentially protected FucNAc4N derivatives 2.25, 2.26, 2.28 or 
2.29 (A’) and 2.27 or 2.30 (A’’). 
 
 
2.4  Towards the synthesis of the protected FucNAc4N derivative via the thiazoline 
sugar – evaluation of option 1 
Starting with the commercially available 2-acetamido-1,3,4,6-tetra-O-acetyl-β-D-glucopyranose, 
the thiazoline 2.17 was synthesised using either Lawesson’s reagent (LR)20 or phosphorus 
pentasulfide  (P4S10)26 as the thiolating agent which proceeds via the thiophosphine ylide 
(Scheme 2.10).27–29 LR is costly and purification is troublesome on larger scales, so in this 
instance it was used on small scale reactions (< 2 g) while P4S10 was used on larger scale (˃ 2 g). 
In both cases, the reaction proceeded smoothly under anhydrous conditions to give 82% and 
96% yields respectively of the thiazoline 2.17. The use of hexamethyldisiloxane (HMDO) was 
found by Curphey et al.,30 to reduce the formation of phosphorus and sulfur by-products, 
eliminating any purification complications. In addition, HMDO is also thought to quench acetic 







Scheme 2.10: Towards the synthesis of theFucNAc4N derivative via the thiazoline route (Option 1). 
Reagents & conditions: (i) Lawesson’s reagent, toluene, 3Å MS, reflux, 4.5 hrs, 82% (ii) P2S10,  
hexamethyldisiloxane, CH(CH3)2OAc, 3Å MS, 100°C, 12 hrs, then r.t., 24 hrs, 96% (iii) TFA, H2O, MeOH, 0°C 
to 5°C overnight, r.t., 4 hrs, 57% (iv) ACCN, cyclohexene, CHCl3 , 75°C, 37 hrs, 66% (v) NaOMe, MeOH, 0°C 
to r.t., 30 mins, 63% (vi) CBr4, PPh3, pyridine, 3Å MS, 0°C to 35°C, 23 hrs (vii) CBr4, PPh3, pyridine, 3Å MS, 
50°C, 13 hrs (viii) I2, PPh3, imidazole, THF, reflux, 5 hrs (ix) SOCl2, DMF, 3Å MS, 0°C to r.t., 1 hr. (x) p-TsCl, 
pyridine, 3Å MS, 0°C, 2 hrs, 81% (xi) NaI, 2-butanone, reflux, 7 hrs, then r.t., 18 hrs, 97%. 
 
 
Following this, 2.17 was hydrolysed to the 2-acetamido-1-thiol 2.31 in yields ranging between 
20% and 57%.20,21,‡ This was then set up for the free-radical addition to cyclohexene using ACCN 
as an initiator. Knapp and co-workers only ever carried out these reactions on small scale (~200 
mg), and so considerable optimisation was required in order to achieve reasonable yields (66%) 
on a large scale. This involved altering the ratio of dry and degassed cyclohexene and 
chloroform as co-solvent, adjusting the rate of addition of the radical initiator, which was found 
to be critical, and monitoring the reaction time to decrease degradation. Once the cyclohexyl 
thioglycoside 2.32 had been synthesised, transesterification under Zemplén conditions gave the 
triol 2.18.24  
 
                                                          




Various attempts at conversion to the C-6 halo derivative were then explored. Unfortunately, all 
attempts at direct formation of halides 2.33 – 2.35 failed and so in the end, a two-step sequence 
was adopted in which the 6-OH was selectively tosylated to give 2.36 (81%), which after 
treatment with NaI in refluxing 2-butanone gave the 6-iodo analogue 2.34 (97%) in a yield of 
78% over the two steps. Confirmation of the introduction of iodine at C-6 was seen in the 13C 
NMR spectrum (Appendix 2), where C-6 was now significantly shielded with a signal upfield at 
9.26 ppm.31 With the halogen in place at C-6, reduction was required (Scheme 2.11). Metal 
hydrides such as LiAlH4 and NaBH4 could not be used due to the presence of the 2-acetamido 
group. So instead Zn/AcOH was used as described by Medgyes et al.32 but this led to the 
formation of multiple unidentified products. However, simple reduction using H2 over Pd/C at 4 
bar for 6 hours cleanly gave the 6-deoxy sugar 2.19, with the appearance of the shielded three-
proton doublet at 1.24 ppm in the 1H NMR spectrum (Figure 2.1) providing clear evidence of 
this transformation. This set the stage for the challenge of differentiating the trans-vicinal 
equatorial hydroxyl groups at C-3 and C-4, presumably characterized by only very subtle 




Scheme 2.11: Towards the synthesis of the protected FucNAc4N derivative via the thiazoline route 
(Option 1) continued. Reagents & conditions: (i) Zn, AcOH, DCM, r.t., 5.5 hrs (ii) H2, Pd/C, MeOH, 4 bar, r.t., 
6 hrs, 97% (iii) BzCl (1.1 eq.), pyridine, 3Å MS, -35°C, 3.5 hrs, 5°C, 14 hrs (iv) BzCl, (1.1 eq., drop wise), 
Et3N (1.1 eq.), 3Å MS, DCM, 5°C, 22 hrs (v) BzCl (1.2 eq.), pyridine, 0°C, 2 hrs, 2.20: 35%, 2.37: 24% (vi) 
TMSCl (1.1 eq. + 0.6 eq.), Et3N (3 eq.), THF, 0°C to 5°C, 99 hrs, 49% (vii) TBDMSCl (1.1 eq.), imidazole (1.5 








Figure 2.1: 1H NMR spectrum of the cyclohexyl 2-acetamido-2,6-dideoxy-1-thio-α-D-glucopyranoside 
(2.19) in MeOD. 
 
 
The simple, direct regioselective protection of trans-vicinal diols in α- and β-6-deoxy sugars 
using 1.1 equivalents of protecting reagent at low temperatures (0°C to -80°C) has been 
described by various authors,25,33–35 with many others reporting similar selective O-3 protection 
on other sugar substrates.36–41 In light of this, several reaction conditions were investigated. 
Firstly, direct benzoylation of O-3 was attempted, using one equivalent of benzoyl chloride at 
low temperatures in either pyridine or dichloromethane with trimethylamine as base. No 
reaction was observed under either conditions. A slight increase in the number of equivalents of 
BzCl resulted in formation of two products in low yield, duly identified as isomeric mono-
benzoates 2.20 and 2.37. Here the increased reactivity of the 4-O-position in 2.19 may be 
attributed to the electron withdrawing nature of the acetamido functionality at C-2,41 or 
alternatively may be due to intramolecular hydrogen bonding between the 3-OH and acetamido 
carbonyl group, although this contradicts the reported literature findings. On the other hand, 
acyl migration of an initially selectively formed 3-O-benzoate may be possible. As an alternative, 
treatment of 2.19 with TMSCl yielded a single product together with unreacted starting 
material as judged by TLC, with 1H NMR revealing the disilylated derivative 2.38 to have 
formed. The more bulky silylating reagent TBDMSCl proved unreactive in these conditions, with 
no evidence of formation of a silyl ether.  
 
Various methods have been explored for obtaining selectively protected carbohydrates using 
reagents or catalysts that enhance the reactivity at one of several hydroxyl groups. One such 
approach is the use of a stannylene compounds.42–50 Other examples  include the use of chiral 
and achiral diamines;40,51 boronic acid catalysts52–55 (those reported by Lee and Taylor55,56 are 




and silver carbonate;58 MoCl559 (limited scope on diols); CuCl2;53,60 ZnCl2;61 and the in situ 
generation of 1-acyloxy-1-H-benzotriazoles.62,63 In addition, a complementary approach is to 
proceed via full protection followed by regioselective deprotection.64–66  
 
While we were aware of all of these approaches, the results at this point indicated a very subtle 
difference in reactivity and stereoelectronic environment of O-3 and O-4 in 2.19. The decision 
was therefore taken to explore the alternative options which provided the more unambiguous 
differentiation, utilizing the simultaneous protection of O-4 and O-6 to set up selective 
protection of the 3-OH.  
 
2.5 Towards the synthesis of the protected FucNAc4N derivative via a 4,6-O-
benzylidene derivative of the thiazoline sugar – evaluation of option 2 
In order to prepare the 4,6-O-benzylidene acetal, triol 2.18 was treated with a catalytic amount 
of CSA and benzaldehyde dimethyl acetal in DMF to give the desired sugar acetal 2.2167 in low 
yield. The use of benzaldehyde and ZnCl2 gave higher yields and despite a lengthier and more 
complicated purification procedure, was chosen as the method of choice for this conversion 
(Scheme 2.12).68 Benzylation at O-3 proceeded smoothly to yield 2.21, which after treatment 
with TFA/H2O yielded the diol 2.39. This was then regioselectively tosylated (2.40) and then 
further converted to the 6-iodo analogue 2.41 as before. Since hydrogenation of 2.41 could 
potentially remove the 3-O-benzyl group, alternative conditions were required for the reduction 
at C-6. So, iodide 2.41 was treated with Bu3SnH and ACCN,69 yielding the 6-deoxy sugar 2.22 in 
a low yield of 20%, accompanied by other products as judged by TLC.  
 
At this point, the regioselective reductive cleavage70 of the 4,6-O-benzylidene acetal 2.23 would 






Scheme 2.12: Alternative synthesis towards the protected FucNAc4N derivative via the thiazoline route 
(Option 2). Reagents & conditions: (i) CSA, benzaldehyde dimethyl acetal, DMF, 3Å MS, 0°C to 50°C, 16 
hrs, 34% (ii) ZnCl2, benzaldehyde, 3Å MS, r.t., 17.5 hrs, 76% (iii) NaH, BnBr, TBAI, THF, 0°C to 2.5 hrs, 
72% (iv) TFA/H2O, DCM, 0°C ,1.5 hrs, 75% (v) p-TsCl, pyridine, 3Å  MS, 0°C, 2 hrs, 42% (vi) NaI, 2-
butanone, reflux, 7 hrs, then r.t., 18 hrs. 90% (vii) ACCN, Bu3SnH, toluene, 3Å MS, 75°C, 2 hrs, 20%. 
 
 
It is pertinent to note at this point that in the process of preparing a further sample of the 4,6-O-
benzylidene 2.23, by repeating the sequence outlined above, the sulfone 2.42 (Scheme 2.13) 
was instead obtained.‡ It is not at all clear how oxidation of the sulfur occurred, although it was 
not viewed as problematic since glycosyl sulfones are capable of being activated with MgBr2 
etherate in glycosylation reactions, and is therefore a viable masked glycosyl donor.71,72 Since 





                                                          
‡ The only difference in the preparation of 2.23 and 2.42 was in the work-up: in the case of 2.23, work-up 
involved washing the reagent mixture with water, before concentrating the organic phase and 
chromatographing the residue, whereas in the formation of 2.42, the water wash was omitted and 






Scheme 2.13: Oxidation of 2.18 forming the sulfone 2.42. Reagents and conditions: (i) ZnCl2, 
benzaldehyde, 3Å MS, r.t., 19 hrs, 61%. 
 
 
2.6 Towards the synthesis of the protected FucNAc4N derivative via alternative 
processing of the 4,6-O-benylidene derivative of the thiazoline sugar – evaluation 
of option 3 
Next, the Hanessian-Hullar radical-mediated acetal fragmentation reaction was explored 
(Scheme 2.14). This potentially offered an efficient way of obtaining the desired C-6 
halogenated derivative, while simultaneously allowing for differentiation of O-3 and O-4. This 
one-step transformation should reduce the amount of manipulations in the overall sequence 
despite requiring the extra protection at O-3 and deprotection of O-4. So, treatment of 
benzylidene acetal 2.42 with NBS and BaCO3 successfully yielded the 4-O-benzoyl-6-bromo-6-
deoxy intermediate 2.43 in a 70% yield (Scheme 2.14).  Evidence for the formation of 2.43 was 
seen in the 1H NMR spectrum (Figure 2.2), with the disappearance of the signal for the benzylic 
methine proton, while a more deshielded H-4, resonating at 4.56 ppm (vs. 3.58 ppm for 2.42) 
was noted. The HMBC experiment definitively confirmed 4-O-benzoylation by virtue of the 
observable long-range coupling between the benzoyl carbonyl carbon and H-4. With 2.43 in 





Scheme 2.14: Alternative synthesis towards the protected FucNAc4N derivative via the thiazoline route 
(Option 3). Reagents & conditions: (i) NBS, BaCO3, CCl4, 3Å MS, reflux, 2 hrs, 70% (ii) H2, Pd/C, MeOH, 4 bar, r.t., 












It is worth noting that no acyl migration or intramolecular substitution to give the 3,6-anhydro 




Scheme 2.15: Potential formation of the 3,6-anhydro sugar 2.45. 
 
 
Two different mechanisms have been proposed for the Hanessian-Hullar reaction (Scheme 
2.16), both of which begin with the initial abstraction of the benzylic hydrogen by the bromine 
radical to give A.73–75 In 1966, Hullar proposed a radical fragmentation to form B, even though 
this primary radical is less stable than the radical that could form at C-4. B then undergoes 
radical bromination to form the 4-O-benzoyl-6-bromo-6-deoxy-β-D-glucopyranoside.74 At the 
same time, Hanessian proposed that the reaction could proceed via an ionic termination 
mechanism where the unstable bromoacetal intermediate C forms and then collapses to give the 
benzoxonium ion D, which upon SN2-like displacement by the bromide at the least hindered 
carbon gives the 4-O-benzoyl-6-bromo-6-deoxy-β-D-glucopyranoside product.73 Although 
subsequent publications by  Hanessian75–77 proposed that the reaction could also proceed via a 




be the most plausible mechanism78 with indirect support of this pathway published by McNulty 
et al.79 In both instances, the reaction proceeds almost always with the bromine atom attacking 








The successful conversion of the 4,6-O-benzylidene (2.42) to the 6-deoxy sugar 2.44 represents 
a proof of concept that this as a viable method of obtaining the FucNAc4N derivative. However, 
at this stage the efficiency of the overall route was re-evaluated: the earlier steps of the 
synthesis, in particular the hydrolysis of the thiazoline 2.17 to form the 2-acetamido-1-thiol 
2.31 and the radical-mediated formation of the thioglycoside (2.32), were not amenable to 
efficient scale-up and were not reproducible, thus limiting the material available for subsequent 
steps.  An additional drawback was the unexpected oxidation of the sulfur during the formation 
of the benzylidene acetal, and in view of all of these factors, and results in a parallel study of an 







2.7 Proposed synthesis of the FucNAc4N derivative via the 2,3-oxazolidinone sugar 
route 
An alternative route to the FucNAc4N derivative is illustrated in Scheme 2.17. In this approach, 
the 2,3-oxazolidinone 2.47, efficiently synthesised by Benakli and co-workers80 via the free 
amine 2.46, was seen as an ideal intermediate for further manipulations, as the O-3 and O-4 
positions are differentiated. The 2,3-oxazolidinone 2.47 could easily be converted to the 6-
deoxy sugar 2.48 by methods previously employed in the thiazole route, leaving the 4-position 
free for inversion and conversion to 4-azido sugar 2.49 (using Mitsunobu conditions or via 
triflation followed by SN2 substitution with NaN3) to give the desired galacto-configuration. 
Hydrolysis of the oxazolidinone, although reportedly not without complications, could then 
yield the FucNAc4N derivative 2.50 (A’’), which after C-3 protection can give 2.51 (A’). If 










2.8 Scope of 2,3-oxazolidinones 
The use of 2,3-oxazolidinones as protecting groups in carbohydrate synthesis gives rise to 
highly functionalised and selectively protected building blocks. Their synthesis on a large scale 
and in high yield has also been possible.80–88 Furthermore, 2,3-oxazolidinone-protected glycosyl 
donors stereoselectively yield  1,2-cis glycosides (see discussion in Ch. 3.3)80,82–86 although 1,2-
trans glycosides can be also be obtained by altering the promoter conditions, as found by the 
Oscarson research group.83,86 Glycosyl acceptors incorporating the 2,3-oxazolidinone have also 
been found to have enhanced reactivity at the 4-position.41,87,88 This is from the prevention of 
intermolecular hydrogen bond formation, which is generally the cause of poor reactivity of 2-
acetamido glycosyl acceptors88,89 while the ‘tied back nature’ of the protecting group reduces 
steric hindrance around the 4-position.87,88 
 
2.9 Synthesis of the protected FucNAc4N derivative via the 2,3-oxazolidinone 
The thioglycoside 2.52 (Scheme 2.18) was obtained from the commercially available 2-
acetamido-1,3,4,6-tetra-O-acetyl-β-D-glucopyranose. The β-anomer is obtained exclusively due 
to the participation of the 2-acetamido group, blocking the α-face of the oxocarbenium ion. 
Thioglycoside 2.52 was easily transformed to the free amine 2.46 via a sequence involving 
initial N-Boc protection to give 2.53, (amide rotamers) followed by global deacetylation under 
Zemplén conditions, and finally N-deprotection with TFA.  The common method of removing an 
N-acetate involves refluxing in NaOH for several days, and involves a complicated extraction and 
purification procedure.90 In contrast, this method uses only catalytic amounts of base and easily 
removable TFA.80 De-N-acetylation occurs due to the enhanced electrophilicity of the N-acetate 
carbonyl group which results from the delocalization of electrons that extends into the N-Boc 
protecting group.  
 
The free amine 2.46 was then readily converted in an excellent yield to the 2,3-oxazolidinone 
2.47 using p-nitrophenyl chloroformate. At this point, separation of the oxazolidinone 2.47 
from the concomitantly formed p-nitrophenol presented no purification problems as described 
by Nagai et al.41 Transformation to the 6-deoxy sugar 2.48 proceeded smoothly as previously 
discussed (via the 6-O-tosylate 2.54 and the 6-iodo-derivative 2.55), with no purification 
required after tosylation of O-6.  
 
In the first attempt at inversion of configuration at C-4 to give the galacto-derivative, 2.48 was 
treated under Mitsunobu-type conditions with diphenylphosphoryl azide, but proved 
unreactive even after 20 hours reaction time. However, the 4-azido sugar 2.49 was readily 




inversion as seen from the change in the three-bond homonuclear coupling constants (2.48: J3,4 
= 9.7 Hz, J4,5 = 8.4 Hz vs. 2.49:  J3,4 = 2.9 Hz, J4,5 = 1.7 Hz), while the presence of the azide was 




Scheme 2.18: Towards the synthesis of the protected FucNAc4N derivative via the 2,3-oxazolidinone 
sugar route. Reagents & conditions: (i) HSPh, SnCl4, DCM, 3Å MS, reflux, 18 hrs, 86% (ii) Boc2O, DMAP, 
THF, 70°C, 3 hrs, 98% (iii) NaOMe, MeOH, r.t., 45 mins (iv) TFA, 0°C  to r.t., 3 hrs, 83% (v) 4-nitrophenyl 
chloroformate, NaHCO3, ACN, H2O, 0°C, 2.5 hrs, 94% (vi) p-TsCl, pyridine, 0°C, 4.5 hrs, 89% (vii) NaI, 2-
butanone, reflux, overnight, 79% (viii) H2, Pd/C, MeOH, 4 bar, r.t., 25 hrs, 60% (ix) PPh3, DIAD, 




During the first large scale attempt at selective formation of the 6-tosylate 2.54 from diol 2.47, 
the di-tosylate 2.56 in addition to the desired mono-tosylate 2.54 was formed (Scheme 2.19).‡ 
The possibility of conversion of this di-tosylate to the desired FucNAc4N derivative was 
therefore evaluated by selectively converting it to the 6-iodo-4-O-tosyl intermediate 2.57 as 
described by Medgyes et al.32 and then reducing to give the 6-deoxy-4-O-tosyl sugar 2.58. 
                                                          
‡ 1.5 eq. of p-TsCl was used for this reaction and from this point onwards only 1.2 eq. of p-TsCl was used. 




However, all attempts to carry out the subsequent SN2 displacement of the tosyl group to yield 
azide 2.49 failed. The first three attempts using NaN3 in DMF and H2O with conventional or 
microwave heating returned only starting material, while the last attempt with NaN3 in DMF at a 
higher temperature for an extended period of time revealed the formation of multiple polar 
products as judged by TLC. It was assumed that degradation as well as hydrolysis of the 2,3-
oxazolidinone was occurring possibly due to the basicity of NaN3.12 Since 2.49 had already been 
synthesised via triflation, no further attempts were made to achieve this conversion using the 6-




Scheme 2.19: Towards the synthesis of the protected FucNAc4N derivative via the di-tosylate 2.56. 
Reagents & conditions: (i) p-TsCl, pyridine, 3Å MS, 0°C to r.t., 2 hrs, 54% mono-tosylate, 24% di-tosylate  
(ii) NaI, 2-butanone, reflux, 16.5 hrs, 71% (iii) H2, Pd/C, MeOH, 4 bar, 20 hrs, 52% (iv) NaN3, DMF, H2O, r.t. 
to 70°C, 39.5 hrs (v) NaN3, DMF, H2O, MW, 90°C, 3 mins (vi) NaN3, DMF, H2O, MW, 100°C, 10 mins  
(vii) NaN3, DMF, 120°C, 16 hrs.  
 
 
At this point N-acetylation of the 4-azido sugar 2.49 would yield a potential glycosyl donor as 
reported by Oscarson and co-workers.83,86 However, hydrolysis (deprotection) of the 2,3-
oxazolidinone group was a priority in order to establish the appropriate conditions for this step  
and eliminate a potentially difficult deprotection of the disaccharide at a later stage of the 
synthesis. 
 
A review of the literature revealed that base hydrolysis or mild reducing agents have been used 
to deprotect the oxazolidinone.41,80,83,87,88,91–93 Benakli and co-workers80 treated their 2,3-




amine.‡ However, treatment of 2.49 with 1M NaOH in THF (Table 2.1, entry 1) gave unreacted 
starting material after 1 hour together with various more polar products, whereas after 4 hours 
no starting material remained, but a range of products could be seen from TLC, with no major 
product identifiable. Doubling the concentration of NaOH (entry 2) yielded the same results.‡ 
When 2.49 was heated at 60°C with 2M NaOH in THF (entry 3) a major product was evident 
from TLC after 20 mins (together with other minor polar products), and so the reaction was 
terminated and after workup the crude products were immediately acetylated in order to 
facilitate isolation and characterization. The major product was in due course identified as the 
diacetate 2.51 (A’), though unfortunately in a low yield of 35%.  
 
Based on the limited success of the attempted deprotection, an alternative method reported by 
Calveras et al.93 was investigated. They found that treatment of their β-cis-2,3-oxazolidinone 
with LiOH in refluxing EtOH, followed by acidification with AcOH and then acetylation using 
Ac2O yielded the desired N-acetylated, 3-hydroxy intermediate. Here, AcOH was used to collapse 
the carbamic acid lithium salt and prevent re-formation of the cyclic carbamate. However, upon 
treatment of 2.49 with LiOH in refluxing ethanol, followed by full acetylation (entry 4) the 
carbamate 2.59 was formed, probably through the addition of ethanol to the isocyanate 
intermediate.94 Interestingly, the carbamate 2.59 could potentially be used as an N-protecting 
group in the desired glycosyl donor, since this functional group is capable of anchimeric 
assistance through the formation of an oxazolinium intermediate, which should be more 












                                                          
‡ Treatment of their derivative in the presence of a mild base (Cs2CO3) in alcohol deprotected the 3-
position with simultaneous formation of the C-2 carbamate. 
‡ In both these cases TLC did not show degradation, but the formation of distinct products. These were 








Entry R Reagents & conditions Product Yield 
1 H NaOH (1M), THF, r.t., 4 hrs Multiple products - 
2 H NaOH (2M), THF, r.t., 2.5 hrs Multiple products - 
3 H 
i.)   NaOH (2M), THF, 60°C, 25 mins 
ii.)  Amberlist IR 120, 20 mins 
iii.) Ac2O, DMAP, pyridine, r.t., 2 hrs 
2.51 (A’) 35% 
4 H 
i.)   LiOH.H2O, EtOH, reflux, 18 hrs 
ii.)  AcOH, r.t., 1 hr 
iii.) Ac2O, r.t., 22 hrs, no rxn 
iv.) Ac2O, pyridine, r.t., 6 hrs 
2.59 75%  
5 Ac LiCl, LiOH, THF/H2O, r.t., 30 mins 2.50 (A’’)  90% 
 
 
Since the conditions used in entries 1 – 4 (Table 2.1) had not been successful, attention next 
turned to the possibility of chemoselectively hydrolysing the N-acetyl oxazolidinone. A review of 
the literature revealed that the methods used to deprotect the N-acetyl 2,3-oxazolidinone are 
not of the ‘one hat fits all’ nature. Instead, the rate of cleavage is very much dependent on cis or 
trans configuration of the oxazolidinone,92,93 as well as the anomeric configuration of the sugar 
derivative. Crich and Vinod reported an example of the latter, where the use of Ba(OH)2 in 
refluxing ethanol chemoselectively cleaved their methyl N-acetyl-2-amino-2-N,3-O-carbonyl-2-
deoxy-β-D-pyranoside to give the 2-acetamido derivative (A) (Scheme 2.20A), while the α-
anomer under the same conditions yields the 2-amino sugar (B) (Scheme 2.20B).88 This 
selectivity can be explained by the chelation of the Lewis acidic barium cation and the oxygen of 
the anomeric methoxyl in the β-anomer, making the oxazolidinone group more exposed and 
therefore susceptible to attack. Alternatively, the barium cation chelates between the two syn 







Scheme 2.20: Crich’s explanation for the observed chemoselectivity for N-acetyl or N-oxazolididone 
hydrolysis in the α- and β-series.88 
 
 
Contrasting results were however reported by Nagai et al.41 where treatment of their 1,6-di-O-
tert-butyldiphenylsilyl-2-N,3-O-carbonyl-2-deoxy-β-D-glucopyranose with LiCl and LiOH in an 
alcohol (MeOH or EtOH) with H2O and THF yielded the C-3 carbonate. Strangely, no reaction 
was reported to occur without the alcohol, potentially due to solubility issues. Again, these 
results are in contrast with those reported by Wei and Kerns who conducted a helpful study in 
the chemoselective deprotection of the 2,3-oxazolidinones, where treatment of their 4-O-
allyloxycarbonyl-1-O-benzyl-6-O-tert-butyldiphenylsilyl-2-N,3-O-carbonyl-2-deoxy-β-D-
glucopyranose with either NaOMe or Cs2CO3 in methanol yielded the N-acetyl methyl 
carbamate. Successful results were however obtained when their oxazolidinone was treated 
with either LiOH/H2O2 in THF/H2O at -40 to 0°C or LiCl and LiOH in EtOH/H2O at room 
temperature. 
 
These observations suggested that carrying out the reaction in the absence of an alcohol would 
prevent any carbamate or carbonate formation, and consequently the N-acetyl 2,3-
oxazolidinone 2.60 (Scheme 2.21) was treated with LiCl and LiOH in THF/H2O (Table 2.1, 
entry 5) which yielded the desired N-acetyl intermediate 2.50 (A’’) cleanly and in an excellent 
yield (90%). Here the addition of LiCl prior to LiOH is crucial, and it is suspected that the weakly 
Lewis acidic Li+ chelates with the carbonyl carbon of the acetate and the anomeric sulfur as seen 







Scheme 2.21: Synthesis of the protected FucNAc4N derivative 2.50 (A’’). Reagents & conditions:  
 (i) AcCl, DIPEA, DCM, 0°C, 2.5 hrs, 87% (ii) LiCl, LiOH,THF, H2O, r.t., 1 hr 20 mins, 90%. 
 
 
In a separate investigation which parallels reactions carried out in Ch. 3.3, the anomerization of 
2.60 was also investigated (Scheme 2.22). Treatment of 2.60 with SnCl4 yielded the α-anomer 
2.61, which after hydrolysis of the 2,3-oxazolidinone with LiCl/LiOH yielded the α-FucNAc4N 
derivative 2.62, again in the form of A’’. These results indicate that, in contrast to Crich’s 
conclusions88 discussed above, the anomeric configuration has no bearing on chemoselectivity.‡ 
The reasons for this are not clear. There are key differences between the substrates in this study 
and those in the study reported by Crich, notably in the anomeric substituents (SPh vs. OMe), 
the configuration at C-4 (galacto vs. gluco), and the substituents at C-4 and C-6.  The nature and 
configuration of C-4 and C-6 substituents may well have a decisive influence on the 
conformation and hence ring-strain in the fused system, so that the anomeric configuration 
plays less of a role. Alternatively, or in addition, it is possible that the larger  sulfur atom can 
effectively co-ordinate with the Li+  together with the carbonyl oxygen of the N-acetyl group in 






Scheme 2.22: Synthesis of the α-FucNAc4N derivative 2.62 (A’’). Reagents & conditions: (i) SnCl4, DCM, 





                                                          
‡ The hydrolysis of the 2,3-oxazolidinone of the α-anomer 2.61 is however, faster, taking almost half of 




2.10  Synthesis of alternative FucNAc4N derivatives 
With the FucNAc4N derivative 2.50 (A’’) and its corresponding O-acetyl 2.51 (A’) successfully 
synthesised, attention turned to synthesising the glycosyl acceptor 2.63 for potential use as a 
standard (Scheme 2.23). Treatment of 2.50 (A’’) with NCS in methanol and DCM gave the 
methyl glycoside 2.63 in a moderate yield (55%, α/β 3.3:1). In addition, it was worth 
investigating the conditions for azide reduction, and after optimisation using hydrogenation, the 




Scheme 2.23: Synthesis of alternative the protected FucNAc4N derivative. Reagents & conditions: (i) 
NCS, MeOH, DCM, r.t., 20 mins, 55% (α/β 3.3:1) (ii) H2, Pd/C, MeOH, DCM, r.t., 4 hrs, 80%. 
 
 
The full scope of 2.50 (A’’) and 2.51 (A’) as glycosyl donors could have been explored further, 
but at this point the primary focus of the project was on establishing efficient routes to the 
required monosaccharide derivatives. 
 
2.11  Summary 
Five different routes to the FucNAc4N derivative were investigated and evaluated. The first 
route via the 1,6-anhydro sugar involved the synthesis of the key intermediate 2.3 which after 
further manipulations could yield the desired FucNAc4N derivatives, A’ and A’’. However, 
obtaining the regioselectively protected derivative 2.3 in a reasonable yield could not be 







Scheme 2.24: Summary of synthesis via the 1,6-anhydro sugar route. 
 
 
Instead, attention then turned to synthesising the triol 2.18 via the thiazoline 2.17 (Scheme 
2.25) as described by Knapp and co-workers.20–24 This intermediate allowed for further 
elaboration and exploration of three different alternatives to obtaining the FucNAc4N 
derivative. However, the low yields for the synthesis of the 2-acetamido-1-thiol 2.31 and the 
radical-mediated formation of the thioglycoside (2.32) were not amenable to efficient scale-up, 
thus limiting the material available for subsequent steps. Regardless, all three options were 
partially investigated. In the first instance, attempts to regioselectively benzoylate O-3 instead 
yielded a mixture of the 3-O and 4-O-benzoyl derivatives (2.20 and 2.37 respectively). Next, 
option 2 was evaluated, but reduction to yield the 6-deoxy intermediate 2.22 gave poor yields 
and upon resynthesizing the 4,6-O-benzylidene derivative 2.23, the sulfonyl derivative 2.42 
was obtained.  This was instead used to evaluate option 3 which made use of the Hanessian-
Hullar radical-mediated acetal fragmentation reaction and successfully yielded the 6-bromo-
derivative 2.43 which after reduction gave the 6-deoxy sugar 2.44. Options 2 and 3 both had 
potential; however, after a complete evaluation of the synthesis via the thiazoline sugar route, it 







Scheme 2.25: Summary of synthesis via the thiazoline sugar route. 
 
 
The synthesis of the FucNAc4N derivative via the 2,3-oxazolidinone route efficiently yielded the 
phenyl 2-acetamido-4-azido-2,4,6-trideoxy-1-thio-β-D-galactopyranoside (2.50) (A’’) in 10 
steps from the commercially available 2-acetamido-1,3,4,6-tetra-O-acetyl-β-D-glucopyranose 
(Scheme 2.26) in a 17% overall yield. This compares well with previous FucNAc4N synthesis 
where overall yields for a similar FucNAc4N derivative range between 8-39%.  
 
The inadvertent di-tosylation of 2.47 to give 2.56 and hydrolysis of the 2,3-oxazoldinone 
protecting group of the 4-azido sugar 2.49 (Table 2.1) presented the only challenges in the 
synthesis. Di-tosylation was further prevented by reducing the number of equivalents of p-TsCl, 
while 2,3-oxazolidinone hydrolysis was easily overcome by N-acetylation followed by 2,3-
oxazolidinone hydrolysis with LiCl and LiOH to yield the 2-acetamido derivative 2.50 (A’’) 




free amine 2.64 were also obtained. Subsequent protection of 2.50 (A’’) could then yield the 




Scheme 2.26: Summary of synthesis via the 2,3-oxazolidinone sugar route. 
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Chapter 3: Design and evaluation of alternative synthetic routes to 





3.1  Towards the synthesis of a protected AltNAcA derivative: first approach via a 
fused furanolactone 
This part of the study involved the development of a synthetic route to the unusual AltNAcA 
sugar which would combine inherent synthetic interest and a reasonable degree of efficiency. 
The approach was chosen on the basis of recent literature reports on the viability of strategies 
for preparing L-sugars1 via inversion of configuration at C-5 of the D-sugars, and was based on 
the initial preparation of L-iduronic acid derivative 3.2 as reported by Ke and Whitefield.2 The 
proposed synthetic route is outlined in Scheme 3.1.  It involved the initial key inversion at C-5 of 
the readily available protected glucuronolactone to yield the 5-O-benzoyl furanolactone 3.1 
(Scheme 3.1), via triflation and displacement with benzoate.2,3 This would be followed by base-
catalysed methanolysis of the lactone, accompanied by migration of the benzoate from O-5 to O-
3, and then acid hydrolysis to give iduronic acid derivative 3.2. This derivative then requires the 
following key transformations: inversion of configuration at C-4, introduction of the acetamido 
functionality at C-2 with retention of configuration and installation of a suitable anomeric 
substituent, allowing for selective activation at a later stage. One possible strategy to achieve all 
of this would start with preparation of the cis-1,2-O-isopropylidene derivative using Seeberger’s 
methodology,4 which after an inversion sequence at C-4 using the nitrite-mediated substitution 
of the 4-O-triflate,5 followed by benzylation at O-4 would give the altruronic acid derivative 3.3. 
After removal of the isopropylidene group, selective oxidation of the 2-hydroxy group could be 
attempted using the cupric acetate methodology of Hanaya et al.6,7 followed by simple 
acetylation to protect the anomeric position (3.4). The final steps would involve an oxidation-
oximation-reduction sequence or oxidation-reductive amination sequence to form 3.5 with the 
2-acetamido functionality in the correct configuration. The stereoselective reduction of the 
oxime could be a challenge and it would depend, in part, on the preferred conformation of this 
altrose derivative, as well as the extent to which the substituents at C-1, C-3 and C-4 influence 
the face selectivity of the addition of hydrogen to the oxime. The use of a variety of reducing 
agents (e.g. LiAlH4; H2, PtO2, HCl;8 MoO3, NaBH4;9 NiCl2, NaBH4;10 Zn/HCOONH;11 SmI212) may 
need to be investigated in order to obtain the desired 2,3-trans stereochemistry in 3.5. Earlier 
inversion of the 4-position will also helpfully reduce any 2,4-steric interactions. Conversion of 
3.5 to the thioglycoside would then yield 3.6 in the form of B’’, while hydrogenolysis would 







Scheme 3.1: Proposed synthesis of the protected AltNAcA derivatives 3.6 (B’’) and 3.7 (B’) via the 5-O-
benzoyl furanolactone (3.1).  
 
 
Beginning with the commercially available 1,2-O-isopropylidene-β-D-glucofuranurono-6,3-
lactone (Scheme 3.2), the first sequence, with the objective of achieving the crucial inversion of 
configuration at C-5, involved esterification of the free 5-OH using triflic anhydride followed by 
SN2 inversion with benzoate to give the key 5-O-benzyl furanolactone (3.1), with the assumed R-
configuration at C-5.2,3 This proceeded in good yield, but there was no direct proof of this 
inversion from the 1H NMR of the product, as the J-coupling constants in the starting material 
and product were virtually the same, as is expected from bond orientations in substituents on 
the furanosyl ring. This result was, however, consistent with that reported in the literature, 
where the authors also report use of sodium pivaloate as an alternative.2,13 The next step 
involved the base-catalysed cleavage of the lactone with subsequent migration of the benzoyl 
group to form (3.8B). Ojeda et al.3 originally reported the selective cleavage of the lactone ring 
using methanolic 1% Et3N at low temperatures (-60°C to -40°C), but found that increasing the 
amount of Et3N or increasing the temperature led to the undesired (in their case) migration of 
the pivaloyl group from the 5-O-position to the 3-O-position. By exploiting this side reaction, Ke 





upon treatment with Et3N (8 eq.) in methanol at 0°C for 1 hour.2,‡ However, in our hands under 
these conditions on both a small and larger scale, some starting material was recovered, 
together with an almost inseparable mixture of the 5-benzoate (3.8A) and 3-benzoate (3.8B). 
Nevertheless, after repeated column chromatography on silica, the desired product 3.8B was 
isolated in moderate yield. The failure to achieve a clean, efficient lactone opening and benzoyl 





Scheme 3.2: Towards the synthesis of the protected AltNAcA derivative via the fused furanolactone 
route. Reagents and conditions: (i) a.) Tf2O, pyridine, -40°C, 1.5 hrs, 98% b.) NaOBz, DMF, 0°C to r.t., 6 hrs, 
88% (ii) Et3N, MeOH, 0°C, 1.5 hrs, 15% (3.8A), 36% (3.8B) (iii) 90% TFA, 0°C, 15 mins, 78% (iv) 90% 
TFA, 3 hrs, r.t., 45%. 
 
 
In an attempt to better understand the conversion of 3.1 to 3.8B, the reaction was repeated in 
an NMR tube, in order to monitor progress by NMR and acquire evidence for the proposed 
sequence of steps. The reactants were combined at room temperature using 5 eq. of Et3N (a 
reduced amount of Et3N was used so as not to saturate the spectra) in anhydrous MeOD and 
CDCl3, with 1H NMR spectra recorded at the intervals indicated (Figure 3.1). Figure 3.1 shows 
the set of spectra obtained, with the spectrum of the starting material 3.1 shown at the bottom, 
and those of the two products 3.8A and 3.8B shown at the top. The spectra of 3.1, 3.8A and 
3.8B are of the purified compounds and have been run in CDCl3 only, hence the differences in 
chemical shifts of these three spectra vs. spectra 1-9. The most diagnostic signals in all the 
spectra are from H-3 and H-5 in compounds 3.1, 3.8A and 3.8B, and the shifts of these can be 
monitored. The spectrum of 3.1 shows the relatively shielded H-3 and H-5 signals, while H-5 in 
                                                          






the spectrum of 3.8A is shifted significantly downfield due to the combined electron-
withdrawing effects of the attached benzoate ester, and the adjacent carboxyl group. On the 
other hand, H-3 of 3.8B is significantly more deshielded due to the attached benzoate ester, 
with H-5 appearing upfield and giving evidence for the migration of the benzoate to O-3. After 
the addition of the reagents, changes in the spectra can already be seen after only 10 minutes 
(spectrum 1), with the noticeable appearance of H-5 of 3.8A and H-3 of 3.8B. In the period from 
30 minutes to 270 minutes (spectra 2-8) the decrease in intensity of the H-2, H-3, H-4 and H-5 
signals of 3.1 can be seen, while a subsequent increase in the amount of the 3-benzoate, 3.8B is 
accompanied by a reduction in the amount of 3.8A as seen from the decrease in intensity of the 
H-5 signal. Finally, after 24 hours (spectrum 9) only a minor amount of the starting material 
(3.1) can be seen, while the desired 3-benzoate 3.8B was formed in majority as seen from H-3 
and the most deshielded anomeric signal, with the persistent presence of the 5-benzoate 3.8A, 











1  - 10 mins
2  - 30 mins
5  - 90 mins
4 - 70 mins
3  - 50 mins
6  - 110 mins
7  - 130 mins
8  - 270 mins













H-3 of 3.8BH-5 of 3.8A
 
 
Figure 3.1: NMR-monitoring of the reaction of 3.1 with MeOD under basic conditions. Reagents & 
conditions: Et3N (dry) (5 eq.), MeOD (dry) (10 eq.), CDCl3 (dry), spectra recorded at 30°C, NMR tube kept 
at r.t.. Concentration of starting material = 74 mg/mL in CDCl3. Chemical shifts (δ) referenced relative to 
the internal TMS standard. . The spectra of 3.1, 3.8A and 3.8B are of the purified compounds and have 
been run in CDCl3 only, hence the differences in chemical shifts of these three spectra vs. spectra 1-9. 
 
 
An investigation was then carried out to determine the effect of various bases and 
temperatures, but this gave similar results in all instances. With hindsight, the use of a stronger 
base (such as NaOMe in MeOH) may have been required in order to effect the required 
conversion, although this would also potentially have deprotected the benzoyl ester.14  
 
Once a substantial amount of pure 3.8B had been obtained from these experiments, attention 
turned to the deprotection of the 1,2-O-isopropylidine acetal and rearrangement to the 
pyranoside 3.2. Following literature precedent, 3.8B was treated with 90% aqueous TFA for 15 
minutes at 0°C yielding  a single more polar product, as judged by TLC, but shown by 1H NMR to 





was confirmed, after isolation of the products from the reaction mixture, by a detailed 2D NMR 
study with the COSY in particular confirming the presence of the distinct spin systems and 
revealing the very deshielded H-3 protons, consistent with the presence of the 3-O-benzoyl 
ester. The HSQC spectrum allowed full assignment of carbon signals, and the complex HMBC 
spectrum gave evidence for both α- and β-pyranose (3.2-α and 3.2-β) forms, with clear 
crosspeaks between C-1α and H-5α, and C-1β and H-5β, while no C-1 to H-4 crosspeaks could be 
seen in either cases (Figure 3.3). Evidence for the α-furanose (3.9-α) is likewise seen in the 
HMBC, where a C-1α to H-4α crosspeak can be seen clearly, but no C-1 to H-5 crosspeak. 
Unfortunately, neither C-1 to H-5 nor C-1 to H-4 crosspeaks could be seen for the β-furanose 
(3.9-β), and these assignments were based on COSY and HSQC data only. Assignments of 
furanose anomeric protons were based on 13C NMR chemical shifts, where carbons appear more 
deshielded when their C-1 and C-2 substituents are trans-oriented.16–18 The most deshielded 13C 
signal at 103.77 ppm was therefore assigned to the α-furanose. The assignments for the 
anomeric protons in the α- and β-pyranose sugars were based on J-coupling values from the 1H 













Figure 3.3: HMBC spectrum of anomeric region showing distinctive C-1 to H-5 crosspeaks for α- and β-
pyranose sugars (3.2-α and 3.2-β) and C-1 to H-4 for the α-furanose (3.9-α), whole no C-1 to H-4 
crosspeak could be seen for the β-furanose (3.9-β). 
 
 
From the integration of the protons in the anomeric region, the ratio of the different forms of 
the sugars were found to be approximately 1.5 : 1 : 1 : 1.5 (3.2-α : 3.2-β : 3.9-α : 3.9-β). Lastly, 
the presence of these proposed structures was confirmed by HRMS which gave a molecular ion 
at 330.1185 corresponding to [M+NH4]+.  
 
Following these observations, a further survey of the literature revealed that application of 
similar conditions to the hydrolysis of analogous substrates achieved exclusive formation of the 
α- and β-pyranoses, with no furanoses detected, with reaction times ranging from 15 
minutes15,19 to 3 hours.2,20–22 This is expected since the furanoses are formed faster (kinetic 
product) but are generally less stable.23 The persistence of the furanose sugars in our case was 
therefore somewhat surprising. Repeating the reaction over 3 hours at room temperature gave 
the same mixture of all forms as discussed above, but in a lower yield. In a final experiment, the 





NMR spectra recorded at intervals. It was clear from the results (Appendix 2) that the 1,2-O-
isopropylidene group was rapidly cleaved, with the α- and β-furanoses and pyranoses forming 
almost instantly, and that there was no detectable change in the product distribution after 2 
hours. A further exhaustive review of the literature revealed a paper by Dilhas et al.24 and 
showed that when a corresponding 3-O-benzyl ether (and not a 3-O-benzoyl ester, as in this 
case) was treated with 90% TFA, it resulted in formation of an equilibrium mixture of both the 
furanose and pyranose forms, with the α-pyranose the major product after only 3 minutes, 
followed by subsequent equilibration to a more-or-less equimolar mixture of the four 
compounds after a 120 minute interval. These findings are in close agreement with the results 
described above. In order to obtain increased amounts of the pyranose sugar (3.2), acetylation 
of the crude reaction mixture after hydrolysis could have been explored at various 
temperatures as described by Dilhas and co-workers, where their β-pyranose (3.2-β) was 
trapped in an 83% yield after recrystallization.24  
 
Thus, although new insights into this fascinating sequence of reactions were obtained by careful 
monitoring of reaction progress by 1H NMR, as well as by using detailed 2D NMR analysis of the 
products of the final hydrolysis step, there were already clear indications that this would not be 
an efficient route to the AltNAcA derivative. The sequence of lactone opening and acyl migration 
was not completely selective, and prospects of obtaining high yields of the desired 
glycopyranose 3.2 in the hydrolysis step seemed low. Together, these would have serious 
implications for the challenging steps that were to come in the proposed sequence. It was 
therefore decided to abandon this route and focus on an alternative strategy to obtain the 
desired AltNAcA derivative.  
 
3.2  Towards the synthesis of a protected AltNAcA derivative: second approach via the 
2,3-oxazolidinone derivative 
Based on our findings in the attempt to synthesize the AltNAcA derivative via a 
glucofuranolactone, and observations in our parallel attempts to synthesize a FucNAc4N 
derivative (Ch. 2), a potential alternative synthetic route to an AltNAcA derivative emerged, 
involving a key intermediate used in the FucNAc4N synthesis. One obvious advantage of this 
option lay in having the 2-amino group already in place and in the correct configuration. It also 
presented a simple solution to the challenge of selective protections of O-3 and N-2, and allowed 
for creative modifications at C-4, C-5 and C-6. In addition, it appeared to offer a considerably 
shortened and more efficient route to the AltNAcA derivative, compared with those reported by 





implication of this option is that it would provide access, from the same chemical intermediate, 
to derivatives of both components of the repeating unit of S. sonnei.   
 
The proposed synthetic route is outlined in Scheme 3.3. The starting point would be the 6-iodo 
derivative 2.55 which is a key intermediate in the accompanying synthesis of FucNAc4N (Ch. 
2.9). It was envisaged that a one-pot, sodium hydride-mediated benzylation at O-4 and 
elimination at C-5/6 would give the 5-enopyranoside 3.10, which upon face-selective 
hydroboration/oxidation27–30 would give the desired R-configuration at C-5 (3.11), which is 
required in an L-sugar. In order to ensure high diastereoselectivity in the 
hydroboration/oxidation step, various borane complexes could be evaluated, in different 
concentrations, taking into account the observation of Takahashi et al.29 The early protection of 
the 4-position would be required in order to ensure selective oxidation at C-6 in a subsequent 
step,# whereas a late-stage inversion to a C-4 axial substituent was envisaged to cause an 
unfavourable influence on the facial selectivity of the hydroboration step, as also seen in studies 
by Takahashi et al.29 Oxidation, followed by methylation, would then yield ester 3.12. It was 
then reasoned that the inversion at C-4 would be best achieved after removal of the 2,3-
oxazolidinone group, since the latter is removed under basic conditions which would not be 
compatible with an ester protecting group at O-4, potentially installed during a Mitsunobu 
inversion or triflation/SN2 benzoate substitution. Therefore the plan involved cleavage of the 
2,3-oxazolidinone group,‡ followed by N-protection (with HAc, Phth or HCOCCl3) and  silylation 
at O-3 to give 3.13, which upon de-benzylation at O-4 is set up for inversion to yield the fully 











                                                          
# Selective oxidation can in fact be carried out.  
‡ Cleavage of the 2,3-oxazolidinone at this point in the synthesis, which is prior to any glycosylation 












This proposed synthesis of the AltNAcA derivative is much shorter than that proposed earlier 
(Ch 3.1) and offers a novel and more efficient route to the synthesis of protected derivatives of 
both FucNAc4N and AltNAcA, allowing for assembly of the disaccharide.     
 
The synthesis of the 6-iodo derivative 2.55 was achieved in a 79% yield over 6 steps via the 
methods described in Ch 2.9. In the first attempt at simultaneous protection at O-4 and 
elimination of the 6-iodide, 2.55 was treated with NaH and an inadvertent excess of BnBr in 
DMF for 1.5 hours at low temperature, yielding the N-benzyl-O-benzyl derivative 3.14 in a 90% 
yield. The dibenzylation was apparent from the 1H NMR spectrum, with an AB quartet appearing 
at 4.75 ppm and two AB doublets at 4.75 ppm and 4.62 ppm (Figure 3.4) and the structure was 
confirmed by single crystal x-ray diffraction (Scheme 3.4 and Appendix 3). Although 
introduction of the N-benzyl group had not been part of the plan, it did not seem to present any 
problems in the ongoing synthesis, and selective preparation of the 4-O-benzyl-2,3-





N-benzyl derivative was in fact seen as a potential benefit, as hydrolysis of the 2,3-oxazolidinone 
and N-acetylation would result in the N-acetamido, N-benzyl derivative, which could serve as an 








Scheme 3.4: Towards the synthesis of a protected AltNAcA derivative via 2.55. Reagents and conditions: 
(i) NaH, BnBr, DMF, 0°C,30 mins, r.t. for 1.5 hrs, 90% (ii) a.) 0.5M 9-BBN, THF, -10°C, to r.t., 2 hrs, then 











Figure 3.4: 1H NMR spectrum of the 5-enopyranoside 3.14. This shows the presence of two benzyl CH2 
groups with an AB quartet appearing at 4.75 ppm and two AB doublets at 4.75 ppm and 4.62 ppm.  
 
 
The selective hydroboration of 3.14 was then attempted using both borane and the more 
sterically demanding 9-borabicyclo[3.3.1]nonane (9-BBN). In the latter case, even with up to 10 
equivalents of 9-BBN, there was no reaction at all after 6 hours, suggesting that both faces of the 
5-ene were sterically inaccessible. However, when 3.14 was treated with 10 eq. of BH3.THF for 
1.5 hours at 0°C followed by oxidative work-up, a single oxidation product was formed, 
although the 1H NMR spectrum did not provide conclusive evidence for the formation of an L-
idose derivative 3.15a (which was anticipated to be the major product for this transformation) 
as the J-coupling constants for H-4 and H-5 were not well resolved. However, the NOESY 
spectrum (Figure 3.5) gives proof of the formation of the D-sugar 3.15b, with the clear NOE 
between H-5 and both H-1 and H-3, which is expected as seen in Figure 3.6. If an α-L-idose 
derivative (3.15a) had formed, then there would be no NOEs between H-1 and H-5, and H-3 and 
H-5, since H-5 is on the opposite face, with the only observable NOE crosspeak between the H-1 
and H-3 signals (the latter is not detectable in this case since the signals for H-1 and H-3 
overlap). It is also noted that the 1C4 chair conformer of the L-sugar is not possible due to the 
conformational restrictions of the 2,3-oxazolidinone group. This therefore gave clear evidence 
that oxidation had taken place from the α-face to give the D-sugar 3.16 rather than the L-sugar. 
In addition, the HRMS data suggested that in this process, the sulfide unexpectedly underwent 
oxidation to the sulfoxide. This provided an explanation for the fact that signals in the 1H NMR 
spectrum for certain protons were poorly resolved or appeared to indicate two closely similar 
products. This may be due to the presence of two sulfoxide diastereomers. While the oxidation 





overall strategy for fine-tuning the reactivity of the glycosyl donor and acceptor (discussed in 




Figure 3.5: NOESY NMR spectrum of compound 3.16. The distinct NOEs between H-5, H-1 and H-3 




Figure 3.6: The expected NOE interactions of 3.15a and 3.15b. 
 
 
The foregoing result led to a re-evaluation of the proposed route towards the L-sugar, and in 
particular, the stereo-electronic requirements for facial-selectivity in the hydroboration step. A 





crucial in determining this selectivity in the attempted hydroboration-oxidation 
sequence.27,29,38,39 This led to a brief molecular modelling investigation of the conformational 
preferences of the α- and β-phenylthio-2,3-oxazolidino-5-eno-glucopyranosides (3.14) using 
Spartan (Figure 3.7).40 A conformer distribution search of 100000 conformers using MMFF 
force field of both 3.14α and 3.14β in the gas phase was carried out. The probable facial 
selectivity of the both anomers was then investigated using the lowest energy conformer. As 
seen in Figure 3.7A, the β-face (top face) in the β-anomer is sterically hindered by the anomeric 


































                                                          
‡ There is free rotation around the C-O-Bn bond of the benzyl group, so steric hindrance from these 
functional groups is not taken into consideration when using this model for the basis of facial approach. 
Also, the conformer obtained is assumed to be the global lowest energy conformer, and not a local minima 
























   
Figure 3.7A: Van der Waals diagram of the  
experimentally obtained β-anomer (3.14-β). 
This illustrates the less-hindered α-face of the 5-
6-ene, and the expected preference for α-facial 
attack, which corresponds to the experimental 
result. From the modelling, the β-anomer is in a 
distorted boat, rather than a chair conformation. 
 Figure 3.7B: Van der Waals diagram of the the 
theoretical α-anomer  (3.14-α) This shows that 
the less hindered environment should favour the 
β-facial approach of the borane complex which 
should yield the L-sugar. 
 
 
The modelling results suggested that a higher selectivity towards the L-sugar might be possible 
via the α-anomer. This analogue could be prepared in at least two distinctive ways, either 
starting with the α-anomer and continuing to form the 2,3-oxazolidinone, or by attempting an 
anomerization of the β-thioglycoside at a strategic point in the synthesis, with the latter being 






3.3 Towards the synthesis of a protected AltNAcA derivative: third approach via the 
2,3-oxazolidinone derivative 
Having identified the α-thioglycoside as a better substrate for the attempted 
hydroboration/oxidation, consideration was given to whether this should be synthesized de 
novo, or via anomerization of the β-thioglycoside which we had in hand.  A survey of the 
literature revealed that Lewis acids such as FeCl3, SnCl4 or TiCl4 could be used to epimerize the 
anomeric centre of various β-glycosides even when C-2 substituents offering anchimeric 
assistance were in place.41–43 Furthermore, a study by Satoh et al.44 found that the presence of 
the 2,3-oxazolidinone ring in fact facilitates anomerization, with theoretical density functional 
theory (DFT) calculations showing that 2,3-oxazolidinone protected pyranosides undergo 
anomerization much more easily than their unprotected counterparts. Intriguing experimental 
results obtained by Vinod et al.45 while cleaving a 4,6-O-benzylidene protecting group using 
NaBH3CN, HCl/Et2O show that it is possible to partially anomerize the 2,3-oxazolidinone using a 
Brønsted acid. Ollson et al.46 were able to anomerize a 2,3-oxazolidinone substrate with AgOTf, 
while an extensive study carried out by Ito et al.44,47 showed that anomerization was possible 
using BF3.Et2O. In addition, various publications by Manabe and Ito studied the effect of the 
Lewis acid (BF3.OEt2, FeCl3, Cu(OTf)2 and Tf2NH),48 the solvent49 and various protecting 
groups47,48,50 on the degree of anomerization. 
 
This ease of anomerization of the 2,3-oxazolidinone protected pyranosides can be explained 
through their mode of cleavage. Since carbohydrates are asymmetrical acetals, cleavage can 
occur via two different pathways.51–56 Exocyclic cleavage (Scheme 3.5A) is the more commonly 
encountered mechanism in carbohydrate chemistry and involves the cleavage of the bond 
between the exocyclic oxygen and the anomeric carbon atom (bond highlighted in red) to form 
the cyclic oxocarbenium ion. This is attacked by a nucleophile from either the α- or β-face 
depending on steric (β-destabilisation), stereoelectronic (anomeric effect) and neighbouring 
group participation (anchimeric) effects.57 On the other hand, endocyclic cleavage (Scheme 
3.5B) occurs when the bond between the ring oxygen and anomeric carbon breaks (bond 
highlighted in red) to yield an acyclic intermediate. This is less commonly postulated in 
carbohydrate chemistry despite various authors providing extensive experimental evidence for 
it,53,58–62 and being the proposed mechanism among aldofuranosides.63–65 The acyclic 
intermediate can then recyclise (blue mechanism), or the exocyclic oxocarbenium ion can be 







Scheme 3.5: Exocyclic vs. endocyclic cleavage of a pyranoside. 
 
 
Manabe and Ito44,48,50,66 have comprehensively shown that 2,3-oxazolidinone protected β-
glycosides undergo endocyclic cleavage to reform the α-anomer. This is illustrated in Scheme 
3.6 where the β-anomer (A) when treated with acid forms the charged species B. The C1-C2 
bond can rotate (C) and the ring can re-form in the more thermodynamically stable α-anomeric 
form (D). Both B and C can be reduced to form E, or intercepted by a nucleophile to form F. 
Various adducts of the acyclic cations produced via endocyclic cleavage were obtained 
experimentally by Manabe et al.50 after treatment of their 2,3-oxazolidinone substrates with 
NaBH3CN, HCl/THF or BF3.OEt2, Et3SiH. In addition, intra- and intermolecular Friedel-Crafts 
products were obtained upon treatment with only BF3.OEt2, proving that the 2,3-oxazolidinone 
compounds undergo endocyclic cleavage.50 In this early report, they postulated that this was 
due to the locked 4C1 conformer that the bicyclic structure adopts, which together with the β-
configuration makes exocyclic cleavage unfavourable stereoelectronically. Various early 
publications also report this finding, where β-anomers undergo predominantly endocyclic 
cleavage.59–61 Later studies by Manabe et al. however showed via QM calculations that the 
locked 4C1 conformer is in fact a secondary factor, with the inner ring strain caused by the 







Scheme 3.6: Anomerization of a β-2,3-oxazolidinone protected pyranoside. Pathway proceeds via 
endocyclic cleavage, which yields the α-anomer D. E or F can also be formed.  
 
 
Careful consideration was therefore given to the most appropriate stage in the synthesis for the 
anomerization to be attempted. Firstly, it was noted that attempted anomerization at a later 
stage in the synthesis, for example of either compound 2.55 or 3.14 (Scheme 3.7) under Lewis 
acid conditions could potentially be in competition with a Ferrier Type II rearrangement,67,68 
forming the rearranged cyclohexanone 3.17. This has been reported by various authors69–72 and 




Scheme 3.7: Treatment of either 2.55 or 3.14 with a Lewis acid would undergo Ferrier Type II 
rearrangement to give the cyclohexanone 3.17. 
 
 
Secondly, in considering the role of protecting groups, it was noted that higher ratios of the α-
anomer were obtained with N-acetylated rather than N-benzylated derivatives.47,48,50 Based on 
these observations, and the absence of reports in the literature of anomerizing an unprotected 
2,3-oxazolidinone, it was decided to first prepare the fully acetylated derivative 3.18 from 2.47 
(Scheme 3.8).‡,74 In the first attempt at anomerization, the fully acetylated sugar (3.18) was 
treated with 0.02 eq. of AgOTf for 20 hours, but this gave a mixture of α- and β-anomers. 
However, treatment of 3.20 with 2.5 eq. of SnCl4 for 25 hours gave exclusively the α-anomer 
                                                          
‡ At the time of writing, a publication by Manabe et al. showed that anomerization on an unprotected 2,3-





(3.19) in an 89% yield. Confirmation of the anomeric stereochemistry was gained from the 1H 
NMR spectrum (Figure 3.8) where the J-coupling constant for the anomeric proton in the β-
anomer (3.18) is 8.3 Hz, while the signal for the anomeric proton in the α-anomer (3.19) is 




Scheme 3.8: Anomerization of 3.18 followed by de-O-acetylation of 3.19. Reagents and conditions: (i) 
AcCl, DIPEA, DCM, 0°C, 45 mins, 96% (ii) AgOTf, DCM, r.t., 20 hrs, 77% (9:1 α/β mixture from NMR) (iii) 




Figure 3.8: 1H NMR spectra of α-anomer 3.19 (top) and the β-anomer 3.18 (bottom), where the clear 
difference in J-coupling and chemical shift is indicative that anomerization has taken place.  
 
 
Having efficiently achieved the anomerization, the next step required the chemoselective de-O-
acetylation of 3.19. In Ch. 2.9, the chemoselective cleavage of the 2,3-oxazolidinone ring was 
explored, whereas in this case it was hoped that under selected basic conditions only de-O-





for later differentiation of O-3 and O-4. To this end, a variety of deacetylation conditions were 
explored (Table 3.1). 
 




Entry Reagents & conditions Product Yield 
1 4.62 M  NaOMe (2 drops), MeOH, 0°C to r.t., 30 mins. 3.21 55% 
2 4.62 M NaOMe (0.4 eq.), MeOH, 0°C to r.t., 30 mins. 3.22, 3.23 & 3.24 
22 mg recovered 
from 68 mg SM 
3 K2CO3, MeOH, H2O, 10 mins, r.t. 3.22, 3.23 & 3.24 
36 mg recovered 
from 100 mg SM 
4 LiOH, H2O2, THF, H2O, 0°C, 2 hrs. Degraded - 
5 LiOH, H2O2, THF, H2O, -40°C, 5 mins. Multiple products - 
6 NaOH (2M), THF, 0°C to r.t., 2 hrs. Degraded - 
7 HCl, acetone, H2O, 65°C, 4.5 hrs, r.t., 18 hrs. 3.20 29% 
8 HCl, acetone, H2O, 65°C, 4 hrs. 3.20 49% 
 
 
Initial attempts using NaOMe (entry 1) surprisingly achieved chemoselective cleavage of the N-
acetate to give the 4,6-di-O-acetate (3.21) (Table 3.1). Another attempt in which the number of 
equivalents of NaOMe was increased (entry 2) or where K2CO3 (entry 3) was used, gave 
interesting results where the formation of a single product with lower Rf was evident from TLC. 
Upon purification, the 1H NMR (Appendix 2) revealed that it was in fact a complex mixture of 
compounds with HRMS providing evidence for the presence of compounds 3.22, 3.23 and 3.24. 





previous experimental results (Ch. 2.9). However, the formation of 3.24 is unexpected, as 
thiophenol, as well as acidic conditions would be required to give the exo- and endocyclic 
cleaved products in order to form the di-thioacetyl.‡ So next, LiOH and H2O2 was used (entries 4 
and 5). Wei et al.76 found these conditions to give the highest chemoselectivity when 
hydrolysing their N-acetyl-2,3-oxazolidinone. Unfortunately, entry 4 conditions led to 
degradation, while entry 5 conditions gave multiple product spots as seen from TLC. Following 
this, NaOH in THF (entry 6) was used and again led to degradation of the starting material. 
Finally, since base hydrolysis yielded futile results, acid was instead used in an attempt to 
remove the O-acetates (entry 7, Table 3.1) as described by Khiar et al.77 This yielded the 
desired de-O-acetylated product (3.20), albeit in a low yield with evidence for formation of 
other unidentified minor products (as seen per TLC), possibly resulting from hydrolysis of the 
phenylthioglycoside.# However, repetition using less HCl over a shorter duration (entry 8) gave 
a reasonable yield of 49% which was suitable for continuation of the synthesis.  
 
Given the mixed success of the foregoing experiments, anomerization of the un-protected 2,3-
oxazolidinone was investigated (Scheme 3.9). This would circumvent the problems 
encountered above. Unfortunately, when 2.47 was treated with SnCl4 at r.t for 20 hours with 
monitoring by TLC, multiple products had formed. Attempts to repeat this reaction at lower 
temperatures with alternative Lewis acids and solvents could have been investigated, however, 
a recent publication by Manabe and Ito78 reported that the N-substituent on the oxazolidinone 




Scheme 3.9: Attempts at anomerization of the unprotected 2,3-oxazolidinone. Reagents and conditions: 
(i) SnCl4, DCM, r.t., 20 hrs. 
 
 
In light of this, the next step required conversion of 3.20 to the 6-iodo derivative in order to set 
up the elimination to give the 5-enopyranoside. As before, a sequence of regioselective 
tosylation (2.25) (Scheme 3.10), followed by substitution by the iodide gave 3.26. Treatment 
                                                          
‡ The Amberlite used to neutralize the reaction mixture could however have been too acidic and 
responsible for this. The low mass recovery suggests that degradation also occurred and could possibly 
be the source of thiophenol. 





of 3.26 with standard benzylation conditions either at room temperature or at 0°C using 2-3 
equivalents of NaH produced a single less polar product.79 However, there was no spectroscopic 
evidence for the formation of the 5-enopyranoside (3.27), with the 1H NMR spectrum (Figure 
3.9) lacking the distinctive signals for the exocyclic alkene.# The COSY spectrum showed a 
distinct crosspeak between H-5 and H-6, with the H-6’s appearing as a doublet and a doublet of 
doublets respectively (normally both appear as dd), indicating potential conformational 
restriction at this carbon. Further evidence from the NMR spectra as well as HRMS ([M+H]+ of 
386.1428 m/z) pointed towards the proposed 3,6-anhydro sugar 3.28 having formed instead of 
the expected 5-enopyranoside 3.27. Compound 3.28 is assumed to adopt the 1C4 conformation 
due to the 3,6-bridge, where evidence for this is seen in the small equatorial-equatorial 
couplings between H-3, H-4 and H-5 as opposed to the larger J-values (axial-axial) which would 
be seen if it was in the 4C1 conformer.  
 
The formation of 3.28 can be accounted for by a sequence involving initial protection at O-4, 
followed by hydrolysis of the 2,3-oxazolidinone and subsequent intramolecular SN2 substitution 
at C-6 by O-3 to give the 3,6-anhydro sugar.‡ The formation of 3,6-anhydro rings is not 




Scheme 3.10: Attempts to obtain the 5-enopyranoside 3.27. Reagents and conditions: (i) 10.2M HCl, 
acetone/H2O (2:1), 65°C for 4.5 hrs, 49% (ii) p-TsCl (1.2 eq.), pyridine, 0°C 3 hrs, r.t., 1.5 hrs, 77% (iii) NaI, 
2-butanone, reflux, 17 hrs, 67% (iv) BnBr, NaH, DMF, r.t., 6 hrs, 65% (v) BnBr, NaH, DMF, 0°C, 2 hrs, r.t., 6 
hrs, 49% 
 
                                                          
# Interestingly, H-1 of 3.20 and 3.26 appear as doublet of doublets.  







Figure 3.9: 1H NMR of the 3,6-anydro sugar 3.28. 
 
 
While this was not the desired result, it presented the intriguing outcome where the 2,3-
oxazolidinone is cleaved under these conditions. At first, it was suspected that H2O may have 
been present in the reaction mixture, but the reaction was repeated using freshly activated 3Å 
powdered molecular sieves and under these conditions the same result was obtained.  
Dimethylamine could potentially be responsible for this, since it can form through the 
disproportionation reaction of DMF,84 and is also known to exist in old bottles of DMF.85 
However, the most likely source is probably the dimethylamide anion which forms in situ from 
NaH and DMF, and could be responsible for SNAc attack at the 2,3-oxazolidinone carbonyl group. 
Evidence for this has been proposed by Hesek et al.86 who isolated the N-dibenzyl-dimethyl 
bromide salt (C) (Scheme 3.11), the formation of which can only be explained by the reaction 
between NaH and DMF, giving either the sodium (dimethylamino)methanolate (A) or 
dimethylamide anion (B) which reacts with the excess BnBr present. With this, the sodium 









Scheme 3.11: Proposal  by Hesek et al.86 for formation of C which can form either via generation of the 
sodium (dimethylamino)methanolate (A) or the dimethylamide anion (B).  
 
 
In order to probe whether this is in fact the case, these reactions could be repeated by first 
protecting the 4-O-position as the silyl ether or another non-base sensitive protecting group and 
treating this derivative with NaH in DMF or alternatively repeating this reaction with NaH in 
anhydrous THF, and then compare the results. However, time did not permit for any of these 
reactions to be explored further.  
 
The next intriguing result from this reaction is that complete chemoselectivity in the 2,3-
oxazolidinone cleavage is observed. As has been stated earlier, poor chemoselectivity has 
previously been reported for this attempted transformation,76,87,88 and our results may 
contribute to the development of a viable and efficient alternative for this conversion. In this 
instance, the chemoselectivity can potentially be explained (as in Ch. 2.9) by the chelation of the 
Lewis acidic Na+ with the carbonyl carbon of the N-acetyl group and the anomeric sulfur atom. 
However, the effect of the anomeric substituent and the configuration will also need to be 
evaluated.  
 
By this stage, it was apparent that although the anomerization to the α-thioglycoside could be 
achieved with high efficiency, the resultant α-anomer 3.26 significantly impedes the possible E1 
or E2 elimination reaction at C-5/6. This may potentially be based on steric interactions from 
the α-thioglycoside with the trans-2,3-oxazolidinone in place. Alternatively, the increased ring 
strain associated with the elimination product, where an sp2 centre at C-5 of the 5-
enopyranoside 3.27 is formed, and the combination of a fused oxazolidinone ring at C-2/3 as 





points to conditions of the reaction and/or the reactivity of the 6-iodo derivative 3.26 not 
favouring elimination at C-5 to form the 5-enopyranoside 3.27.  
 
3.4  Summary 
Different approaches to the preparation of the AltNAcA derivative were investigated. In the first 
instance, starting from a furanolactone offered access to the 5-O-benzoyl furanolactone 3.1 
(Scheme 3.12) and the subsequent L-iduronic acid derivative 3.2 as reported by Ke and 
Whitefield.2 This allowed for an interesting and moderately efficient route to obtaining the 
AltNAcA derivative. However, in the key base-catalysed methanolysis of the lactone 3.1, it 
proved difficult to control the migration of the benzoate from O-5 to O-3, and the 5-benzoate 
(3.8A) and 3-benzoate (3.8B) were obtained as an almost inseparable mixture. When a 
sufficient quantity of 3.8B had accumulated following careful separation of the benzoates, the 
subsequent acid hydrolysis step yielded an inseparable mixture of anomers of the desired 
pyranose 3.2 and the undesired furanose 3.9. In the light of these inefficiencies, this route was 
not pursued further.  
 
 
Scheme 3.12: Summary of synthesis via a fused furanolactone sugar. 
 
 
The idea of synthesising both sugars from an intermediate in the FucNAc4N synthesis was then 
explored. They key challenge here was to form a 5-enopyranoside derivative, which could be 
transformed to the L-sugar via a selective hydroboration-oxidation. Conversion of the 
oxazolidinone-protected-6-iodo derivative 2.55 to the 5-enopyranoside 3.14 proceeded 
smoothly, but upon hydroboration/oxidation yielded the D-sugar 3.16 only (Scheme 3.13). 
From modelling and a survey of the literature,27,29,38,39 it was postulated that the anomeric 





borane complex, and this led to synthesis of an α-anomer. Serendipitously, the presence of the 
2,3-oxazolidinone facilitated the efficient anomerization of the β-sulfide to form α-D-
glucopyranoside 3.19, presumably via initial endocyclic cleavage of the anomeric thioacetal. 
Chemoselective hydrolysis to the diol 3.20 was achieved in a moderate yield, and subsequent 
transformation to the 6-iodo derivative 3.26 was successful. This was then set up for the one-
pot benzylation at O-4 and elimination step. This however was not achieved, with the 3,6-
anhydro sugar 3.28 obtained instead, through the premature cleavage of the 2,3-oxazolidinone 
under these conditions. It was hoped that having an α-5-enopyranoside in hand would 
predominantly yield an L-sugar after hydroboration/oxidation, and despite anomerization of 
the β-derivative 2.47 to give the α-D-glucopyranoside 3.19 working well, it now seemed that the 
presence of the α-sulfur substituent, along with the trans-fused-2,3-oxazolidinone in fact 











The idea of obtaining both sugars from a common intermediate is still worth pursuing. In order 
to obtain the AltNAcA derivative via the 2,3-oxazolidinone route, an alternative has been 
proposed (Scheme 3.14), which will attempt to deal with the limitations exposed from the 
reactions carried out.   
 
3.5 Proposed synthesis of the protected AltNAcA derivative  
Taking stock of the results presented, an alternative route to the AltNAcA derivative is proposed 
and deals with the premature hydrolysis of the 2,3-oxazolidinone ring, which in turn will 
prevent the formation of the 3,6-anhydro sugar and hopefully facilitate elimination at C-5 to 
form a 5-enopyranoside derivative. This is outlined in Scheme 3.14.  Firstly, the diol 3.20 could 
be converted to the 6-O-tosyl derivative as before and can immediately be protected as the silyl 
ether, giving 3.33. At this point, deliberate cleavage of the 2,3-oxazolidinone with LiCl and LiOH, 
followed by 3-O-protection with BnBr can give 3.34, which will block any 3,6-anhydro 
formation later. The cleavage of the 2,3-oxazolidinone and 3-protection can also potentially be 
done in one pot with an excess of BnBr and NaH in DMF as per our observations. Following this, 
halogen substitution to give 3.35 can be carried out as before, which with the reduced steric 
interactions and ring strain will hopefully allow for the E2 elimination reaction to take place 
giving 3.36. After hydroboration/oxidation the L-sugar 3.37 should be formed in majority. 
Subsequent oxidation to the acid and methylation to give the L-ido derivative 3.38 then sets the 
stage for C-4 inversion via triflation followed by a benzoate or nitrite-mediated substitution to 














The proposed synthesis would allow both the FucNAc4n derivatives (A’ and A’’) and AltNAcA 
derivatives (B’ and B’’) to be obtained from a common intermediate.  
 
The use of the thiazoline 2.17 (Scheme 2.10, Ch. 2.4) could be investigated as a suitable 
starting point, as the conversion to the 2-acetamido-1-thiol 2.28 gives the desired α-
configuration, eliminating the need for any anomerization reactions. However, since the yields 
for the synthesis of 2.28 and 2.29 were low, this would not be as efficient.  
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The aim of the project was to synthesize derivatives of the two monomers, 2-acetamido-4-
amino-2,4,6-trideoxy-β-D-galactopyranose  (FucNAc4N/AAT) and  2-acetamido-2-deoxy-α-L-
altruronic acid  (AltNAcA) found in the S. sonnei repeating unit. These were required in the 
suitably protected forms of A’, A’’, B’, B’’ (see Scheme 1.21), which could then be coupled to 
give the desired disaccharides AB and BA. 
 
Synthetic derivatives of these unusual monosaccharides can be obtained from a variety of 
starting materials, some more readily available than others. Although brief attempts were made 
to modify derivatives of D-glucose, this project focused mainly on the use of D-glucosamine or its 
simple derivatives, where the amine functionality at C-2 is already installed with the desired 
stereochemistry.  As is common to any modification of a carbohydrate starting material, the task 
required the selection or development of protection/deprotection strategies which effectively 
exploited structural and stereoelectronic features of the sugar template to achieve the required 
stereo-, chemo- and regioselective modifications, in the most efficient way possible. Despite 
many years of progress in the field of carbohydrate synthesis, the ability to obtain a 
differentially protected sugar through regioselective modifications generally remains difficult to 
achieve. In addition, the effect that each protecting group has on the overall reactivity of the 
monosaccharide building block is often unpredictable and poorly understood, as seen in many 
instances throughout this study. A further challenge was the difficulties often encountered in 
repeating literature procedures: a welcome development in recent years in this regard is the 
emergence of the series, Carbohydrate Chemistry: Proven Synthetic Methods, which “addresses 
concerns to chemists regarding irreproducibility of synthetic protocols, lack of data in many 
chemical communications, and inflated yields, which has recently become a serious, widely 
recognized problem”.1 
 
The first attempt to obtain the FucNAc4N derivative via the 1,6-anhydro-2-azido-2,4-dideoxy-4-
O-tosyl-β-D-glucopyranose 2.32 was abandoned on account of difficulties encountered in its 
formation and therefore any further efficient transformations. This led to evaluation of a route 
via the cyclohexyl 2-acetamido-2-deoxy-1-thio-α-D-glucopyranoside 2.18, an intermediate 
readily available according to a procedure of Knapp and co-workers.3–7 Subsequent access to 
either of the regioselectively protected 6-deoxy sugars 2.20 or 2.22, could be achieved either 
via a seemingly straightforward regioselective protection or via manipulations of a 4,6-O-




 intermediate, 2-acetamido-2-deoxy-3,4,6-tri-O-acetyl-1-thio-α-D-glucopyranose (2.31) and the  
cyclohexyl 2-acetamido-2-deoxy-1-thio-3,4,6-tri-O-acetyl-α-D-glucopyranoside (2.32) were low  
yielding and  unreproducible on a large scale.  Despite the steps involving the manipulation of 
the 4,6-O-benzylidene acetal showing potential as practicable routes to obtaining the FucNAc4N 
derivative, this route was not pursued any further. The final, most successful approach involved 
efficient preparation, even on a large scale, of the 2,3-oxazolidinone 2.47 using procedures first 
described by Benakli et al.8 This achieved a successful circumvention of the previously 
encountered problems of differentiating O-3 and O-4. From this intermediate, the desired 
derivative of FucNAc4N (2.50, A’’) was obtained over 10 steps in an overall yield of 17% from 
the commercially available 2-acetamido-1,3,4,6-tetra-O-acetyl-β-D-glucopyranose. In many 
respects, this route is more viable than those previously published and does not yield the 
diastereomeric mixtures encountered in some of the more efficient published routes.  However, 
the effectiveness of this, or closely related derivatives as either a glycosyl donor or acceptor in 
the preparation of the disaccharide remains to be evaluated. 
 
The synthesis of the AltNAcA derivative was also attempted by several approaches. In the first 
instance, the key inversion at C-5 of the benzoyl furanolactone (3.1) was achieved, but 
difficulties were encountered with the subsequent cleavage of the lactone, opening of the 
furanose ring and equilibration to the desired pyranose. With these early indications that this 
would not be a practical route to the desired target, attention turned to the possibility of 
synthesising both the FucNAc4N and AltNAcA derivative from a common intermediate, the 6-
iodo-derivative 2.55. The elimination of the iodide to form the 5-ene was achieved, but 
hydroboration/oxidation led exclusively to the undesired D-sugar (3.16). It was suspected that 
the anomeric configuration (β- in 3.14) seriously restricted the desired β-face approach of the 
borane complex, and this led to a successful preparation of the required 6-iodo-α-thioglycoside 
by facile anomerization of a β-thioglycoside 3.26 in order to evaluate its elimination to the 
corresponding 5-ene and subsequent hydroboration. However, base-mediated elimination to 
the 5-enopyranoside was not possible, and attempts to achieve this simply resulted in cleavage 
of the 2,3-oxazolidinone, followed by formation of the 3,6-anhydro sugar 3.28. It appears that 
formation of the 5-ene is significantly disfavoured in this highly strained trans-fused ring 
system with the bulky, α-oriented anomeric substituent. It became clear from this that the 
pursuit of this strategy for inversion of configuration at C-5 would require an early removal of 






Considerations of all of these results and experiences led to the proposal, for future 
investigation, of an alternative route to both sugars, retaining the attractive option of utilizing a 
common intermediate, as outlined in Ch. 3.5 and summarized in Scheme 4.1. The upper part of 
this scheme summarizes the successful synthesis of the FucNAc4N derivative 2.50 from the key 
intermediate 2.47. The suggested alternative route to the AltNAcA derivative is then illustrated 
in the lower part of the scheme. The possibility of efficient formation of the α-thioglycoside 3.20 
has been demonstrated, and from this it should be possible to form differentially protected 6-
iodo-intermediate 3.35 over steps 1 – 6 which is based on chemistry already well established 
from this study. The key difference in this strategy is in step 3, involving the deliberate, early 
cleavage of the 2,3-oxazolidinone using methods previously employed, followed by protection at 
O-3. The presence of the tosyloxy group at C-6 would prevent any intramolecular substitution 
from occurring. Following this, elimination in step 6 should proceed smoothly, as the steric 
demands of the α-thiophenol substituent and 2,3-oxazolidinone ring have been removed, to 
yield the 5-enopyranoside 3.36. Hydroboration/oxidation could then be attempted in step 7 to 
yield the desired L-sugar 3.37 as the major product, based on literature precedent and our own 
observations. Subsequent steps (8 – 11) would  be directed towards achieving the desired 
oxidation at C-6 and inversion of configuration at C-4, yielding fully protected derivative 3.39 as 










While the route to AltNAcA outlined in Scheme 4.1  is longer, requiring a further 14 steps from 
2.47, the chemistry for the majority of these reactions is either acknowledged as standard in the 
literature, or has been established during this study. It also has the advantage of avoiding 
starting from the expensive L-sugar,9,10 and the need to install the 2-acetamido functionality. In 
addition, it incorporates the novel and elegant prospect of preparing both sugars found in the S. 
sonnei repeating unit from a common precursor.  
 
In summary, this work has highlighted the difficulties in differentiating hydroxyl groups of 




not worked, showing that despite literature precedent, this still remains a non-trivial task. This 
work has also revealed the poorly understood effects that protecting groups have on the 
conformation and stereoelectronics of the ring, and therefore the overall reactivity, which in 
this case has made certain transformations difficult to achieve.  In addition, configurational 
influences of various functional groups have impacted certain conversions, the effect of which is 
not predictable, nor initially obvious. More broadly, this leaves the synthetic carbohydrate 
chemist with the only conclusion that can in fact be drawn – firstly, that serendipity plays a 
minor part, and secondly, that a great deal of work still needs to be carried out in order to gain a 
better understanding in the exciting and unpredictable field of synthetic carbohydrate 
chemistry.   
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5.1 General Experimental 
All commercial chemicals were purchased from Merck (South Africa) or Sigma-Aldrich except 
for the 2-acetamido-1,3,4,6-tetra-O-acetyl-2-deoxy-β-D-glucopyranose and 1,2-O-
isopropylidene-β-D-glucofuranurono-6,3-lactone which were purchased from Carbosynth. 
Acetonitrile, DCM, isopropyl acetate and toluene were freshly distilled from calcium hydride, 
CDCl3 was dried with freshly activated 3Å molecular sieves (beads) and anhydrous DMF, MeOH, 
THF and pyridine were purchased from Sigma Aldrich. Microwave reactions were carried out 
using a CEM Discoverer microwave (μλ=150 W, P = 17.2 bar, mixing time = 15 minutes). 
Hydrogenation reactions with reduced pressure were carried out using a Parr Hydrogenator 
3911. Molecular sieves were activated in a 400°C furnace for 3 hours prior reaction start time. 
Reactions were monitored by thin layer chromatography (TLC) using pre-coated 60 F254 silica 
gel alumina plates (Merck) and were visualised under ultraviolet light or by staining with 
acidicfied p-anisaldehyde solution (1:2:37 p-anisaldehyde/H2SO4 (conc)/EtOH) or acidified 
ceric ammonium sulphate solution (5g CAS/50 mL EtOH/50 mL 2M H2SO4) followed by charring 
with a heat gun. Silica gel chromatography was performed using Merck silica gel 60, 70–230 
mesh for gravity columns. Automated flash chromatography was performed on a Biotage Isolera 
system, using either Biotage prepacked SNAP columns, or self-packed Biotage SNAP columns 
with gravity silica. Purification using preparative TLC was carried out using Analtech glass 
backed (20x20 cm, 1.5 mm thickness) plates. 1H, 13C and 2D NMR spectra were recorded on a 
Varian Mercury 300 MHz Spectrometer, a Varian Unity 400 MHz Spectrometer or a Bruker 
Advance III with Ultra Shield 400 Plus magnet and all spectra were recorded at 303K. All 
spectra were recorded in deuterated solvent as indicated and referenced with respect to 
deuterated solvent peaks: CDCl3, δ 7.26 ppm for 1H and 77.16 ppm for 13C; (CD3)2CO, δ 2.05 ppm 
for 1H and 29.84 ppm for 13C; (CD3)2SO, δ 2.50 ppm for 1H and 39.52 ppm for 13C; CD3OD, δ 3.31 
ppm for 1H and 49.00 ppm for 13C; D2O, δ 4.76 ppm for 1H. Assignments were aided by 1H–1H 
and 1H–13C correlation experiments. HRMS data were obtained using a Waters Synapt G2 with 
direct injection (1 μl) into a stream of 80% acetonitrile, 0.1% formic acid using a Waters UPLC 
at flow rate of 0.1 mL/min. Source: Electrospray positive/negative, Capillary voltage 3 kV, Cone 
Voltage 25 V. Melting points were determined on a Reichert-Jung Thermovar hot-stage 
microscope and are uncorrected. Infrared spectra were recorded on a Perkin-Elmer Spectrum 
100 FT-IR spectrometer in the range 4000 – 500 cm-1 using thin films of compound on NaCl 
disks. All care was taken between carrying out reactions to ensure compounds did not degrade 
and were evaporated to dryness and stored in a -20°C freezer until needed. 
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5.2 Chapter 2 Experimental Procedures 
1,6-anhydro-2-deoxy-2-iodo-β-D-glucopyranose (2.8)1 
 
A solution of tri-O-acetyl-D-glucal (5.18 g, 19.03 mmol, 1 eq.) in MeOH/H2O/Et3N (46.2 mL) 
(10:10:1) was stirred for half an hour at room temperature, then concentrated by repeated 
evaporations with EtOH and kept overnight under vacuum in the presence of P2O5. The syrupy 
D-glucal was treated with bis(tributyltin)oxide (7.76 mL,15.22 mmol, 0.8 eq.) and freshly 
activated 3Å powdered molecular sieves in refluxing dry acetonitrile (35 mL) for 3 hours under 
argon. The reaction mixture was cooled to 5 °C and iodine (7.25 g, 28.55 mmol, 1.5 eq.) was 
added in one portion. The dark brown mixture was stirred for 15 minutes at 5 °C, and then at r.t. 
for 2 hours. The reaction mixture was filtered through celite, concentrated and then stirred with 
sat. aq. Na2S2O3 and hexane (40 mL) for 3 hrs at r.t. This was then transferred to a separating 
funnel and washed with EtOAc (3 x 60 mL) and combined organic fractions were dried over 
Na2SO4, concentrated and purified using silica gel chromatography (1:1 hexane/EtOAc) to yield 
4.39 g (85%) of 2.8 as a clear oil, which was recrystallized to give off-white crystals. Rf = 0.45 
(1:1 toluene/acetone); mp 102 – 104°C;  1H NMR (300 MHz, (CD3)2SO) δ 5.62 (s, 1H), 5.42 (d, J = 
4.3 Hz, 1H), 5.07 (d, J = 4.3 Hz, 1H), 4.48 – 4.38 (m, 1H), 4.02 (dd, J = 7.1, 1.2 Hz, 1H), 3.99 – 3.89 
(m, 1H), 3.87 – 3.79 (m, 1H), 3.53 (dd, J = 7.0, 5.8 Hz, 1H), 3.51 – 3.42 (m, 1H); 13C NMR (101 





The 1,6-anhydro-2-deoxy-2-iodo-β-D-glucopyranose (2.8) (1.52 g, 5.61 mmol, 1 eq.) and 
NaHCO3 (1.08 g, 12.90 mmol, 2.3 eq.) in DMF/H2O (1.35 mL) (10:3) was heated to 120 °C for 4 
hrs. The reaction mixture was cooled, concentrated and purified using silica gel 
chromatography (0–10% MeOH/EtOAc) to yield 0.69 g (85%) of 2.1 as a light yellow oil. Rf = 
0.71 (9.5:0.5, EtOAc/MeOH);  1H NMR (400 MHz, CDCl3) δ 5.68 (d, J = 3.1 Hz, 1H), 4.46 – 4.38 (m, 
1H), 3.91 (s, 1H), 3.77 (dd, J = 7.3, 2.2 Hz, 1H), 3.77 – 3.69 (m, 1H), 3.47 – 3.40 (m, 1H), 3.14 
(ddd, J = 3.7, 1.6, 0.8 Hz, 1H), 2.42 (bs, 1H); 13C NMR (75 MHz, CDCl3) δ 97.82, 74.32, 67.22, 
65.64, 54.35, 49.39. NMR values agree with published values.2 
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First attempt:3  
The di-anhydro sugar (2.1) (95 mg, 0.66 mmol, 1 eq.) was dissolved in MeOH/H2O (2 mL) (9:1) 
and to this the NaN3 (0.43 g, 6.59 mmol, 10 eq.) and NH4Cl (0.26 g, 4.94 mmol, 0.75 eq.) was 
added. The reaction mixture was refluxed overnight after which time TLC indicated multiple 
products had formed with SM still remaining.  
 
Second attempt:  
The di-anhydro sugar (2.1) (25 mg, 0.18 mmol, 1 eq.) and NaN3 (0.11 g, 1.80 mmol, 10 eq.) in 
DMF/H2O (1.1 mL) (1:0.1) was heated at 80°C  for 9 hrs after which time TLC indicated that no 




The di-anhydro sugar (2.1) (0.69 g, 4.82 mmol, 1 eq.) was dissolved in pyridine (1.55 mL) and to 
this the acetic anhydride (1.14 mL) was added. The reaction mixture was stirred overnight at 
r.t., then cooled to 5°C, quenched with MeOH, diluted with DCM and washed with 5% HCl 
solution. The aqueous layer was washed with DCM (3 x 20 mL), combined organic fractions 
were dried over Na2SO4, concentrated and purified using silica gel chromatography (1:1 
hexane/EtOAc) to yield 0.75 g (84%) of 2.9 as a white solid. Rf = 0.35 (1:1 hexane/EtOAc); mp 
64 – 66°C; 1H NMR (400 MHz, CDCl3) δ 5.73 (d, J = 3.1 Hz, 1H), 4.96 (s, 1H), 4.49 – 4.41 (m, 1H), 
3.80 (dd, J = 7.4, 2.0 Hz, 1H), 3.74 (t, J = 7.1 Hz, 1H), 3.47 (td, J = 3.4, 0.6 Hz, 1H), 3.15 – 3.10 (m, 
1H), 2.20 – 2.13 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 5.72 (d, J = 3.2 Hz, 1H), 4.95 (s, 1H), 4.47 – 
4.40 (m, 1H), 3.79 (dd, J = 7.5, 2.0 Hz, 1H), 3.73 (dd, J = 14.1, 0.5 Hz, 1H), 3.48 – 3.43 (m, 1H), 
3.15 – 3.08 (m, 1H), 2.16 (d, J = 0.6 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 170.19, 97.72, 71.54, 










The acetylated di-anhydro sugar (2.9) (0.41 g, 2.18 mmol, 1 eq.) and NaN3 (0.71 g, 10.91 mmol, 
5 eq.) in DMF/H2O (7 mL) (9:1) was heated to 110°C and left to stir for 9 hrs. The reaction 
mixture was then diluted with EtOAc and sat. aq. NH4Cl, transferred to a separating funnel and 
washed with EtOAc (3 x 30 mL), combined organic fractions were dried over Na2SO4, 
concentrated and purified using silica gel chromatography (1:1 hexane/EtOAc) to yield 0.27 g 
(66%) of 2.2 as a white solid. Rf = 0.2 (7:3 hexane/EtOAc); mp 114 – 116°C; 1H NMR (300 MHz, 
CDCl3) δ 5.51 (t, J = 1.7 Hz, 1H), 4.58 (d, J = 5.5 Hz, 1H), 4.21 (d, J = 7.4 Hz, 1H), 3.89 (bs, 1H), 3.80 
(dd, J = 7.7, 5.4 Hz, 1H), 3.66 (bs, 1H), 3.50 (bs, 1H), 2.58 (bs, 1H), 2.45 (bs, 1H); 13C NMR (75 
MHz, (CD3)2SO) δ 99.82, 76.37, 71.51, 70.94, 64.87, 62.37. NMR values agree with published 
values.2,3  
 
1,6-Anhydro-2-azido-2,4-dideoxy-4-O-tosyl-β-D-glucopyranose (2.3)  
 
First attempt:5 
The 1,6-anhydro-2-azido-2-deoxy-β-D-glucopyranose (2.2) (90 mg, 0.48 mmol, 1 eq.) and 
freshly recrystallized p-TsCl (0.10 g, 0.52 mmol, 1.1 eq.) in dry pyridine (1.3 mL) were stirred 
under argon at r.t. for 48 hrs after which time TLC indicated no reaction had taken place.  
 
Second attempt: 
The 1,6-anhydro-2-azido-2-deoxy-β-D-glucopyranose (2.2) (84 mg, 0.45 mmol, 1 eq.) and Et3N 
(63 μL, 0.45 mmol, 1 eq.) in dry DCM (1.5 mL) was cooled to 0°C under argon and to this freshly 
recrystallized p-TsCl (94 mg, 0.49 mmol, 1.1 eq.) was added. This was allowed to slowly warm 
to r.t. overnight after which time TLC indicated SM and a more non-polar product. The reaction 
mixture was then quenched with MeOH, diluted with DCM, washed with 5% HCl solution. The 
aqueous layer was washed with DCM (3 x 10 mL), combined organic fractions were dried over 
Na2SO4, concentrated and purified using silica gel chromatography (1:1 hexane/EtOAc) to yield 
20 mg (19%) of 2.3 as a clear oil and 41 mg of SM. Rf = 0.25 (1:1 hexane/EtOAc); 1H NMR (300 
MHz, CDCl3) δ 7.84 (d, J = 8.3 Hz, 2H), 7.37 (d, J = 7.9 Hz, 2H), 5.43 (bs, 1H), 4.62 (dd, J = 5.5, 1.1 
Hz, 1H), 4.43 (dd, J = 3.7, 1.5 Hz, 1H), 4.04 (dd, J = 7.9, 0.9 Hz, 1H), 3.89 (bs, 1H), 3.71 (dd, J = 7.9, 
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5.5 Hz, 1H), 3.25 (d, J = 3.7 Hz, 1H), 3.00 (s, 1H), 2.45 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 145.73 , 
133.15, 130.22, 128.00, 101.11, 79.63, 75.10, 70.38, 66.20, 62.64 , 21.81; IR (NaCl, dry film) νmax 
(cm-1): 3594 (O-H), 2926 (C-H Ar), 2920 (C-H aliphatic), 2108 (N3), 1599 (C=C). NMR values 
agree with published values;5 HRMS (ESI-TOF): [M+HCO2]- Calcd for C14H16N3O8S: 386.0658 
found: 386.0674.  
 
Third attempt:6 
The 1,6-anhydro-2-azido-2-deoxy-β-D-glucopyranose (2.2) (55 mg, 0.29 mmol, 1 eq.) and 
dibutyltin oxide (50 mg, 0.20 mmol, 0.7 eq.) in dry toluene (1.5 mL) was refluxed under argon 
for 3 hrs. The toluene was then removed under reduced pressure and the reaction mixture dried 
using a Schlenk line, dissolved in dry 1,4-dioxane (1.4 mL) under argon and cooled to 0°C. To 
this freshly recrystallized p-TsCl (0.12 g, 0.59 mmol, 1.2 eq.) and cat. amount of DMAP was 
added and left to stir at r.t. for 3 hrs after which time TLC indicated SM and the mono-tosylated 
product 2.3. After 18.5 hrs another 47 mg (0.5 eq.) of p-TsCl was added and left for a further 5.5 
hrs after which time TLC indicated that SM was still present. The reaction mixture was 
quenched with MeOH, concentrated and purified using silica gel chromatography (1:1 
hexane/EtOAc) to yield 26 mg (25%) of 2.3 as a clear oil and 22 mg of SM. Rf = 0.25 (1:1 
hexane/EtOAc). Characterized as above.  
 
(3aR,5R,6S,7R,7aR)-5-(Acetoxymethyl-6,7-diacetoxy-2-methyl-5,6,7,7a-tetrahydro-3aH-
pyrano[3,2-d]thiazole (2.17).  
 
Using Lawesson’s reagent:7,8 
The 2-acetamido-1,3,4,6-tetra-O-acetyl-2-deoxy-β-D-glucopyranose (1.61 g, 4.13 mmol, 1 eq. ), 
Lawesson’s reagent  (1.80 g, 4.46 mmol, 1.08 eq.) and freshly activated 3Å powdered molecular 
sieves in dry toluene (20 mL) was refluxed under argon for 4.5 hours after which time the 
reaction mixture turned a dark orange colour. This was allowed to cool to r.t., neutralized by the 
addition of 160 mg of sodium bicarbonate, filtered through celite and purified using silica gel 
chromatography (7:3 EtOAc/hexane) to yield 1.17 g (82%) of 2.17 as a yellow syrup. Rf = 0.58 
(9.5:0.5 DCM/MeOH); 1H NMR (300 MHz, CDCl3) δ 6.24 (d, J = 7.1 Hz, 1H), 5.56 (dd, J = 3.3, 1.9 
Hz, 1H), 4.95 (ddd, J = 9.5, 1.9, 1.1 Hz, 1H), 4.53 – 4.42 (m, 1H), 4.12 (app d, J = 4.4 Hz, 2H), 3.55 
(dt, J = 9.1, 4.4 Hz, 1H), 2.32 (d, J = 2.2 Hz, 3H), 2.13 (s, 3H), 2.08 (s, 3H), 2.07 (s, 3H); 13C NMR 
(101 MHz, CDCl3) δ 170.67, 169.67, 169.39, 168.20, 89.01, 76.91, 70.93, 69.51, 68.65, 63.45, 
21.05, 20.97, 20.83, 20.79. NMR values agree with published values.8  
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Using P4S10:9 
The freshly activated 3Å powdered molecular sieves and anhydrous isopropyl acetate (115 mL) 
were stirred in a dry round bottom flask under argon at r.t. for 10 mins. To this the phosphorus 
pentasulfide (8.57g, 19.28 mmols, 0.5 eq.) was added in two lots followed by the addition of 
hexamethyldisiloxane (29 mL) over 10 mins with vigorous stirring. The reaction mixture was 
then heated to 100°C for 10 mins. The round bottom flask was removed from the heat, cooled, 
and to this the 2-acetamido-1,3,4,6-tetra-O-acetyl-2-deoxy-β-D-glucopyranose (15.00 g, 38.55 
mmol, 1 eq.) was added in small portions. This was refluxed for 12 hours after which time the 
reaction mixture turned a dark orange colour and then stirred at r.t. for an additional 24 hours. 
The reaction mixture was filtered through celite, concentrated to approx. 50 mL, cooled to 0°C 
and  stirred with 5.3 M K2CO3 (20 mL) for 30 mins.  This was then transferred to a separating 
funnel, diluted with water (50 mL) and the aqueous layer was washed with EtOAc (4 x 60 mL) 
and combined organic fractions concentrated and purified using silica gel chromatography (7:3 
EtOAc/hexane) to yield 12.87 g (96%) of 2.17 as a yellow syrup. Rf = 0.58 (9.5:0.5 DCM/MeOH). 




A solution of (3aR,5R,6S,7R,7aR)-5-(Acetoxymethyl-6,7-diacetoxy-2-methyl-5,6,7,7a-tetrahydro-
3aH-pyrano[3,2-d]thiazole (GlcNAc-thiazoline triacetate) (2.17) (3.85 g, 11.12 mmol, 1 eq.) in 
degassed MeOH (40 mL) was cooled to 0°C and treated with trifluoroacetic acid (1.7 mL, 22.25 
mmol, 2 eq.) and water (1.7 mL). The reaction was stirred at 5°C overnight followed by stirring 
at r.t. for 4 hours. The reaction mixture was then concentrated and purified using flash silica gel 
chromatography (1:1 hexane/DCM) to yield 2.31 g (57%) of 2.31 as a colourless syrup. Rf  = 
0.36 (6:4 EtOAc/DCM); 1H NMR (400 MHz, CDCl3) δ 5.88 (d, J = 8.4 Hz, 1H), 5.78 (dd, J = 6.8, 5.4 
Hz, 1H), 5.16 – 5.07 (m, 2H), 4.53 – 4.44 (m, 1H), 4.33 – 4.29 (m, 1H), 4.26 (d, J = 12.3 Hz, 1H), 
4.12 (br d, J = 11.9 Hz, 1H), 2.10 (s, 3H), 2.05 (s, 3H), 2.05 (s, 3H), 1.97 (s, 3H); 13C NMR (101 
MHz, CDCl3) δ 171.8, 170.7, 170.1, 169.3, 79.0, 70.8, 69.2, 68.1, 61.9, 52.7, 23.2, 20.8, 20.7. NMR 
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Cyclohexyl 2-acetamido-2-deoxy-1-thio-3,4,6-tri-O-acetyl-α-D-glucopyranoside (2.32).10,11 
 
The 2-acetamido-2-deoxy-3,4,6-tri-O-acetyl-1-thio-α-D-glucopyranose (2.31) (3.58 g, 9.85 
mmol, 1 eq.) and activated 3Å powdered molecular sieves were dried using a Schlenk line and 
dissolved in dry and degassed cyclohexene (50 mL) under argon. To this was added drop wise 
(using a syringe pump) over 45 mins 1,1′-Azobis(cyclohexanecarbonitrile) (ACCN) (1.44 g, 5.91 
mmol, 0.6 eq.) in dry and degassed chloroform (10 mL) (co-solvent, 2:1 
cyclohexene/chloroform ratio) and the reaction mixture was stirred at 75°C for 3 hours after 
which time another 0.6 eq. of ACCN in chloroform (10 mL) was added drop wise over 45 mins. 
At 15 hours another 0.3 eq. of ACCN in chloroform (5 mL) was added drop wise over 45 mins to 
the reaction mixture and left to stir until TLC indicated complete conversion of the starting 
material (total 37 hours). The reaction mixture was filtered through celite, concentrated and 
purified using silica gel chromatography (6:4 DCM/EtOAc) to yield 2.19 g (66%) of 2.32 as a 
white solid. Rf  =  0.44 (6:4 DCM/EtOAc); 1H NMR (400 MHz, CDCl3) δ 5.71 (br d, J = 9.0 Hz, 1H), 
5.44 (d, J = 5.4 Hz, 1H), 5.06 (t, J = 9.5 Hz, 1H), 5.03 (t, J = 10 Hz, 1H), 4.47 (ddd, J = 10.7, 9.1, 5.4 
Hz, 1H), 4.36 (ddd, J = 9.7, 4.7, 2.3 Hz, 1H), 4.22 (dd, J = 12.3, 4.8 Hz, 1H), 4.05 (dd, J = 12.3, 2.3 
Hz, 1H), 2.80 (tt, J = 10.2, 3.6 Hz, 1H), 2.05 (s, 3H), 2.00 (s, 3H), 1.98 (s, 3H), 1.92 (s, 3H), 1.95 – 
1.91 (m, 2H), 1.76 – 1.67 (m, 2H), 1.60 – 1.52 (m, 1H), 1.45 – 1.19 (m, 5H); 13C NMR (101 MHz, 
CDCl3) δ 171.47, 170.66, 169.85, 169.35, 83.65, 71.66, 68.59, 68.44, 62.23, 52.43, 45.09, 34.32, 
33.77, 26.00, 25.91, 25.63, 23.30, 20.74, 20.65. NMR values agree with published values.10 
 





A solution of the cyclohexyl 2-acetamido-2-deoxy-1-thio-3,4,6-tri-O-acetyl-α-D-glucopyranoside 
(2.32) (2.91 g, 6.54 mmol, 1 eq.) in MeOH (30 mL) was cooled to 0°C and treated with NaOMe 
solution (25 wt. % in MeOH, 0.28 mL, 1.3085 mmol, 0.2 eq.). The reaction mixture was stirred at 
r.t. for 30 mins. This was then treated with DOWEX 50WX8–100 ion exchange resin, filtered, 
concentrated and purified using silica gel chromatography (9.5:0.5 DCM/MeOH) to yield 1.32 g 
(63%) of 2.18 as a white solid. Rf = 0.27 (9:1 DCM/MeOH); mp 207 – 209°C; 1H NMR (400 MHz, 
CD3OD) δ 5.52 (d, J = 5.3 Hz, 1H), 4.01 (dd, J = 11.0, 5.3 Hz, 1H), 3.97 (ddd, J = 9.6, 5.2, 2.0 Hz,1H), 
Chapter 5 
  129 
 
3.80 (dd, J = 12.0, 2.5 Hz, 1H), 3.72 (dd, J = 12.0, 5.2 Hz, 1H), 3.54 (dd, J = 11.0, 8.7 Hz, 1H), 3.36 
(dd, J = 9.8, 8.7 Hz, 1H), 2.87 – 2.76 (m, 1H), 1.97 (s, 3H), 2.02 – 1.92 (m, 2H), 1.80 – 1.69 (m, 2H), 
1.63 – 1.54 (m, 1H), 1.46 – 1.22 (m, 5H); 13C NMR (101 MHz, CD3OD) δ 173.56, 84.08, 74.36, 
72.84, 72.63, 62.62, 55.93, 44.79, 35.30, 34.95, 27.04, 26.86, 26.81, 22.57. NMR values agree 
with published values.12 
 
Cyclohexyl 2-acetamido-6-bromo-2,6-dideoxy-1-thio-α-D-glucopyranoside (2.33).13 
 
First attempt:  
A solution of the cyclohexyl 2-acetamido-2-deoxy-1-thio-α-D-glucopyranoside (2.18) (85 mg, 
0.27 mmol, 1 eq.) and freshly activated 3Å powdered molecular sieves in dry pyridine (1.8 mL) 
was cooled to 0°C and treated with triphenylphosphine (0.14 g, 0.53 mmol, 2 eq.) and 
tetrabromomethane (97 mg, 0.29 mmol, 1.1 eq.) under argon. The reaction mixture was heated 
at 35°C for 23 hours without any conversion of the starting material. 
 
Second attempt:  
A solution of the cyclohexyl 2-acetamido-2-deoxy-1-thio-α-D-glucopyranoside (2.18) (65 m g, 
0.20 mmol, 1 eq.) and freshly activated 3Å powdered molecular sieves in dry pyridine (1.8 mL) 
was treated with triphenylphosphine (0.10 g, 0.41 mmol, 2 eq.) and tetrabromomethane (75 mg, 
0.22 mmol, 1.1 eq.) under argon at r.t. The reaction mixture was then heated at 50°C for 13 
hours without any conversion of the starting material. 
 
Cyclohexyl 2-acetamido-2,6-dideoxy-6-iodo-1-thio-α-D-glucopyranoside (2.34).14 
 
The cyclohexyl 2-acetamido-2-deoxy-1-thio-α-D-glucopyranoside (2.18) (80 mg, 0.2505 mmol, 
1 eq.), imidazole (34 mg, 0.50 mmol, 2 eq.) and triphenylphosphine (99 mg, 0.38 mmol, 1.5 eq.) 
in THF (2.5 mL) was treated with iodine (95 mg, 0.38 mmol, 1.5 eq.) under argon at r.t. The 
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Cyclohexyl 2-acetamido-6-chloro-2,6-dideoxy-1-thio-α-D-glucopyranoside (2.35).15 
 
The cyclohexyl 2-acetamido-2-deoxy-1-thio-α-D-glucopyranoside (2.18) (60 mg, 0.19 mmol, 1 
eq.) and 3Å powdered molecular sieves were dried using a Schlenk line. To this dry DMF (0.7 
mL) was added under argon, cooled to  0°C and treated with freshly distilled thionyl chloride 
(16 μL, 0.2254 mmol, 1.2 eq.). This was allowed to slowly warm to r.t. and stirred for 1 hour 
after which time TLC indicated no conversion of SM, but increasing amounts of degradation.  
 





A solution of cyclohexyl 2-acetamido-2-deoxy-1-thio-α-D-glucopyranoside (2.18) (1.28 g, 4.00 
mmol, 1 eq.) and freshly activated 3Å molecular sieves in dry pyridine (10 mL) was stirred 
under argon and cooled to 0°C. To this freshly recrystallized p-toluenesulfonyl chloride (1.14 g, 
6.00 mmol, 1.5 eq.) was added and stirred for 2 hours at this temperature. The reaction mixture 
was filtered through celite, transferred to a separating funnel and washed with 5% HCl solution. 
The aqueous layer was washed with DCM (4 x 20 mL), combined organic fractions were dried 
over Na2SO4, concentrated and purified using flash chromatography (9.7:0.3 EtOAc/MeOH) to 
yield 1.54 g (81%) of 2.36 as a white solid. Rf = 0.41 (9:1 EtOAc/MeOH); mp 145-147°C; 1H NMR 
(400 MHz, CDCl3) δ 7.79 (d, J = 8.3 Hz, 1H, Ar-H), 7.33 (d, J = 8.0 Hz, 1H, Ar-H), 6.19 (d, J = 8.4 Hz, 
1H, NH), 5.32 (d, J = 5.3 Hz, 1H, H-1), 4.34 (dd, J = 10.9, 5.0 Hz, 1H, H-6), 4.26 (dd, J = 10.9, 2.0 Hz, 
1H, H-6’), 4.22 – 4.13 (m, 2H, H-2, H-5), 3.53 – 3.43 (m, 2H, H-4, H-3), 2.81 – 2.69 (m, 1H, H-1’), 
2.43 (s, 3H, CH3), 2.01 (s, 3H, CH3CO), 1.97 – 1.87 (m, 2H, cyclohexyl), 1.75 – 1.66 (m, 2H, 
cyclohexyl), 1.61 – 1.52 (m, 1H, cyclohexyl), 1.42 – 1.18 (m, 5H, cyclohexyl); 13C NMR (101 MHz, 
CDCl3) δ 172.02 (C=O), 145.08 (Ar), 133.13 (Ar), 129.98 (Ar), 128.17 (Ar), 83.87 (C-1), 74.73 (C-
3), 71.43 (C-4), 70.24 (C-5), 68.76 (C-6), 53.77 (C-2), 45.31 (C-1’), 34.40 (cyclohexyl), 33.88 
(cyclohexyl), 26.01 (2 x cyclohexyl), 25.71 (cyclohexyl), 23.50 (CH3CO), 21.80 (CH3); HRMS (ESI-
TOF): [M+H]+ Calcd for C21H32NO7S2: 474.1620 found: 474.1621; IR (NaCl, dry film) νmax (cm-1): 
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Cyclohexyl 2-acetamido-2,6-dideoxy-6-iodo-1-thio-α-D-glucopyranoside (2.34).16 
 
The cyclohexyl 2-acetamido-2-deoxy-1-thio-6-O-tosyl-α-D-glucopyranoside (2.36) (1.44 g, 3.05 
mmol, 1 eq.) and NaI (1.01 g, 6.71 mmol, 2.2 eq.) were dried using a Schlenk line, dissolved in 2-
butanone (12 mL) under argon, refluxed for 7 hours and then stirred at r.t. for 18 hrs. The 
reaction mixture was concentrated, diluted with EtOAc (20 ml) and aq. Na2S2O3 (20 mL), 
transferred to a separating funnel and the aqueous layer was washed with EtOAc (4 x 15 mL). 
The combined organic fractions were dried over Na2SO4, concentrated and purified using silica 
gel chromatography (9.7:0.3 EtOAc/MeOH) to yield 1.26 g (97%) of 2.34 as a white solid. Rf =  
0.40 (9:1 EtOAc/MeOH);  mp 169 – 171°C; 1H NMR (400 MHz, (CD3)2SO) δ 7.77 (d, J = 7.1 Hz, 1H, 
NH), 5.42 (d, J = 5.3 Hz, 1H, H-1), 5.39 – 5.34 (m, 1H, OH-4), 4.88 (d, J = 5.9 Hz, 1H, OH-3), 3.79 
(ddd, J = 11.0, 7.1, 5.3 Hz, 1H, H-2), 3.64 (ddd, J = 9.2, 6.6, 2.2 Hz, 1H, H-5), 3.54 (dd, J = 10.7, 2.4 
Hz, 1H, H-6), 3.44 – 3.34 (m, 1H, H-3), 3.35 (dd, J = 10.7, 6.8 Hz, 1H, H-6’), 3.02 (td, J = 9.0, 5.8 Hz, 
1H, H-4), 2.90 – 2.80 (m, 1H, H-1’), 1.93 – 1.84 (m, 2H, cyclohexyl), 1.82 (s, 3H, CH3CO), 1.72 – 
1.61 (m, 2H, cyclohexyl), 1.57 – 1.48 (m, 1H, cyclohexyl), 1.39 – 1.17 (m, 5H, cyclohexyl); 13C 
NMR (101 MHz, (CD3)2SO) δ 169.47 (C=O), 81.97 (C-1), 74.76 (C-4), 71.42 (C-5), 70.19 (C-3), 
54.24 (C-2), 42.07 (C-1’), 33.63 (cyclohexyl), 33.20 (cyclohexyl), 25.53 (cyclohexyl), 25.23 
(cyclohexyl), 25.14 (cyclohexyl), 22.49 (cyclohexyl), 9.26 (C-6); HRMS (ESI-TOF): [M+H]+ Calcd 
for C14H25INO4S: 430.0549 found: 430.0546.  
 
Cyclohexyl 2-acetamido-2,6-dideoxy-1-thio-α-D-glucopyranoside (2.19).17 
 
The cyclohexyl 2-acetamido-2,6-dideoxy-6-iodo-1-thio-α-D-glucopyranoside (2.34) (61 mg, 0.14 
mmol, 1 eq.) in DCM (2 mL) and AcOH (68 μL, 1.20 mmol, 8.4 eq.) was treated with 0.20 g of Zn 
dust. The reaction mixture was vigorously stirred at r.t. for 5.5 hours during which time TLC 
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Cyclohexyl 2-acetamido-2,6-dideoxy-1-thio-α-D-glucopyranoside (2.19). 
 
The cyclohexyl 2-acetamido-2,6-dideoxy-6-iodo-1-thio-α-D-glucopyranoside (2.34) (0.10 g, 0.25 
mmol, 1 eq.) and NaHCO3 (0.10 g, 1.19 mmols, 2 eq.) was dissolved in dry MeOH and to this a 
suspension of 10 wt % Pd/C (0.1 g, 0.09 mmol, 2.6 eq.) in dry MeOH was added. The reaction 
mixture was flushed three times with hydrogen and using a hydrogenator the pressure was 
increased to 4 bar and left at r.t. for 6 hours. The reaction mixture was filtered through celite, 
concentrated and columned using flash chromatography (100% EtOAc) to yield 1.26 g (97%) of 
2.19 as a white crystalline solid. Rf  = 0.44 (9:1 EtOAc/MeOH); mp 200 – 202°C; 1H NMR (400 
MHz, CD3OD) δ 5.44 (d, J = 5.4 Hz, 1H, H-1), 4.04 – 3.96 (m, 2H, H-2, H-5), 3.47 (dd, J = 11.3, 8.7 
Hz, 1H, H-4), 3.03 (dd, J = 9.5, 8.7 Hz, 1H, H-3), 2.80 – 2.69 (m, 1H, H-1’), 1.97 (s, 3H, CH3CO), 
1.99 – 1.90 (m, 2H, cyclohexyl), 1.79 – 1.70 (m, 2H, cyclohexyl), 1.64 – 1.55 (m, 1H, cyclohexyl), 
1.44 – 1.26 (m, 5H, cyclohexyl), 1.24 (d, J = 6.2 Hz, 3H, C-6); 13C NMR (101 MHz, CD3OD) δ 173.55 
(C=O), 84.33 (C-1), 78.34 (C-3), 72.66 (C-4), 69.68 (C-2), 56.22 (C-5), 45.31 (C-1’), 35.47 
(cyclohexyl), 35.00 (cyclohexyl), 27.01 (cyclohexyl), 26.88 (cyclohexyl x2), 22.58 (CH3CO), 17.99 
(C-6); HRMS (ESI-TOF): [M+H]+ Calcd for C14H26NO4S: 304.1583 found: 304.1590, [M+Na]+ Calcd 
for C14H25NNaO4S: 326.1402 found: 326.1394.  
 
Cyclohexyl 2-acetamido-3-O-benzoyl-2,6-dideoxy-1-thio-α-D-glucopyranoside (2.20).  
 
First attempt:13 
The cyclohexyl 2-acetamido-2,6-dideoxy-1-thio-α-D-glucopyranoside (2.19) (0.14 g, 0.47 mmol, 
1 eq.) and freshly activated 3Å powdered molecular sieves in dry pyridine (2.5 mL) was cooled 
to -35°C under argon. To this was added benzoyl chloride (60 μL, 0.52 mmols, 1.1 eq.) and 
stirred for 3.5 hrs after which time TLC indicated no reaction had taken place. The reaction 
mixture was then taken up to 5°C and stirred at this temperature for 14 hrs, after which time 
TLC still indicated that no reaction had taken place.  
 
Second attempt:18 
A solution of cyclohexyl 2-acetamido-2,6-dideoxy-1-thio-α-D-glucopyranoside (2.19) (87 mg, 
0.29 mmol, 1 eq.) and freshly activated 3Å powdered molecular sieves in dry DCM (2 mL) and 
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Et3N (44 μL, 0.32 mmol, 1.1 eq.) was cooled to 0°C under argon. To this the BzCl (37 μL, 0.32 
mmol, 1.1 eq.) in DCM (1 mL) was added drop wise to the reaction mixture over 10 mins. This 
was left to stir at 5°C for 22 hrs after which time TLC indicated no reaction had taken place.   
 
Third attempt: 
The cyclohexyl 2-acetamido-2,6-dideoxy-1-thio-α-D-glucopyranoside (2.19) (61 mg, 0.20 mmol, 
1 eq.) and freshly activated 3Å powdered molecular sieves in dry pyridine (2 mL) was cooled to 
0°C under argon. To this was added benzoyl chloride (28 μL, 0.24 mmols, 1.2 eq.) and stirred for 
2 hrs after which time TLC indicated two more non-polar products. The reaction mixture was 
quenched with MeOH, diluted with DCM, filtered through celite and washed with 5% HCl 
solution. The aqueous layer was washed with DCM (3 x 15 mL), combined organic fractions 
were dried over Na2SO4, concentrated and purified using flash chromatography (8:2 
EtOAc/hexane) to yield two products. 3-benzoate (2.20): 29 mg (35%) of white solid. Rf  = 0.38 
(100% EtOAc); mp 132 – 134°C; 1H NMR (400 MHz, CDCl3) δ 8.09 – 8.03 (m, 2H, Ar-H), 7.62 – 
7.54 (m, 1H, Ar-H), 7.49 – 7.41 (m, 2H, Ar-H), 5.86 (d, J = 8.0 Hz, 1H, NH), 5.41 (d, J = 5.4 Hz, 1H, 
H-1), 4.90 (dd, J = 9.7, 9.1 Hz, 1H, H-4), 4.41 (ddd, J = 10.8, 8.1, 5.3 Hz, 1H, H-2), 4.34 (dq, J = 9.6, 
6.1 Hz, 1H, H-5), 3.72 (bt, J = 9.8 Hz, 1H, H-3), 2.86 (tt, J = 10.4, 3.7 Hz, 1H, H-1’), 2.04 (s, 3H, 
CH3CO), 2.04 – 1.97 (m, 1H, cyclohexyl), 1.82 – 1.72 (m, 2H, cyclohexyl), 1.65 – 1.54 (m, 2H, 
cyclohexyl), 1.47 – 1.28 (m, 5H, cyclohexyl), 1.25 (d, J = 6.3 Hz, 3H, H-6); HRMS (ESI-TOF): 
[M+H]+ Calcd for C21H30NO5S: 408.1845 found: 408.1845, [M+Na]+ Calcd for C21H29NNaO5S: 
430.1664 found: 430.1662. 4-benzoate (2.37): 19 mg (24%) of white solid. Rf  = 0.55 (100% 
EtOAc); 1H NMR (400 MHz, CDCl3) δ 8.03 – 7.98 (m, 2H, Ar-H), 7.58 – 7.53 (m, 1H, Ar-H), 7.46 – 
7.39 (m, 2H, Ar-H), 5.85 (d, J = 9.2 Hz, 1H, NH), 5.38 (d, J = 5.4 Hz, 1H, H-1), 5.07 (dd, J = 11.1, 8.9 
Hz, 1H, H-4), 4.62 (ddd, J = 10.9, 9.3, 5.4 Hz, 1H, H-2), 4.19 (dq, J = 9.5, 6.2 Hz, 1H, H-5), 3.50 (td, J 
= 9.1, 4.2 Hz, 1H, H-3), 2.84 (tt, J = 10.3, 3.6 Hz, 1H, H-1’), 2.04 – 1.95 (m, 2H, cyclohexyl), 1.85 (s, 
3H, CH3CO), 1.67 – 1.56 (m, 2H, cyclohexyl), 1.48 – 1.37 (m, 3H, cyclohexyl), 1.36 (d, J = 6.2 Hz, 




The cyclohexyl 2-acetamido-2,6-dideoxy-1-thio-α-D-glucopyranoside (2.19) (74 mg, 0.24 mmol, 
1 eq.) was dissolved in dry DCM (2 mL) and cooled to 0°C. To this the Et3N (0.10 mL, 0.73 mmol, 
3 eq.) followed by TMSCl (34 μL, 0.27 mmol, 1.1 eq.) was added and stirred at 5°C for 18 hours. 
After 95 hrs SM was still present and another 0.6 eq. TMSCl (20μL) was added and left for a 
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further 4 hrs after which time TLC indicated no further conversion of the SM (total 99 hrs). The 
reaction mixture was then transferred to a separating funnel and washed with sat. aq. NaHCO3. 
The aqueous layer was washed with EtOAc (3 x 15 mL), combined organic were dried over 
Na2SO4, concentrated and columned using flash chromatography (100% EtOAc) to yield 53 mg 
(49%) of the disilyl product 2.38 as a clear oil. Rf = 0.48 (100% EtOAc); 1H NMR (400 MHz, 
CDCl3) δ 5.66 (d, J = 9.6 Hz, 1H), 5.23 (d, J = 4.6 Hz, 1H), 4.25 (td, J = 9.5, 4.6 Hz, 1H), 4.05 – 3.94 
(m, 1H), 3.49 (dd, J = 9.2, 7.3 Hz, 1H), 3.26 (t, J = 7.6 Hz, 1H), 2.79 (ddd, J = 10.2, 7.0, 3.7 Hz, 1H), 
1.98 – 1.92 (m, 2H), 1.79 – 1.70 (m, 2H), 1.45 – 1.27 (m, 6H), 1.25 (d, J = 6.5 Hz, 3H), 0.15 (s, 9H), 





The cyclohexyl 2-acetamido-2,6-dideoxy-1-thio-α-D-glucopyranoside (2.19) (0.12 g, 0.39 mmol, 
1 eq.) was dissolved in dry DMF (2 mL) and cooled to 0°C. To this the imidazole (40 mg, 0.58 
mmol 1.5 eq.) followed by TBDMSCl (65 mg, 0.43 mmol, 1.1 eq.) was added and stirred at 0°C 
for 2.5 hrs after which time TLC indicated only SM present, so was left to warm to r.t. and stirred 
at this temperature for 17 hrs, after which time TLC indicated no further reaction had taken 
place.  
 
Cyclohexyl 2-acetamido-4,6-O-benzylidene-2-deoxy-1-thio-α-D-glucopyranoside (2.23) 
 
Using benzaldehyde dimethyl acetal:22  
A solution of cyclohexyl 2-acetamido-2-deoxy-1-thio-α-D-glucopyranoside (2.18) (96 mg, 0.30 
mmol, 1 eq.) and activated 3Å powdered molecular sieves in dry DMF (2 mL) was stirred under 
argon and cooled to 0°C. To this (1S)-(+)-10-camphorsulfonic acid (7 mg, 0.03 mmol, 0.1 eq.) 
was added, followed by the addition of the benzaldehyde dimethyl acetal (64 μL, 0.42 mmol, 1.4 
eq.). The ice bath was removed and the reaction mixture was stirred at 50°C for 16 hours. TLC 
showed no further conversion of the starting material at this point. The reaction mixture was 
filtered through celite, concentrated and purified using flash chromatography (5:5 
hexane/EtOAc) to yield 35 mg (34%) of 2.23 as a white solid (53% of starting material was 
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recovered). Rf = 0.60 (100% EtOAc); mp 181 – 183°C; 1H NMR (400 MHz, CDCl3) δ 7.53 – 7.46 
(m, 2H, Ar-H), 7.36 (dd, J = 5.1, 2.0 Hz, 3H, Ar-H), 5.95 (d, J = 8.1 Hz, 1H, NH), 5.55 (s, 1H, H-7), 
5.47 (d, J = 5.4 Hz, 1H, H-1), 4.37 (ddd, J = 10.6, 8.1, 5.4 Hz, 1H, H-2), 4.25 (dd, J = 4.9, 3.2 Hz, 1H, 
H-6), 4.20 (t, J = 4.6 Hz, 1H, H-4), 3.81 – 3.73 (m, 2H, H-3, H-6’), 3.56 (t, J = 9.2 Hz, 1H, H-5), 2.82 
(tt, J = 10.1, 3.5 Hz, 1H, H-1’), 2.04 (s, 3H, CH3CO), 2.00 – 1.88 (m, 2H, cyclohexyl), 1.80 – 1.64 (m, 
2H, cyclohexyl), 1.64 – 1.54 (m, 1H, cyclohexyl), 1.45 – 1.22 (m, 5H, cyclohexyl); 13C NMR (101 
MHz, CDCl3) δ 171.20 (C=O), 137.22 (Ar), 129.38 (Ar), 128.44 (Ar), 126.48 (Ar), 102.18 (C-7), 
84.57 (C-1), 82.61 (C-5), 70.50 (C-3), 68.85 (C-6), 63.75 (C-4), 54.38 (C-2), 45.12 (C-1’), 34.07 
(cyclohexyl), 33.98 (cyclohexyl), 25.75 (cyclohexyl), 25.72 (cyclohexyl), 25.07 (cyclohexyl), 
23.54 (CH3CO); HRMS (ESI-TOF) [M+H]+ Calcd for C21H30NO5S: 408.1845 found: 408.1841. 
 
Using benzaldehyde:23  
The cyclohexyl 2-acetamido-2-deoxy-1-thio-α-D-glucopyranoside (2.18) (1.27 g, 3.97 mmol, 1 
eq.) and anhydrous ZnCl2 (1.08 g, 7.94 mmol, 2 eq.) were dried using a Schlenk line. To this 
Benzaldehyde (8 mL) followed by freshly activated 3Å molecular sieves was added under argon 
and stirred for 17.5 hrs at r.t. The reaction mixture was diluted with DCM, filtered through 
celite, transferred to a separating funnel and washed with water. The aqueous layer was washed 
with DCM (3 x 40 mL), combined organic fractions were dried over Na2SO4 and concentrated. 
The product was recrystallized from hexane and purified using flash chromatography (100% 
DCM to 9.8:0.2 DCM/MeOH) to yield 1.23 g (76%) of 2.23 as a white solid. Rf = 0.60 (100% 
EtOAc). Characterisation as above.  
 
Cyclohexyl 2-acetamido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-1-thio-α-D-
glucopyranoside (2.21).24,25  
 
A solution of the cyclohexyl 2-acetamido-4,6-O-benzylidene-2-deoxy-1-thio-α-D-
glucopyranoside (2.23) (48 mg, 0.12 mmol, 1 eq.) in dry THF (2 mL) was stirred under argon 
and cooled to 0°C. To this NaH (23 mg, 0.59 mmol, 5 eq.) was added and the reaction mixture 
was stirred at 0°C for 30 mins. After this time benzyl bromide (42 μL, 0.35 mmol, 3 eq.) and 
tetrabutylammonium iodide (9 mg, 0.02 mmol, 0.2 eq.) was added and left to stir at r.t. for 2 
hours. The reaction mixture was cooled down to 0°C, quenched with MeOH, concentrated and 
washed with brine and EtOAc (4 x 15 mL). The combined organic fractions were dried over 
Na2SO4, concentrated and purified using flash chromatography (1:1 hexane/EtOAc) to yield 42 
mg (72 %) of 2.21 as a white solid. Rf = 0.31 (1:1 hexane/EtOAc); mp 179 – 182°C; 1H NMR (400 
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MHz, CDCl3) δ 7.55 – 7.47 (m, 2H, Ar-H), 7.42 – 7.35 (m, 3H, Ar-H), 7.36 – 7.27 (m, 5H, Ar-H), 
5.60 (s, 1H, H-7), 5.48 (d, J = 5.4 Hz, 1H, H-1), 5.22 (d, J = 8.2 Hz, 1H, NH), 4.91 (AB d, J = 12.2 Hz, 
1H, CH2OPh), 4.61 (AB d, J = 12.2 Hz, 1H, CH2OPh), 4.37 (ddd, J = 10.6, 8.2, 5.5 Hz, 1H, H-2), 4.30 
– 4.19 (m, 2H, H-5, H-6), 3.78 (m, 2H, H-6’, H-4), 3.58 (dd, J = 10.6, 8.9 Hz, 1H, H-3), 2.77 (tt, J = 
10.1, 3.6 Hz, 1H, H-1’), 1.88 (s, 3H, CH3CO), 1.70 (m, 2H, cyclohexyl), 1.65 – 1.56 (m, 3H, 
cyclohexyl), 1.41 – 1.23 (m, 5H, cyclohexyl); 13C NMR (101 MHz, CDCl3) δ 169.91 (C=O), 138.47 
(Ar), 137.53 (Ar), 129.12 (Ar), 128.64 (Ar), 128.41 (Ar), 128.21 (Ar), 128.03 (Ar), 126.18 (Ar), 
101.53 (C-7), 84.82 (C-1), 83.23 (C-4), 75.98 (C-3), 74.15 (CH2OPh), 68.98 (C-6), 64.05 (C-5), 
53.03 (C-2), 44.80 (C-1’), 34.10 (cyclohexyl), 25.78 (cyclohexyl), 25.74 (cyclohexyl), 25.09 (2 x 
cyclohexyl), 23.51 (CH3CO); HRMS (ESI-TOF) [M+H]+ Calcd for C28H36NO5S: 498.2314 found: 
498.2310. 
 
Cyclohexyl 2-acetamido-3-O-benzyl-2-deoxy-1-thio-α-D-glucopyranoside (2.39).26 
 
A solution of the cyclohexyl 2-acetamido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-1-thio-α-D-
glucopyranoside (2.21) (50 mg, 0.1004 mmol, 1 eq.) in DCM (1 mL) was cooled to 0°C and to 
this 0.18 mL TFA/H2O (3:1) was added stirred at temperature for 1.5 hours.  After this time the 
reaction mixture was transferred to a separating funnel, washed with sat. aq. NaHCO3 and EtOAc 
(4 x 15 mL), combined organic fractions were dried over Na2SO4, concentrated and purified 
using flash chromatography (6:4 EtOAc/hexane) to yield 31 mg (75 %) of 2.39 as a clear oil. Rf  
= 0.27 (100% EtOAc); 1H NMR (400 MHz, CDCl3) δ 7.41 – 7.29 (m, 5H, Ar-H), 5.39 (d, J = 5.2 Hz, 
1H, H-1),  4.70 (AB q, J = 11.8, 6.3 Hz, 2H, CH2OPh), 4.35 (ddd, J = 11.0, 8.7, 5.3 Hz, 1H, H-2), 4.05 
(dt, J = 9.7, 3.9 Hz, 1H, H-5), 3.83 (app d, J = 3.9 Hz, 2H, H-6’s), 3.75 (t, J = 9.2 Hz, 1H, H-4), 3.44 
(dd, J = 10.9, 8.7 Hz, 1H, H-3), 2.83 – 2.74 (m, 1H, H-1’), 2.00 – 1.90 (m, 3H, cyclohexyl), 1.88 (s, 
3H, CH3CO), 1.78 – 1.69 (m, 2H, cyclohexyl), 1.63 – 1.54 (m, 1H, cyclohexyl), 1.43 – 1.25 (m, 5H, 
cyclohexyl); 13C NMR (101 MHz, CDCl3) δ 138.29 (Ar), 128.90 (Ar), 128.29 (Ar), 128.27 (Ar), 
84.39 (C-1), 80.40 (C-3), 74.05 (CH2OPh), 72.39 (C-5), 71.26 (C-4), 62.57 (C-6), 52.37 (C-2), 
44.94 (C-1’), 33.77 (2 x cyclohexyl), 29.04 (cyclohexyl), 26.10 (cyclohexyl), 25.90 (cyclohexyl), 










A solution of cyclohexyl 2-acetamido-3-O-benzyl-2-deoxy-1-thio-α-D-glucopyranoside (2.39) 
(0.23 g, 0.55 mmol, 1 eq.) and freshly activated 3Å powdered molecular sieves in dry pyridine (3 
mL ) was stirred under argon and cooled to 0°C. To this freshly recrystallized p-toluenesulfonyl 
chloride (0.15 g, 0.83 mmol, 1.5 eq.) was added and stirred for 2 hours at this temperature. The 
reaction mixture was filtered through celite, transferred to a separating funnel and washed with 
5% HCl solution. The aqueous layer was washed with DCM (3 x 20 mL), combined organic 
fractions were dried over Na2SO4, concentrated and purified using flash chromatography 
(9.7:0.3 DCM/MeOH) to yield 0.13 g (42%) of 2.40 as a white solid. Rf = 0.60 (19:1 DCM/MeOH); 
1H NMR (400 MHz, CDCl3) δ 7.83 – 7.72 (m, 2H, Ar-H), 7.41 – 7.27 (m, 7H, Ar-H), 5.31 (d, J = 5.29 
Hz, 1H, H-1), 5.28 (d, J = 8.8 Hz, 1H, NH), 4.69 (AB q, J = 19.0, 11.8 Hz, 2H, CH2OPh), 4.37 (dd, J = 
11.1, 4.6 Hz, 1H, H-6), 4.32 – 4.23 (m, 1H, H-2), 4.24 (dd, J = 11.1, 2.1 Hz, 1H, H-6’), 4.17 (ddd, J = 
9.8, 4.7, 2.0 Hz, 1H, H-5), 3.62 (t, J = 9.2 Hz, 1H, H-4), 3.38 (dd, J = 10.9, 8.7 Hz, 1H, H-3), 2.77 – 
2.71 (m, 1H, H-1’), 2.44 (s, 3H, CH3), 1.94 – 1.87 (m, 2H, cyclohexyl), 1.84 (s, 3H, CH3CO), 1.75 – 
1.64 (m, 2H, cyclohexyl), 1.62 – 1.52 (m, 1H, cyclohexyl), 1.36 – 1.20 (m, 5H, cyclohexyl); 13C 
NMR (101 MHz, CDCl3) δ 169.89 (C=O), 145.04 (Ar), 138.25 (Ar), 133.11 (Ar), 129.92 (Ar), 
128.84 (Ar), 128.26 (Ar), 128.13 (2 x Ar), 84.12 (C-1), 80.00 (C-3), 74.14 (CH2OPh), 70.72 (C-5), 
70.36 (C-4), 68.70 (C-6), 52.23 (C-2), 44.83 (C-1’), 34.30 (cyclohexyl), 33.85 (cyclohexyl), 26.04 





The cyclohexyl 2-acetamido-2-deoxy-1-thio-6-O-tosyl-α-D-glucopyranoside (2.40) (89 mg, 0.16 
mmol, 1 eq.) and NaI (52 mg, 0.35 mmol, 2.2 eq.) were dried using a Schlenk line, dissolved in 2-
butanone (2 mL) under argon, refluxed for 7 hours and then stirred at r.t. for 18 hrs. The 
reaction mixture was concentrated, diluted with EtOAc (20 mL) and aq. Na2S2O3 (20 mL), 
transferred to a separating funnel and the aqueous layer was washed with EtOAc (3 x 15 mL). 
The combined organic fractions were dried over Na2SO4, concentrated and purified using silica 
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gel chromatography (9:1 EtOAc/hexane) to yield 74 mg (90%) of 2.41 as a white solid. Rf = 0.62 
(9:1 EtOAc/hexane); 1H NMR (400 MHz, CDCl3) δ 7.42 – 7.28 (m, 5H, Ar-H), 5.38 (d, J = 5.3 Hz, 
1H, H-1), 5.35 (d, J = 9.1 Hz, 1H, NH), 4.68 (AB q, J = 11.7, 5.0 Hz, 2H, CH2OPh), 4.44 (ddd, J = 
10.6, 9.0, 5.3 Hz, 1H, H-2), 3.81 (ddd, J = 8.8, 5.9, 2.6 Hz, 1H, H-5), 3.58 – 3.48 (m, 1H, H-6, H-4), 
3.45 (dd, J = 10.6, 8.6 Hz, 1H, H-3), 3.39 (dd, J = 10.8, 6.1 Hz, 1H, H-6), 2.96 – 2.84 (m, 1H, H-1’), 
2.32 (d, J = 3.5 Hz, 1H, OH-4), 2.04 – 1.93 (m, 2H, cyclohexyl), 1.89 (s, 3H, CH3CO), 1.81 – 1.68 (m, 
2H, cyclohexyl), 1.64 – 1.52 (m, 1H, cyclohexyl), 1.48 – 1.25 (m, 5H, cyclohexyl); 13C NMR (101 
MHz, CDCl3) δ 169.79 (C=O), 138.14 (Ar), 128.96 (Ar), 128.39 (Ar), 128.26 (Ar), 84.06 (C-1), 
80.42 (C-3), 74.50 (C-4), 74.11 (CH2OPh), 71.13 (C-5), 52.28 (C-2), 44.64 (C-1’), 34.47 
(cyclohexyl), 34.03 (cyclohexyl), 26.23 (cyclohexyl), 26.00 (cyclohexyl), 25.76 (cyclohexyl), 
23.62 (CH3CO), 7.15 (C-6); HRMS (ESI-TOF): [M+H]+ Calcd for C21H31INO4S: 520.1018 found: 
520.1015.  
 
Cyclohexyl 2-acetamido-3-O-benzyl-2,6-dideoxy-1-thio-α-D-glucopyranoside (2.22).27  
    
The cyclohexyl 2-acetamido-3-O-benzyl-2,6-dideoxy-6-iodo-1-thio-α-D-glucopyranoside (2.41) 
(40 mg, 0.08 mmol, 1 eq.) was dried using a Schlenk line and dissolved in dry degassed toluene 
(2 mL) under argon. To this this freshly activated 3Å molecular sieves, 1,1′-
azobis(cyclohexanecarbonitrile) (ACCN) (14 mg, 0.06 mmol, 0.75 eq.) and Bu3SnH (0.13 mL, 
0.46 mmol, 6 eq.) was added and heated at 75°C for 2 hrs. The reaction mixture was then 
filtered through celite, concentrated and purified using flash chromatography (9:1 
DCM/hexane) to yield 6 mg (20%) of the 6-deoxy sugar 2.22 as an oil. Rf = 0.56 (9:1 
EtOAc/hexane); 1H NMR (400 MHz, CDCl3) δ 7.42 – 7.28 (m, 5H, Ar-H), 5.39 (d, J = 9.1 Hz, 1H, 
NH), 5.30 (d, J = 5.3 Hz, 1H, H-1), 4.69 (A2 s, 2H, CH2OPh), 4.41 (ddd, J = 10.5, 9.0, 5.2 Hz, 1H, H-
2), 4.05 (dq, J = 8.8, 6.2 Hz, 1H, H-5), 3.37 (dd, J =8.73, 5.55 Hz, 1H, H-4), 3.35 (dd, J = 2.8, 1.6 Hz, 
1H, H-3), 2.79 (td, J = 10.2, 3.7 Hz, 1H, H-1’), 2.18 (d, J = 3.2 Hz, 2H, cyclohexyl), 2.01 – 1.91 (m, 













The cyclohexyl 2-acetamido-2-deoxy-1-thio-α-D-glucopyranoside (2.18) (1.55 g, 4.87 mmol, 1 
eq.) and anhydrous ZnCl2 (1.33 g, 9.73 mmol, 2 eq.) were dried using a Schlenk line. To this 
Benzaldehyde (17 mL) followed by freshly activated 3Å powdered molecular sieves was added 
under argon and stirred for 19 hrs at r.t. The reaction mixture was wet loaded and purified 
using flash chromatography (8:2 EtOAc/hexane) to yield 1.30 g (61%) of 2.42 as a white solid. 
Rf = 0.40 (18.5:1.5 DCM/MeOH); mp 107 – 182°C;  1H NMR (400 MHz, CDCl3) δ 7.50 – 7.44 (m, 
2H, Ar-H), 7.37 – 7.30 (m, 3H, Ar-H), 6.81 (d, J = 7.7 Hz, 1H, NH), 5.48 (s, 1H, H-7), 5.29 (d, J = 
6.38, 1H, H-1), 4.58 (ddd, J = 10.7, 7.7, 6.3 Hz, 1H, H-2), 4.50 (dd, J = 10.7, 8.8 Hz, 1H, H-3), 4.34 
(td, J = 9.7, 4.9 Hz, 1H, H-5), 4.26 (dd, J = 10.3, 4.9 Hz, 1H, H-6), 3.66 (t, J = 10.1 Hz, 1H, H-6’), 3.58 
(t, J = 9.2 Hz, 1H, H-4), 3.00 (tt, J = 12.1, 3.4 Hz, 1H, H-1’), 2.15 – 2.01 (m, 2H, cyclohexyl), 1.99 (s, 
3H, CH3CO), 1.96 – 1.90 (m, 1H, cyclohexyl), 1.91 – 1.82 (m, 1H, cyclohexyl), 1.75 – 1.65 (m, 1H, 
cyclohexyl), 1.58 – 1.44 (m, 2H, cyclohexyl), 1.34 – 1.16 (m, 3H, cyclohexyl) 13C NMR (101 MHz, 
CDCl3) δ 172.42 (C=O), 136.87 (Ar), 129.38 (Ar), 128.37 (Ar), 126.44 (Ar), 102.10 (C-7), 85.13 
(C-1), 81.40 (C-4), 68.53 (C-6), 67.90 (C-3), 67.32 (C-5), 60.48 (C-1’), 52.45 (C-2), 26.07 
(cyclohexyl), 25.20 (cyclohexyl), 25.11 (2 x cyclohexyl), 23.04 (cyclohexyl), 22.75 (CH3CO); 





The cyclohexyl 2-acetamido-4,6-O-benzylidene-2-deoxy-1-sulfonyl-α-D-glucopyranoside (2.42) 
(0.52 g, 1.19 mmol, 1 eq.), N-bromosuccinimide (0.27 g, 1.54 mmol, 1.3 eq.), BaCO3 (0.10 g, 0.51 
mmol, 0.4 eq.) and freshly activated 3Å powdered molecular sieves were dissolved in dry and 
degassed CCl4 (20 mL) under argon. The reaction mixture was then refluxed for 2 hours, cooled, 
filtered through celite, washed 1M NaOH and DCM (3 x 40 mL). The combined organic fractions 
were dried over Na2SO4, concentrated and purified using flash chromatography (1:1 
hexane/EtOAc) to yield 0.43 g (70%) of 2.43 as a white solid. Rf  = 0.56 (7:3 EtOAc/hexane); mp 
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107 – 111°C; 1H NMR (400 MHz, CDCl3) δ 8.08 – 7.96 (m, 2H, Ar-H), 7.64 – 7.54 (m, 1H, Ar-H), 
7.50 – 7.40 (m, 2H, Ar-H), 6.62 (d, J = 8.0 Hz, 1H, NH), 5.27 (d, J = 5.9 Hz, 1H, H-1), 5.10 (t, J = 
8.62, 1H, H-3), 4.75 – 4.62 (m, 2H, H-2, H-5), 4.58 (dd, J = 10.3, 8.3 Hz, 1H, H-4), 3.55 (dd, J = 11.6, 
2.7 Hz, 1H, H-6), 3.53 – 3.43 (m, 2H, H-6’, H-1’), 2.20 – 2.07 (m, 2H, cyclohexyl), 2.01 (s, 3H, 
CH3CO), 1.94 – 1.84 (m, 2H, cyclohexyl), 1.76 – 1.68 (m, 1H, cyclohexyl), 1.65 – 1.45 (m, 6H, 
cyclohexyl); 13C NMR (101 MHz, CCDCl3) δ 172.22 (C=O), 166.03 (Ar), 133.93 (Ar), 130.13 (Ar), 
128.72 (Ar), 82.65 (C-1), 74.98 (C-5), 73.64 (C-3), 69.03 (C-4), 59.66 (C-1’), 51.95 (C-2), 31.51 
(C-6), 26.45 (cyclohexyl), 25.22 (cyclohexyl), 25.17 (cyclohexyl), 24.90 (2 x cyclohexyl), 23.08 
(CH3CO). 
 
Cyclohexyl 2-acetamido-4-O-benzoyl-2,6-dideoxy-1-sulfonyl-α-D-glucopyranoside (2.44). 
 
The cyclohexyl 2-acetamido-4-O-benzoyl-6-bromo-2,6-dideoxy-1-sulfonyl-α-D-glucopyranoside 
(2.43) (0.18 g, 0.35 mmol, 1 eq.) and NaHCO3 (31 mg, 0.37 mmols, 1.1 eq.) was dissolved in dry 
MeOH and to this a suspension of 10 wt % Pd/C (0.18 g, 0.17 mmol, 0.5 eq.) in dry MeOH was 
added. The reaction mixture was flushed three times with hydrogen and using a hydrogenator 
the pressure was increased to 4 bar and left at r.t. for 7.5 hours. The reaction mixture was 
filtered through celite, concentrated and columned using flash chromatography (100% EtOAc) 
to yield 0.13 g (86%) of 2.44 as a clear oil. Rf  = 0.56 (7:3 EtOAc/hexane); 1H NMR (400 MHz, 
CDCl3) δ 8.08 – 8.02 (m, 2H, Ar-H), 7.63 – 7.55 (m, 1H, Ar-H), 7.49 – 7.42 (m, 2H, Ar-H), 6.50 (d, J 
= 8.3 Hz, 1H, NH), 5.19 (d, J = 6.1 Hz, 1H, H-1), 4.96 (dd, J = 9.4, 8.8 Hz, 1H, H-4), 4.68 (ddd, J = 
10.7, 8.3, 6.1 Hz, 1H, H-2), 4.66 – 4.54 (m, 1H, H-5), 4.55 – 4.45 (m, 1H, H-3), 3.11 – 2.97 (m, 1H, 
H-1’), 2.15 – 2.05 (m, 1H, cyclohexyl), 2.04 (s, 3H, CH3CO), 2.01 – 1.89 (m, 2H, cyclohexyl), 1.78 – 
1.69 (m, 1H, cyclohexyl), 1.66 – 1.53 (m, 7H, cyclohexyl), 1.30 (d, J = 6.2 Hz, 3H, C-6).13C NMR 
(101 MHz, CDCl3) δ 171.94 (C=O), 166.52 (Ar), 133.72 (Ar), 130.11 (Ar), 128.67 (Ar), 84.05 (C-
1), 76.84 (C-4), 71.37 (C-3), 70.12 (C-5), 60.91 (C-1’), 52.88 (C-2), 26.21 (cyclohexyl), 25.31 
(cyclohexyl), 25.22 (cyclohexyl), 25.20 (cyclohexyl), 23.30 (cyclohexyl), 23.00 (CH3CO), 18.20 
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Phenyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-1-thio-β-D-glucopyranoside (2.52).29,30 
 
Thiophenol (7.9 mL, 76.98 mmol, 1.3 eq) and 1 M SnCl4 in DCM (11.8 mL, 11.84 mmol, 0.2 eq) 
were added to a stirred solution of 2-acetamido-1,3,4,6-tetra-O-acetyl-2-deoxy-β-D-
glucopyranose (23.06 g, 59.22 mmol, 1 eq) and 3Å powdered molecular sieves in DCM (120 mL) 
at r.t. The reaction mixture was heated at reflux for 18 hrs, cooled to r.t., filtered through celite 
and quenched by the addition of saturated aqueous NaHCO3 (40 mL). The aqueous layer was 
separated and extracted with DCM (3 × 70 mL). The combined organic layers were dried over 
Na2SO4 and concentrated. The residue obtained was recrystallized in DCM/hexane (10:1) to give 
22.40 g (86%) of 2.52 as a white solid. Rf = 0.24 (9.5:0.5 DCM/MeOH); mp 210-212°C; 1H NMR 
(300 MHz, CDCl3) δ 7.53 – 7.46 (m, 2H, Ar-H), 7.33 – 7.27 (m, 3H, Ar-H), 5.58 (d, J = 9.1 Hz, 1H, 
NH), 5.22 (dd, J = 10.1, 9.4 Hz, 1H, H-3), 5.05 (dd, J = 10.1, 9.4 Hz, 1H, H-4), 4.85 (d, J = 10.4 Hz, 
1H, H-1), 4.22 (dd, J = 12.2, 5.3 Hz, 1H, H-6), 4.16 (dd, J = 12.3, 2.7 Hz, 1H, H-6’), 4.02 (td, J = 10.4, 
9.3 Hz, 1H, H-2), 3.72 (ddd, J = 10.0, 5.2, 2.8 Hz, 1H, H-5), 2.07 (s, 3H, CH3CO), 2.02 (s, 3H, 
CH3CO), 2.01 (s, 3H, CH3CO), 1.98 (s, 3H, CH3CO); 13C NMR (101 MHz, CDCl3) δ 171.14 (C=O), 
170.71 (C=O), 170.11 (C=O), 169.45 (C=O), 132.68 (Ar), 129.06 (Ar), 128.21 (2 x Ar), 86.82 (C-
1), 76.01 (C-5), 73.91 (C-3), 68.65 (C-4), 62.57 (C-6), 53.60 (C-2), 23.45 (CH3CO), 20.84 (CH3CO), 




    
To a stirred mixture of phenyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-1-thio-β-D-
glucopyranoside (2.52) (22.3 g, 50.97 mmol, 1 eq) and DMAP (1.25 g, 10.19 mmol, 0.2 eq) in 
THF (100 mL) was added Boc2O (27.81 g, 127.41 mmol, 2.5 eq) at room temperature. Stirring 
was continued at 70°C for 3 hours. The reaction mixture was concentrated and purified by flash 
chromatography (4:6 hexane/EtOAc) to give 26.83 g (98%) of 2.53 (mixture of rotamers) as a 
yellow oil. Rf = 0.56 (100% EtOAc); 1H NMR (400 MHz,CDCl3) δ 7.49 – 7.38 (m, 4H, Ar-H), 7.30 – 
7.21 (m, 6H, Ar-H), 5.82 (dd, J = 10.1, 8.8 Hz, 1H, H-3), 5.73 (d, J = 10.2 Hz, 1H, H-1), 5.68 (dd, J = 
10.4, 8.9 Hz, 1H, H-3’), 5.43 (d, J = 10.2 Hz, 1H, H-1’), 5.7 (dd, J = 8.8, 3.2 Hz, 1H, H-4’), 5.03 (dd, J 
= 8.8, 3.2 Hz, 1H, H-4). 4.96 (t, J = 10.3 Hz, 1H, H-2’), 4.35 (t, J = 10.1 Hz, 1H, H-2), 4.24 (dd, J = 
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5.6, 1.8 Hz, 1H, H-6a), 4.21 (dd, J = 5.7, 1.9 Hz, 1H, H-6’a), 4.14 (dd, J = 12.2, 2.5 Hz, 1H, H-6’b), 
4.09 (dd, J = 12.2, 2.4 Hz, 1H, H-6b), 3.77 (ddd, J = 10.3, 5.8, 2.4 Hz, 1H, H-5’), 3.69 (ddd, J = 10.3, 
5.5, 2.5 Hz, 1H, H-5), 2.43 (s, 3H, CH3CO), 2.35 (s, 3H, CH3CO), 2.07 (s, 3H, CH3CO), 2.04 (s, 3H, 
CH3CO), 1.99 (s, 6H, 2 x CH3CO), 1.95 (s, 3H, CH3CO), 1.92 (s, 3H, CH3CO), 1.52 (s, 9H, t-butyl), 
1.49 (s, 9H, t-butyl); 13C NMR (101 MHz, CDCl3) δ 173.95 (C=O), 173.07 (C=O), 170.69 (C=O), 
170.64 (C=O), 170.30 (C=O), 170.04 (C=O), 169.73 (C=O), 169.44 (C=O), 153.04 (C=O), 151.81 
(C=O), 133.21 (Ar), 132.96 (Ar), 132.26 (Ar), 132.23 (Ar), 129.04 (2 x Ar), 128.11 (Ar), 127.96 
(Ar), 86.84 (C-1’), 85.21 (C-1), 76.12 (C-5), 75.78 (C-5’), 72.07 (C-3’), 71.60 (C-3), 69.72 (C-4, C-
4’), 62.67 (C-6), 62.63 (C-6’), 60.31 (C-2), 55.72 (C-2’), 28.09 (2 X t-butyl), 28.04 (2 X t-butyl), 
28.01 (2 X t-butyl), 27.61 (CH3CO), 27.90 (CH3CO), 26.82 (2 x CH3CO), 20.72 (2 x CH3CO), 20.64 
(CH3CO), 20.56 (CH3CO). NMR spectrum agrees with literature, although no chemical shifts 
published, only the spectra given.30 
 
Phenyl 2-amino-2-deoxy-1-thio-β-D-glucopyranoside (2.46).29,30 
 
Phenyl 2-(N-tert-butyloxycarbonylacetamido)-2-deoxy-3,4,6-tri-O-acetyl-1-thio-β-D-
glucopyranoside (3.53) (10.80 g, 20.02 mmol, 1 eq) in MeOH (60 mL) containing a catalytic 
amount of freshly prepared 1 M NaOMe solution was stirred for 45 mins at r.t. To this 2 
teaspoons of Amberlite IR-120 (H+ form) was added and stirred for a further 20 mins. The 
Amberlite was filtered off and solvent removed by evaporation.  
The reaction mixture was cooled to 0°C and to this a total of TFA (100 mL, 1.3 mol, 65 
eq) was added in 33.3 mL aquilots over 3 hours. The reaction mixture was left to slowly warm 
to r.t. over 15 hrs after the last addition and TFA removed. Another 100 mL of TFA was added in 
a similar fashion and left to stir at r.t until TLC showed the reaction to be complete. The TFA was 
then removed and the product was purified using a short column of silica gel (9.5:0.5 
EtOAc/MeOH) to yield 4.51 g (83%) of the free amine 2.46 as a brown oil. Rf = 0.26 (9.5:0.5 
EtOAc/MeOH); 1H NMR (400 MHz, D2O) δ 7.75 – 7.68 (m, 2H, Ar-H), 7.59 – 7.51 (m, 3H, Ar-H), 
5.09 (d, J = 10.3 Hz, 1H, H-1), 4.01 (dd, J = 12.5, 2.1 Hz, 1H, H-6), 3.85 (dd, J = 12.5, 5.2 Hz, 1H, H-
6’), 3.79 (dd, J = 10.1, 8.5 Hz, 1H, H-3), 3.63 (ddd, J = 9.7, 5.3, 2.1 Hz, 1H, H-5), 3.58 (dd, J = 9.8, 
8.5 Hz, 1H, H-4), 3.30 (t, J = 10.3 Hz, 1H, H-2); 13C NMR (101 MHz, D2O) δ 132.51 (Ar), 130.39 
(Ar), 129.66 (Ar), 129.12 (Ar), 83.94 (C-1), 80.32 (C-5), 73.58 (C-3), 69.46 (C-4), 60.62 (C-6), 
54.56 (C-2). Note: Reaction proceeds within 3 hrs with 12 eq. TFA on a small scale (between 0.1 
and 0.3 g of starting material). 
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Phenyl 2-amino-2-N,3-O-carbonyl-2-deoxy-1-thio-β-D-glucopyranoside (2.47).30 
 
An ice-cooled solution of p-nitrophenoxycarbonyl chloride (8.37 g, 41.54 mmol, 2.5 eq) in 
acetonitrile (50 mL) was added over 30 minutes to a stirred mixture of the phenyl 2-amino-2-
deoxy-1-thio-β-D-glucopyranoside (2.46) (4.51 g, 16.62 mmol, 1 eq) and NaHCO3 (6.98 g, 83.09 
mmol, 5 eq) in water (200 mL) at 0°C. This was vigorously stirred at this temperature for 2 
hours after the final aliquots of p-nitrophenoxycarbonyl chloride was added. The reaction 
mixture was transferred to a separating funnel and extracted with EtOAc (3 x 50 mL), the 
combined organic layers were dried over Na2SO4, concentrated and purified using flash 
chromatography (100% hexane to 3:7 EtOAc/hexane) to yield 4.67 g (94%) of 2.47 as a yellow 
oil. Rf = 0.38 (9:1 EtOAc/MeOH); 1H NMR (400 MHz, CD3OD) δ 7.62 – 7.57 (m, 2H, Ar-H), 7.37 – 
7.28 (m, 3H, Ar-H), 4.93 (d, J = 9.6 Hz, 1H, H-1), 4.15 (dd, J = 10.5, 9.2 Hz, 1H, H-3), 3.88 (dd, J = 
12.2, 2.2 Hz, 1H, H-6), 3.83 (dd, J = 10.0, 8.8 Hz, 1H, H-4), 3.76 (dd, J = 12.2, 5.2 Hz, 1H, H-6’), 3.46 
(ddd, J = 8.8, 5.2, 2.3 Hz, 1H, H-5), 3.35 (ddd, J = 9.6, 6.4, 4.7 Hz, 1H, H-2); 13C NMR (101 MHz, 
CD3OD) δ 161.93 (C=O), 134.13 (Ar), 133.57 (Ar), 130.07 (Ar), 129.14 (Ar), 86.12 (C-1), 86.08 
(C-5), 83.90 (C-3), 68.53 (C-4), 62.10 (C-6), 60.09 (C-2).   
 
Phenyl 2-amino-2-N,3-O-carbonyl-2-deoxy-1-thio-6-O-tosyl-β-D-glucopyranoside (2.54).16 
 
A solution of the phenyl 2-amino-2-N,3-O-carbonyl-2-deoxy-1-thio-β-D-glucopyranoside (2.47) 
(4.21 g, 14.14 mmol, 1 eq.) and activated 4Å powdered molecular sieves in dry pyridine (20 mL) 
was stirred under argon and cooled to 0°C. To this freshly recrystallized p-toluenesulfonyl 
chloride (3.26 g, 16.95 mmol, 1.2 eq.) was added and stirred for 4.5 hours at this temperature. 
The reaction mixture was filtered through celite, transferred to a separating funnel and washed 
with 1M HCl. The aqueous layer was washed with DCM (4 x 30 mL) and combined organic 
fractions were dried over Na2SO4, concentrated and purified using flash chromatography (3:7 
EtOAc/hexane to  6:4 EtOAc/hexane) to yield 5.68 g (89%) of 2.54 as a yellow oil. Rf = 0.58 
(100% EtOAc); 1H NMR (400 MHz, CDCl3) δ 7.85 – 7.78 (m, 2H, Ar-H), 7.50 – 7.43 (m, 2H, Ar-H), 
7.40 – 7.26 (m, 5H, Ar-H), 5.33 (s, 1H, NH), 4.70 (d, J = 9.6 Hz, 1H, H-1), 4.37 (dd, J = 11.2, 4.1 Hz, 
1H, H-6), 4.33 (dd, J = 11.1, 2.2 Hz, 1H, H-6’), 4.10 (dd, J = 11.1, 10.0 Hz, 1H, H-3), 3.97 (td, J = 9.8, 
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3.6 Hz, 1H, H-4), 3.58 (ddd, J = 8.8, 4.1, 2.3 Hz, 1H, H-5), 3.30 (ddd, J = 11.0, 9.6, 1.2 Hz, 1H, H-2), 
2.42 (s, 3H, CH3); 13C NMR (101 MHz, CDCl3) δ 158.63 (C=O), 145.36 (Ar), 133.71 (Ar), 132.84 
(Ar), 130.15 (Ar), 129.44 (Ar), 129.15 (2 x Ar), 128.18 (Ar), 84.60 (C-1), 84.09 (C-3), 79.19 (C-5), 
67.94 (C-6), 67.32 C-4), 58.25 (C-2), 21.67 (CH3); HRMS (ESI-TOF): [M+H]+ Calcd for  
C20H22NO7S2:  452.0838 found: 452.0838; [M+NH4]+ calc. for C20H25N2O7S2:  469.1103 found: 





The phenyl 2-amino-2-N,3-O-carbonyl-2-deoxy-1-thio-6-O-tosyl-β-D-glucopyranoside (2.54) 
(5.68 g, 12.58 mmol, 1 eq.) and NaI (4.15 g, 27.69 mmol, 2.2 eq.) were dried using a Schlenk line. 
To this dry butanone (63 mL) was added under argon and refluxed overnight. The reaction 
mixture was then concentrated and purified using flash chromatography (3:7 EtOAc/DCM  to 
5:5 EtOAc/DCM) to yield 4.03 g (79%) of 2.55 as a white solid. Rf  0.64 (100% EtOAc); mp 167-
169°C; 1H NMR (400 MHz, CO(CD3)2) δ 7.74 – 7.65 (m, 2H, Ar-H), 7.40 – 7.31 (m, 3H, Ar-H), 6.89 
(s, 1H, NH), 5.23 (d, J = 5.4 Hz, 1H, 4-OH), 5.10 (d, J = 9.6 Hz, 1H, H-1), 4.27 (dd, J = 11.1, 9.9 Hz, 
1H, H-3), 3.83 – 3.76 (m, 1H, H-4), 3.72 (dd, J = 10.8, 2.5 Hz, 1H, H-6), 3.53 (dd, J = 10.8, 6.2 Hz, 
1H, H-6’), 3.45 (ddd, J = 7.6, 5.1, 1.9 Hz, 1H, H-5), 3.41 (ddd, J = 11.1, 6.4, 1.6 Hz, 1H, H-2); 13C 
NMR (101 MHz, CO(CD3)2) δ 159.45 (C=O), 133.85 (Ar), 132.42 (Ar), 129.85 (Ar), 129.02 (Ar), 
85.09 (C-1), 84.12 (C-3), 81.34 (C-5), 72.31 (C-4), 59.60 (C-2), 6.82 (C-6); HRMS (ESI-TOF): 
[M+H]+ Calcd for C13H15INO4S: 407.9766  found: 407.9776; [M+NH4]+ Calcd for C13H18IN2O4S: 
425.0032 found: 425.0021. 
 
Phenyl 2-amino-2-N,3-O-carbonyl-2,6-dideoxy-1-thio-β-D-glucopyranoside (2.48). 
 
The phenyl 2-amino-2-N,3-O-carbonyl-2,6-dideoxy-6-iodo-1-thio-β-D-glucopyranoside (2.55) 
(3.96 g, 9.73 mmol, 1 eq.) and NaHCO3 (0.82 g, 9.73 mmols, 1 eq.) were dissolved in dry MeOH 
(15 mL) and to this a suspension of 10 wt % Pd/C (2.8 g, 0.7 wt eq.) in dry MeOH (10 mL) was 
added. The reaction vessel was evacuated and flushed three times with hydrogen and using a 
hydrogenator the pressure was increased to 4 bar and left at r.t. for 25 hrs. The reaction mixture 
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was filtered through celite, concentrated and columned using silica gel chromatography (3:7 
hexane/EtOAc) to yield 1.63 g (60%) of 2.48 as a white solid. Rf = 0.6 (3:7 hexane/EtOAc); mp 
168-170°C; 1H NMR (400 MHz, CDCl3) δ 7.56 – 7.49 (m, 2H, Ar), 7.38 – 7.31 (m, 3H, Ar-H), 5.13 
(s, 1H, NH), 4.73 (d, J = 9.6 Hz, 1H, H-1), 4.10 (dd, J = 11.3, 9.7 Hz, 1H, H-3), 3.64 (td, J = 9.6, 3.4 
Hz, 1H, H-4), 3.52 (dq, J = 8.4, 6.1 Hz, 1H, H-5), 3.38 (ddd, J = 11.1, 9.6, 1.2 Hz, 1H, H-2), 2.50 (d, J 
= 3.6 Hz, 1H, OH-4), 1.44 (d, J = 6.1 Hz, 3H, H-6); 13C NMR (101 MHz, CDCl3) δ 158.72 (C=O), 
133.40 (Ar), 130.89 (Ar), 129.43 (Ar), 128.96 (Ar), 84.68 (C-3), 84.58 (C-1), 78.27 (C-5), 72.65 
(C-4), 58.97 (C-2), 17.76 (C-6); HRMS (ESI-TOF): [M+H]+ Calcd for C13H16NO4S:  282.0800 found: 






The phenyl 2-amino-2-N,3-O-carbonyl-2,6-dideoxy-1-thio-β-D-glucopyranoside (2.48) (53 mg, 
0.19 mmol, 1 eq.) and PPh3 (54 mg, 0.20 mmol, 1.1 eq.) were dried using a Schlenk line. To this 
THF (3.5 mL) was added under argon followed by the addition of Diisopropyl azodicarboxylate 
(DIAD) (41 μL, 0.20 mmol, 1.1 eq.) and diphenylphosphoryl azide (45 μL, 0.20 mmol, 1.1 eq.). 
The reaction mixture was left to stir for 20 hrs after which time TLC indicated no reaction had 
taken place. SM recovered = 51 mg.  
 
Second attempt: 
A solution of the phenyl 2-amino-2-N,3-O-carbonyl-2,6-dideoxy-1-thio-β-D-glucopyranoside 
(2.48) (1.20 g, 4.27 mmol, 1 eq.) and activated 3Å powdered molecular sieves in dry pyridine 
(10 mL) was stirred under argon and cooled to -30°C. To this trifluoromethanesulfonic 
anhydride (0.79 mL, 4.69 mmol, 1.1 eq.) was added and stirred at this for 1 hr. The reaction 
mixture was diluted with DCM, filtered through celite and washed with 1M HCl. The combined 
organic fractions were dried over Na2SO4, concentrated and used without further purification. Rf 
= 0.56 (1:1  hexane/EtOAc); 1H NMR (300 MHz, CDCl3) 1H NMR (400 MHz, CDCl3) δ 7.56 – 7.47 
(m, 2H, Ar-H), 7.43 – 7.30 (m, 2H, Ar-H), 5.78 (s, 1H, NH), 4.73 (d, J = 9.6 Hz, 1H, H-1), 4.71 – 4.66 
(m, 1H, H-4), 4.33 (dd, J = 11.3, 10.1 Hz, 1H, H-3), 3.78 (dq, J = 8.6, 6.2 Hz, 1H, H-5), 3.43 (ddd, J = 
11.4, 9.6, 1.2 Hz, 1H, H-2), 1.49 (d, J = 6.2 Hz, 3H, H-6).  
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The triflate was then dissolved in dry DMF (6 mL) under argon and to this the NaN3 
(0.39 g, 5.97 mmol, 1.4 eq.) was added and left to stir at r.t. for 18 hours. The reaction mixture 
was then diluted with EtOAc (20 mL) washed with H2O and the combined organic fractions 
were dried over Na2SO4, concentrated and purified using silica gel chromatography (7:3 
hexane/EtOAc) to yield 1.01 g (77%) of 2.49 as a white solid. Rf = 0.56 (1:1 hexane/EtOAc); mp 
90-92 °C;  1H NMR (400 MHz, CDCl3) δ 7.55 – 7.49 (m, 2H, Ar-H), 7.39 – 7.31 (m, 3H, Ar-H), 5.09 
(s, 1H, NH), 4.65 (d, J = 9.6 Hz, 1H, H-1), 4.29 (dd, J = 11.3, 2.9 Hz, 1H, H-3), 3.98 – 3.95 (m, 1H, H-
4), 3.88 (qd, J = 6.3, 1.7 Hz, 1H, H-5), 3.81 (ddd, J = 11.0, 9.7, 1.0 Hz, 1H, H-2), 1.43 (d, J = 6.3 Hz, 
3H, H-6); 13C NMR (101 MHz, CDCl3) δ 157.90 (C=O), 133.36 (Ar), 130.86 (Ar), 129.44 (Ar), 
129.01 (Ar), 85.77 (C-1), 82.02 (C-3), 75.34 (C-5), 60.97 (C-4), 54.59 (C-2), 17.88 (C-6); HRMS 
(ESI-TOF): [M+H]+ Calcd for C13H15N4O3S: 307.0865 found: 307.0866; [M+NH4]+ Calcd for 
C13H18N5O3S: 324.1130 found: 324.1133; [M+Na]+ Calcd for C13H14N4NaO3S: 329.0684 found: 
329.0688; IR (NaCl, dry film) νmax (cm-1): 3413 (O-H), 3051 (C-H Ar), 2926 (C-H aliphatic), 2116 





A solution of the phenyl 2-amino-2-N,3-O-carbonyl-2-deoxy-1-thio-β-D-glucopyranoside (2.47) 
(4.04 g, 13.60 mmol, 1 eq.) and activated 3Å powdered molecular sieves in dry pyridine (20 mL) 
was stirred under argon and cooled to 0°C. To this freshly recrystallized p-toluenesulfonyl 
chloride (3.89 g, 20.40 mmol, 1.5 eq.) was added and stirred for 2 hours at this temperature. The 
reaction mixture was filtered through celite, transferred to a separating funnel and washed with 
1M HCl. The aqueous layer was washed with DCM (4 x 30 mL) and combined organic fractions 
were dried over Na2SO4, concentrated and purified using flash chromatography (3:7 
EtOAc/hexane to  6:4 EtOAc/hexane) to yield  2.79 g (45%) of the mono- tosylate 2.54, 2.04 g 
(24%) of the di-tosylate 2.56, both as yellow oils and 0.31 g of starting material. Rf = 0.71 (8:2 
EtOAc/hexane); 1H NMR (400 MHz, CDCl3) δ 7.87 – 7.80 (m, 2H, Ar-H), 7.80 – 7.74 (m, 2H, Ar-H), 
7.50 – 7.43 (m, 2H, Ar-H), 7.40 – 7.28 (m, 7H, Ar-H), 5.55 (s, 1H, NH), 4.74 (dd, J = 10.0, 9.0 Hz, 
1H, H-4), 4.64 (d, J = 9.6 Hz, 1H, H-1), 4.41 (dd, J = 11.2, 2.0 Hz, 1H, H-6), 4.14 (dd, J = 11.3, 5.0 
Hz, 1H, H-6’), 4.09 (dd, J = 11.3, 10.1 Hz, 1H, H-3), 3.76 (ddd, J = 8.8, 4.9, 2.0 Hz, 1H, H-5), 3.26 
(ddd, J = 11.0, 9.6, 1.0 Hz, 1H, H-2), 2.43 (s, 3H, CH3), 2.42 (s, 3H, CH3);  13C NMR (101 MHz, 
CDCl3) δ 157.54 (C=O), 146.04 (Ar), 145.22 (Ar), 134.20 (Ar), 132.78 (Ar), 132.65 (Ar), 130.11 
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(Ar), 130.08 (Ar), 129.49 (Ar), 129.39 (Ar), 129.21 (Ar), 128.27 (Ar), 128.26 (Ar), 84.12 (C-1), 
80.90 (C-3), 76.85 (C-5), 73.14 (C-4), 67.21 (C-6), 58.01 (C-2), 21.83 (CH3), 21.76 (CH3); HRMS 
(ESI-TOF): [MH]+ Calcd for C27H28NO9S3: 606.0926 found: 606.0926, [MNH4]+ Cald for 





The phenyl 2-amino-2-N,3-O-carbonyl-2-deoxy-1-thio-4,6-di-O-tosyl-β-D-glucopyranoside 
(2.56) (0.70 g, 1.15 mmol, 1 eq.) and NaI ( 0,19 g, 1.27 mmol, 1.1 eq.) were dried using a Schlenk 
line, dissolved in dry 2-butanone (13 mL) under argon and refluxed for 16.5 hrs. The reaction 
mixture was then concentrated, diluted with EtOAc (40 mL) and aq. Na2S2O3 (40 mL), 
transferred to a separating funnel and the aqueous layer washed with EtOAc (4 x 40 mL). The 
combined organic fractions were dried over Na2SO4, concentrated and purified using flash 
chromatography (1:1 EtOAc/hexane) to yield 0.46 g (71%) of 2.57 as an off white solid. Rf  = 
0.71 (100% EtOAc); mp 154-157°C; 1H NMR (400 MHz, CDCl3) δ 7.85 – 7.79 (m, 2H, Ar-H), 7.66 
– 7.61 (m, 2H, Ar-H), 7.42 – 7.32 (m, 5H, Ar-H), 5.33 (s, 1H, NH), 4.73 (d, J = 9.4 Hz, 1H, H-1), 4.72 
(dd, J = 9.7, 7.7 Hz, 1H, H-4), 4.16 (dd, J = 11.3, 10.0 Hz, 1H, H-3), 3.64 (dd, J = 10.9, 2.5 Hz, 1H, H-
6), 3.47 (ddd, J = 8.2, 5.8, 2.5 Hz, 1H, H-5), 3.41 (dd, J = 10.9, 5.8 Hz, 1H, H-6’), 3.33 (ddd, J = 11.1, 
9.6, 1.2 Hz, 1H, H-2), 2.45 (s, 3H, CH3); 13C NMR (101 MHz, CDCl3) δ 157.49 (C=O), 146.01 (Ar), 
134.65 (Ar), 132.91 (Ar), 130.13 (Ar), 129.53 (2 x Ar), 129.11 (Ar), 128.40 (Ar), 84.33 (C-1), 






glucopyranoside (2.57) (0.68 g, 1.21 mmol, 1 eq.) and NaHCO3 (0.10 g, 1.21 mmols, 1 eq.) were 
dissolved in MeOH (10 mL) and dry DCM (2 mL) and to this a suspension of 10 wt % Pd/C (2.8 
g, 0.7 wt eq.) in dry MeOH (5 mL) was added. The reaction vessel was evacuated and flushed 
three times with hydrogen and using a hydrogenator the pressure was increased to 4 bar and 
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left at r.t. for 20 hrs. The reaction mixture was filtered through celite, concentrated and 
columned using silica gel chromatography (7:3 hexane/EtOAc) to yield 0.27 g (52%) of 2.58 as 
a clear oil. Rf = 0.31 (6:4 hexane/EtOAc); 1H NMR (400 MHz, CDCl3) δ 7.83 – 7.77 (m, 2H, Ar-H), 
7.53 – 7.48 (m, 2H, Ar-H), 7.39 – 7.29 (m, 5H, Ar-H), 5.65 (s, 1H, NH), 4.65 (d, J = 9.6 Hz, 1H, H-1), 
4.54 (dd, J = 10.0, 8.5 Hz, 1H, H-4), 4.09 (dd, J = 11.3, 10.0 Hz, 1H, H-3), 3.65 (dq, J = 8.5, 6.2 Hz, 
1H, H-5), 3.33 (app t, J = 11.0 Hz, 1H, H-2), 2.43 (s, 3H, CH3), 1.44 (d, J = 6.2 Hz, 3H, H-6); 13C 
NMR (101 MHz, CDCl3) δ 158.00 (C=O), 145.58 (Ar), 133.87 (Ar), 133.42 (Ar), 129.94 (Ar), 
129.40 (Ar), 129.16 (2 x Ar), 128.16 (Ar), 84.12 (C-1), 81.24 (C-3), 78.63 (C-4), 76.19 (C-5), 
58.88 (C-2), 21.78 (CH3), 17.69 (C-6); HRMS (ESI-TOF): [MNH4]+ Calcd for C20H25N2O6S2: 





First attempt:  
The phenyl 2-amino-2-N,3-O-carbonyl-2,6-dideoxy-1-thio-4-O-tosyl-β-D-glucopyranoside (2.58) 
(57 mg, 0.13 mmol, 1 eq.) and NaN3 (8.5 mg, 0.14 mmols, 1 eq.) was dissolved in DMF (1 mL) 
and H2O (0.7 mL) and stirred at r.t for 18.5 hrs. TLC indicated that no reaction had taken place, 
so was then heated at 50°C for 4 hrs and then at 70°C for 17 hrs after which time TLC indicated 
no reaction had taken place.  
 
Second attempt:32 
The above reaction mixture was then transferred to a microwave tube and heated at 90°C 
(300W) for 3 mins after which time TLC again indicated no reaction had taken place.  
 
Third attempt: 
In a microwave tube the phenyl 2-amino-2-N,3-O-carbonyl-2,6-dideoxy-1-thio-4-O-tosyl-β-D-
glucopyranoside (2.58) (21 mg, 0.05 mmol, 1 eq.) and NaN3 (4.4 mg, 0.0.7 mmols, 1.4 eq.) was 
dissolved in DMF (0.5 mL) and a drop of H2O. This was then heated at 100°C (300W) for 10 mins 
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Fourth attempt: 
The phenyl 2-amino-2-N,3-O-carbonyl-2,6-dideoxy-1-thio-4-O-tosyl-β-D-glucopyranoside (2.58) 
(57 mg, 0.13 mmol, 1 eq.) and NaN3 (8.5 mg, 0.14 mmols, 1 eq.) was dissolved in DMF (1 mL) 
and stirred at 120°C for 16 hrs after which time TLC indicated that multiple more polar 




Table 2.2, entry 1:30  
Phenyl 2-amino-4-azido-2-N,3-O-carbonyl-2,4,6-trideoxy-1-thio-β-D-galactopyranoside (2.49) 
(71.2 mg, 0.23 mmol, 1 eq.) was dissolved in THF (2 mL) and to this  1M NaOH (0.18 mL, 0.18 
mmol,  0.76 eq.) was slowly added at r.t. and left to stir at this temperature for 45 minutes after 
which time TLC analysis revealed starting material to be present as well the minor formation of 
multiple polar products. This was then left for a total of 4 hrs at which point TLC analysis no 
more starting material, but multiple products with no major product visible.  
 
Table 2.2, entry 2:30 
Phenyl 2-amino-4-azido-2-N,3-O-carbonyl-2,4,6-trideoxy-1-thio-β-D-galactopyranoside (2.49) 
(40 mg, 0.13 mmol, 1 eq.) was dissolved in THF (2 mL) and to this  2M NaOH (0.12 mL, 0.24 
mmol,  1.8 eq.) was added at r.t. and left to stir at this temperature for 15 mins. At this point TLC 
analysis revealed starting material to be present as well as the formation of multiple more polar 
products. This was left for a total of 2.5 hrs hrs at which point TLC analysis no more starting 




Table 2.2, entry 3: 
 
Phenyl 2-amino-4-azido-2-N,3-O-carbonyl-2,4,6-trideoxy-1-thio-β-D-galactopyranoside (2.49)  
(57.4 mg, 0.19 mmol, 1 eq.) was dissolved in 2 mL of THF and to this 2M NaOH (0.19 mL, 2 eq.) 
was added. Stirring was continued at 60°C for 20 mins, removed from the heat, stirred with 20 
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mg of Amberlite IR-120 H+ for 20 mins. The Amberlite was filtered off and washed with DCM. 
The crude material was concentrated and re-dissolved in pyridine (1 mL) and to this DMAP 
(4.57 mg, 0.0375 mmol, 0.2 eq.) and acetic anhydride (70.8 μL, 0.7492 mmol, 4 eq.) was added 
and left to stir at r.t. for 2 hours. The reaction mixture was diluted with DCM, transferred to a 
separating funnel and washed with 5% HCl solution. The aqueous layer was washed with DCM 
(3 x 20 mL) and combined organic fractions were dried over Na2SO4, concentrated and purified 
using silica gel chromatography (100% EtOAc) to yield 23.3 mg (35%) of 2.51 as a clear oil. Rf = 
0.42; 1H NMR (400 MHz, CDCl3) δ 7.52 – 7.46 (m, 2H, Ar-H), 7.33 – 7.26 (m, 3H, Ar-H), 5.45 (d, J = 
8.7 Hz, 1H, NH), 5.38 (dd, J = 10.6, 3.6 Hz, 1H, H-3), 4.94 (d, J = 10.3 Hz, 1H, H-1), 4.04 (td, J = 
10.6, 9.0 Hz, 1H, H-2), 3.81 (dd, J = 3.6, 1.3 Hz, 1H, H-4), 3.76 (qd, J = 6.3, 1.3 Hz, 1H, H-5), 2.11 (s, 
3H, CH3CO), 1.97 (s, 3H, OAc), 1.36 (d, J = 6.3 Hz, 3H, H-6);  13C NMR (101 MHz, CDCl3) δ 170.70 
(C=O), 170.29 (C=O), 133.14 (Ar), 132.41 (Ar), 129.07 (Ar), 127.95 (Ar), 86.54 (C-1), 73.56 (C-
3), 73.45 (C-5), 63.84 (C-4), 50.42 (C-2), 23.61 (OAc), 20.72 (CH3CO), 17.91 (C-6). HRMS (ESI-
TOF) [M+H]+ Calcd for C16H21N4O4S: 365.1284 found: 365.1285.  
 
Phenyl 3-O-acetyl-4-azido-2,4,6-trideoxy-2-ethoxycarbonylamino-1-thio-β-D-
galactopyranoside (2.59).  
Table 2.2, entry 4:33 
    
Phenyl 2-amino-4-azido-2-N,3-O-carbonyl-2,4,6-trideoxy-1-thio-β-D-galactopyranoside (2.49) 
(52.2 mg, 0.17 mmol, 1 eq.) was dissolved in EtOH (5 mL) and to this  LiOH.H2O (50.04 mg, 1.20 
mmol,  7 eq.) was added. Stirring was continued at reflux for 18 hours. The reaction mixture was 
removed from the heat, allowed to cool to r.t. and then AcOH (0.13 mL, 2.31 mmol, 13.6 eq) was 
added and stirred at this temperature for 1 hour after which time acetic anhydride (80 μL, 0.85 
mmol, 5 eq.) was added and left to stir at this temperature for 22 hrs. This was diluted with 
EtOAc and H2O, transferred to a separating funnel and the aqueous layer was washed with 
EtOAc (3 x 40 mL) and combined organic fractions were dried over Na2SO4 and concentrated to 
yield 39.6 mg (crude) of a white solid. 
The crude material (39 mg, 0.11 mmol, 1 eq.) was dissolved in dry pyridine (2 mL) and 
to this acetic anhydride (1 mL) was added and stirred at r.t. for 6 hrs. The reaction mixture was 
diluted with DCM, transferred to a separating funnel and washed with 5% HCl solution. The 
aqueous layer was washed with DCM (3 x 20 mL) and combined organic fractions were dried 
over Na2SO4, concentrated and purified using silica gel chromatography (100% hexane to 8:2 
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DCM/hexane) to yield 32.7 mg (75%) of 2.59 as a white solid. Rf = 0.67 (100% DCM); mp 177-
179 °C;  1H NMR (400 MHz, CO(CD3)2) δ 7.52 – 7.47 (m, 2H, Ar-H), 7.35 – 7.24 (m, 3H, Ar-H), 6.32 
(d, J = 8.5 Hz, 1H, NH), 5.29 (d, J = 10.6 Hz, 1H, H-3), 5.03 (d, J = 10.4 Hz, 1H, H-1), 4.09 – 4.02 (m, 
3H, H-4, CH2), 3.99 – 3.90 (m, 2H, H-5, H-2), 2.05 (s, 3H, CH3CO), 1.31 (d, J = 6.3 Hz, 3H, H-6), 1.19 
(t, J = 7.1 Hz, 3H, CH3); 13C NMR (101 MHz, CO(CD3)2) δ 170.30 (C=O), 156.95 (C=O), 135.16 (Ar), 
132.09 (Ar), 129.70 (Ar), 128.00 (Ar), 87.61 (C-1), 74.85 (C-3), 73.76 (C-5), 64.71 (C-4), 61.09 
(CH2), 51.66 (C-2), 20.52 (CH3CO), 17.92 (C-6), 15.02 (CH3); HRMS (ESI-TOF): [M+Na]+ Calcd for  





A solution of phenyl 2-amino-4-azido-2-N,3-O-carbonyl-2,4,6-trideoxy-1-thio-β-D-
galactopyranoside  (2.49) (0.21 g, 0.70 mmol, 1 eq.) in dry DCM (10 mL) was stirred under 
argon and cooled to 0°C. To this DIPEA (0.42 mL, 2.43 mmol, 3.5 eq.) followed by AcCl (0.20 mL, 
2.43 mmol, 3.5 eq.) was added and stirred for 2.5 hours at this temperature. The reaction 
mixture was diluted with DCM, transferred to a separating funnel and washed with 5% HCl 
solution. The aqueous layer was washed with DCM (3 x 20 mL) and combined organic fractions 
were dried over Na2SO4, concentrated and purified using silica gel chromatography (100% 
hexane to 8:2 DCM/hexane) to yield 0.21 g (87%) of 2.60 as a white solid. Rf = 0.60 (100% 
DCM);  1H NMR (400 MHz, CDCl3) δ 7.50 – 7.45 (m, 2H, Ar), 7.32 – 7.26 (m, 3H, Ar), 4.77 (d, J = 
8.6 Hz, 1H, H-1), 4.45 (dd, J = 11.3, 8.6 Hz, 1H, H-2), 4.30 (dd, J = 11.3, 2.6 Hz, 1H, H-3), 4.08 – 
4.04 (m, 1H, H-4), 3.80 (qd, J = 6.4, 1.8 Hz, 1H, H-5), 2.58 (s, 3H, CH3CO), 1.37 (d, J = 6.4 Hz, 3H, 
H-6); 13C NMR (101 MHz, CDCl3) δ 173.05 (C=O), 153.50 (C=O), 134.09 (Ar), 132.75 (Ar), 128.95 
(Ar), 128.11 (Ar), 88.18 (C-1), 79.81 (C-3), 75.07 (C-5), 61.28 (C-4), 56.28 (C-2), 24.97 (OAc 
CH3), 17.49 (C-6); HRMS (ESI-TOF): [M+H]+ Calcd for  C15H17N4O4S: 349.0971 found: 349.0976; 
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Phenyl 2-acetamido-4-azido-2,4,6-trideoxy-1-thio-β-D-galactopyranoside (2.50).35,36 
 
Phenyl 2-N-acetyl-2-amino-4-azido-2-N,3-O-carbonyl-2,4,6-trideoxy-1-thio-β-D-
galactopyranoside (2.60) (0.61 g, 1.76 mmol, 1 eq.) was dissolved in THF/H2O (59 mL) (8:2) 
and to this  LiCl (0.33 g, 7.91 mmol,  4.5 eq.) was added at r.t. This was stirred for 5 mins after 
which time LiOH (0.22 g, 5.27 mmol, 3 eq.) was then added and vigorously stirred for a further 1 
hr 15 mins. To this ~100 mg of Amberlite IR-120 (H+ form) was added and stirred for 20 mins. 
The reaction mixture was then filtered through celite, THF removed by evaporation, diluted 
with EtOAc and H2O and transferred to a separating funnel. The aqueous layer was washed with 
EtOAc (3 x 60 mL) and combined organic fractions were dried over Na2SO4, concentrated and 
purified using flash chromatography (9.5:0.5 DCM/MeOH) to yield 0.51 g (90%) of 2.50 as a 
white solid. Rf = 0.18 (9.5:0.5 DCM/MeOH); mp 206-209 °C; 1H NMR (400 MHz, SO(CD3)2) δ 7.79 
(d, J = 9.0 Hz, 1H, NH), 7.39 – 7.28 (m, 4H, Ar-H), 7.25 – 7.19 (m, 1H, Ar-H), 5.63 (d, J = 3.7 Hz, 1H, 
OH-3), 4.76 (d, J = 10.1 Hz, 1H, H-1), 3.92 – 3.82 (m, 1H, H-3), 3.83 (apparent m, 1H, H-4), 3.80 
(dd, J = 9.3, 8.3 Hz, 1H, H-2), 3.75 (dd, J = 6.3, 1.4 Hz, 1H, H-5), 1.83 (s, 3H, CH3CO), 1.18 (d, J = 6.3 
Hz, 3H, H-6); 13C NMR (101 MHz, SO(CD3)2) δ 169.38 (C=O), 135.01 (Ar), 129.20 (Ar), 128.82 
(Ar), 126.31 (Ar), 85.85 (C-1), 72.19 (C-5), 71.93 (C-3), 65.61 (C-4), 50.58 (C-2), 23.05 (CH3CO), 
17.55 (C-6); HRMS (ESI-TOF) [M+H]+ Calcd for  C14H19N4O3S: 323.1178 found: 323.1167; 
[M+Na]+ Calcd for C14H18N4NaO3S: 345.0997 found: 345.0991; IR (NaCl, dry film) νmax (cm-1): 
3290 (O-H), 3055 (C-H Ar), 2984 (C-H aliphatic), 2119 (N3), 1652 (C=O), 1543 (C=C), 1265 (C-





A solution of phenyl 2-N-acetyl-2-amino-4-azido-2-N,3-O-carbonyl-2,4,6-trideoxy-1-thio-β-D-
galactopyranoside (2.60) (48 mg, 0.14 mmol, 1 eq.) and activated 3Å powdered molecular 
sieves in dry DCM (2 mL) was stirred under argon for 10 minutes. To this 1M SnCl4 (0.35 mL, 
034 mmol, 2.5 eq.) was added and stirred at r.t. for 16 hours. The reaction mixture was filtered 
through celite, diluted with DCM and transferred to a separating funnel and washed with brine 
and DCM (3 x 10 mL). Combined organic fractions were dried over Na2SO4, concentrated and 
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purified using flash chromatography (1:1 hexane/DCM) to yield 34 mg (71%) of 2.61 as a white 
solid. Rf = 0.62 (1:1.5 hexane/DCM); 1H NMR (400 MHz, CDCl3) δ 7.47 – 7.40 (m, 2H, Ar-H), 7.34 
– 7.27 (m, 3H, Ar-H), 6.13 (d, J = 4.1 Hz, 1H, H-1), 4.56 (dd, J = 12.1, 2.5 Hz, 1H, H-3), 4.51 (dd, J = 
12.2, 4.2 Hz, 1H, H-2), 4.50 – 4.41 (m, 1H, H-5), 4.08 (ddd, J = 2.6, 1.8, 0.7 Hz, 1H, H-4), 2.54 (s, 
3H, CH3CO), 1.37 (d, J = 6.4 Hz, 3H, H-6); 13C NMR (101 MHz, CDCl3) δ 171.37 (C=O), 152.65 
(C=O), 132.50 (C=O), 129.35 (2 x Ar), 129.35 (Ar), 128.26 (Ar), 86.96 (C-1), 75.68 (C-3), 67.62 
(C-5), 61.81 (C-4), 55.86 (C-2), 23.98 (CH3CO), 17.28 (C-6). 
 
Phenyl 2-acetamido-4-azido-2,4,6-trideoxy-1-thio-α-D-galactopyranoside (2.62).35,36 
 
Phenyl 2-N-acetyl-2-amino-4-azido-2-N,3-O-carbonyl-2,4,6-trideoxy-1-thio-α-D-
galactopyranoside (2.61) (0.34 g, 0.10 mmol, 1 eq.) was dissolved in THF/H2O (2.7 mL) (3.5:1) 
and to this  LiCl (18.6 mg, 0.44 mmol,  4.5 eq.) was added at r.t. This was stirred for 5 mins after 
which time LiOH (12 mg, 0.29 mmol, 3 eq.) was then added and vigorously stirred for a further 
40 mins. To this Amberlite IR-120 (H+ form) (8 mg) was added and stirred for 20 mins. The 
reaction mixture was then filtered through celite, THF removed by evaporation, diluted with 
EtOAc and H2O and transferred to a separating funnel. The aqueous layer was washed with 
EtOAc (3 x 60 mL) and combined organic fractions were dried over Na2SO4, concentrated and 
purified using flash chromatography (100% EtOAc) to yield 28 mg (82%) of 2.62 as a white 
solid. Rf = 0.22 (100% EtOAc); mp = 213-215 °C; 1H NMR (400 MHz, (CD3)2SO) δ 7.98 (d, J = 6.9 
Hz, 1H, NH), 7.39 – 7.29 (m, 4H, Ar-H), 7.28 – 7.23 (m, 1H, Ar-H), 5.60 (d, J = 5.2 Hz, 1H, H-1), 
5.55 (d, J = 4.7 Hz, 1H, OH-3), 4.33 (qd, J = 6.4, 1.1 Hz, 1H, H-5), 4.17 (ddd, J = 10.6, 7.0, 5.3 Hz, 
1H, H-2), 3.98 – 3.91 (m, 2H, H-3, H-4), 1.86 (s, 3H, CH3CO), 1.14 (d, J = 6.4 Hz, 3H, H-6); 13C NMR 
(101 MHz, (CD3)2SO) δ 169.90 (C=O), 134.39 (Ar), 131.02 (Ar), 129.03 (Ar), 126.92 (Ar), 87.42 
(C-1), 67.61 (C-3), 66.13 (C-4), 65.70 (C-5), 50.50 (C-2), 22.55 (CH3CO), 17.13 (C-6); HRMS (ESI-
TOF) [M+H]+ Calcd for  C14H19N4O3S: 323.1178 found: 323.1176; [M+Na]+ Calcd for 
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Methyl 2-acetamido-4-azido-2,4,6-trideoxy-α/β-D-galactopyranoside (2.63).17,38 
 
Phenyl 2-acetamido-4-azido-2,4,6-trideoxy-1-thio-β-D-galactopyranoside (2.50) (0.16 g,  0.51 
mmol, 1 eq.) was dissolved in dry MeOH/DCM (20 mL) (7:13) under argon and to this NCS (0.13 
g, 1.01 mmol, 2 eq.) was added at r.t. This was stirred for 20 mins, quenched by the addition of 
aq. NaOH, diluted with DCM and transferred to a separating funnel. The aqueous layer was 
washed with DCM (3 x 30 mL) and combined organic fractions were dried over Na2SO4, 
concentrated and purified using silica gel chromatography (9.5:0.5 DCM/MeOH) to yield 52.2 
mg (α) and 15.6 mg (β) (55% overall) of 2.63 as a white solid. α-anomer: Rf = 0.31 (18.5:1.5 
DCM/MeOH); mp 186-189 °C; 1H NMR (400 MHz, CD3OD) δ 4.59 (dd, J = 3.7, 0.6 Hz, 1H, H-1), 
4.18 (dd, J = 11.0, 3.7 Hz, 1H, H-2), 4.04 – 3.97 (m, 2H, H-3, H-5), 3.73 (dd, J = 3.6, 1.4 Hz, 1H, H-
4), 3.32 (s, 3H, OCH3), 1.98 (s, 3H, CH3CO), 1.26 (d, J = 6.5 Hz, 3H, C-6); 13C NMR (101 MHz, 
CD3OD) δ 173.98 (C=O), 99.98 (C-1), 69.91 (C-3), 68.61 (C-4), 66.11 (C-5), 55.66 (OCH3), 51.56 
(C-2), 22.60 (CH3CO), 17.65 (C-6).         β-anomer: Rf = 0.20 (18.5:1.5 DCM/MeOH); mp 192-194 
°C; 1H NMR (400 MHz, CD3OD) δ 4.26 (d, J = 8.3 Hz, 1H, H-1), 3.89 (dd, J = 10.6, 3.7 Hz, 1H, H-3), 
3.79 (dd, J = 10.6, 8.3 Hz, 1H, H-2), 3.72 (qd, J = 6.4, 1.4 Hz, 1H, H-5), 3.68 (dd, J = 5.0, 2.4 Hz, 1H, 
H-4), 3.41 (s, 3H, OCH3), 1.97 (s, 3H, CH3CO), 1.31 (d, J = 6.3 Hz, 3H, H-6);   13C NMR (101 
MHz,CD3OD) δ 174.20 (C=O), 103.55 (C-1), 73.49 (C-3), 70.60 (C-5), 67.77 (C-4), 56.79 (OCH3), 
54.26 (C-2), 22.94 (CH3CO), 17.67 (C-6). NMR of the β-anomer agrees with published values.17 
Mixture of both anomers: HRMS (ESI-TOF): [M+H]+ Calcd for C9H17N4O4: 245.1250 found: 
245.1251.  
 
Phenyl 2-acetamido-4-amino-2,4,6-trideoxy-1-thio-β-D-galactopyranoside (2.64). 
 
Phenyl 2-acetamido-4-azido-2,4,6-trideoxy-1-thio-β-D-galactopyranoside (2.50) (52 mg,  0.16 
mmol, 1 eq.) was dissolved in dry MeOH/DCM (10 mL) (1:1) and to this a suspension of 10 wt % 
Pd/C (34 mg, 0.03 mmol, 0.2 eq.) in dry DCM (2 mL) was added. The round bottom flask was 
evacuated and flushed three times with hydrogen and was stirred vigorously under a balloon of 
H2 at r.t. for 3.5 hrs. The reaction mixture was filtered through celite, concentrated and the solid 
was washed with acetone to yield 38.3 mg (80%) of 2.64 as a white solid. Rf = 0.20 (15:5 
DCM/MeOH); mp 210 – 213°C; 1H NMR (400 MHz, CD3OD) δ 7.52 – 7.44 (m, 2H, Ar-H), 7.33 – 
7.23 (m, 3H, Ar-H), 4.69 (d, J = 10.5 Hz, 1H, H-1), 3.86 (t, J = 10.3 Hz, 1H, H-2), 3.73 (qd, J = 6.4, 
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1.5 Hz, 1H, H-5), 3.65 (dd, J = 10.1, 4.0 Hz, 1H, H-3), 2.89 (dd, J = 4.1, 1.5 Hz, 1H, H-4), 2.00 (s, 3H, 
CH3CO), 1.27 (d, J = 6.5 Hz, 3H, H-6); 13C NMR (101 MHz, CO(CD3)2) δ 173.85 (C=O), 135.44 (Ar), 
132.77 (Ar), 129.85 (Ar), 128.43 (Ar), 88.32 (C-1), 75.85 (C-5), 74.28 (C-3), 55.94 (C-4), 52.33 
(C-2), 22.99 (CH3CO), 17.54 (C-6); HRMS (ESI-TOF): [M+H]+ Calcd for C14H21N2O3S:  297.1273 
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5.3 Chapter 3 Experimental Procedures 
5-O-benzoyl-1,2-O-isopropylidene-β-L-idurono-3,6-lactone (3.1).39–42 
 
Pyridine (3.6 mL) was added to a stirred solution of 1,2-O-isopropylidene-β-D-glucofuranurono-
6,3-lactone (3.60 g, 16.68 mmol, 1 eq.) and 3Å powdered molecular sieves in DCM (40 mL) at r.t. 
under argon and was cooled to -40°C. To this trifluoromethanesulfonic anhydride (3.2 mL, 18.35 
mmol, 1.1 eq.) was added drop wise.  The reaction mixture was stirred for 1.5 hours at this 
temperature, diluted with DCM and washed with cold 5% HCl and DCM (3 x 40 mL). Combined 
organic fractions were dried over Na2SO4, filtered and concentrated to yield 5.70 g (98%) of the 
crude triflate as a brown powder which was used without further purification. Rf = 0.40 (3:2 
hexane/EtOAc); 1H NMR (300 MHz, CDCl3) δ 6.05 (d, J = 3.5 Hz, 1H, H-1), 5.40 (d, J = 4.4 Hz, 1H, 
H-5), 5.06 (dd, J = 4.3, 2.9 Hz, 1H, H-4), 4.92 (d, J = 2.9 Hz, 1H, H-3), 4.86 (d, J = 3.7 Hz, 1H, H-2), 
1.54 (s, 3H, CH3), 1.36 (s, 3H, CH3). NMR values agree with published values.42  
A portion of the crude triflate (1.04 g, 2.97 mmol, 1 eq.) in dry DMF (5 mL) and 3Å 
powdered molecular sieves was cooled to 0°C under argon and to this was added the NaOBz 
(0.60 g, 4.16 mmol, 1.4 eq.).  This was allowed to slowly warm to r.t. over 6 hours. The reaction 
mixture was filtered through celite with EtOAc, diluted with H2O (40 mL), washed with EtOAc (3 
x 40 mL) and the combined organic fractions were dried over Na2SO4, filtered, concentrated and 
purified using silica gel chromatography (8:2 hexane/EtOAc) to yield 0.84 g (88%) of 3.1 as a 
white solid. Rf = 0.63 (6:1 hexane/EtOAc); 1H NMR (400 MHz, CDCl3) δ 8.08 – 7.98 (m, 2H, Ar-H), 
7.66 – 7.57 (m, 1H, Ar-H), 7.51 – 7.42 (m, 2H, Ar-H), 6.01 (d, J = 3.7 Hz, 1H, H-1), 5.21 (d, J = 3.8 
Hz, 1H, H-5), 5.16 (s, 1H, H-3), 4.93 (dt, J = 3.9, 0.7 Hz, 1H, H-4), 4.88 (d, J = 3.9 Hz, 1H, H-2), 1.50 
(s, 3H, CH3), 1.37 (s, 3H, CH3); 13C NMR (101 MHz, CDCl3) δ 170.76 (C=O), 165.43 (C=O), 134.28 
(Ar), 130.36 (Ar), 128.84 (Ar), 128.25 (Ar), 113.45 (C), 106.49 (C-1), 85.58 (C-5), 82.55 (C-2), 




A portion of the crude triflate (0.15 g, 0.43 mmol, 1 eq.) in dry DMF (1.5 mL) and 3Å powdered 
molecular sieves was cooled to 0°C under argon and to this was added the NaOPiv (58.7 mg, 
0.47 mmol, 1.1 eq.).  This was allowed to slowly warm to r.t. over 7 hours. The reaction mixture 
was filtered through celite with EtOAc, diluted with H2O (20 mL), washed with EtOAc (3 x 20 
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mL) and the combined organic fractions were dried over Na2SO4, filtered, concentrated and 
purified using silica gel chromatography (8:2 hexane/EtOAc) to yield 0.13 g (96%) of the 
pivaloate as a white solid. Rf = 0.63 (5:1 hexane/EtOAc); 1H NMR (300 MHz, CDCl3) δ 5.97 (d, J = 
3.8 Hz, 1H), 5.12 (d, J = 3.8 Hz, 1H), 4.86 (s, 1H), 4.84 (d, J = 3.9 Hz, 1H), 4.75 (d, J = 3.9 Hz, 1H), 
1.51 (s, 3H, CH3), 1.36 (s, 3H, CH3), 1.24 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 177.60, 171.05, 
113.31, 106.33, 85.52, 82.38, 81.99, 73.38, 38.82, 27.34, 27.07, 26.74. 
 
Methyl 5-O-benzoyl-1,2-O-isopropylidene-β-L-idofuranuronate (3.8A).40,41 
 
The 5-O-benzoyl-1,2-O-isopropylidene-β-L-idurono-3,6-lactone (3.1) (0.95 g, 0.295 mmol, 1 eq.) 
in dry MeOH (8 mL) and 3Å powdered molecular sieves was cooled to 0°C and to this was added 
drop wise Et3N (3.3 mL, 23.62 mmol, 8 eq.) under argon.  The reaction mixture was stirred for 
1.5 hours at this temperature, diluted with DCM and washed with 5% HCl and DCM (3 x 30 mL), 
combined organic fractions were dried over Na2SO4, filtered and concentrated and purified 
using flash chromatography (x 4) (3:1 hexane/EtOAc to 2:1 hexane/EtOAc)  to yield a mixture of 
starting material (0.16 g), unmigrated ester (3.8A) (0.13 g, 15%) and the desired product 
(3.8B) (0.31 g, 36%). Rf = 0.45 (1:1 hexane/EtOAc); 1H NMR (400 MHz,CDCl3) δ 8.15 – 8.06 (m, 
2H, Ar-H), 7.63 – 7.54 (m, 1H, Ar-H), 7.50 – 7.42 (m, 2H, Ar-H), 6.02 (d, J = 3.6 Hz, 1H, H-1), 5.59 
(d, J = 8.5 Hz, 1H, H-5), 4.60 (dd, J = 3.6, 0.46 Hz, 1H, H-2), 4.56 (dd, J = 8.6, 2.7 Hz, 1H, H-4), 4.36 
(d, J = 2.65 Hz, 1H, H-3), 3.81 (s, 3H, CH3COO), 1.54 (s, 3H, CH3), 1.34 (s, 3H, CH3). 
 
Methyl 3-O-benzoyl-1,2-O-isopropylidene-β-L-idofuranuronate (3.8B).40,41 
 
Rf = 0.49 (1:1 hexane/EtOAc); 1H NMR (400 MHz,CDCl3) δ 8.04 – 7.99 (m, 2H, Ar-H), 7.58 – 7.52 
(m, 1H, Ar-H), 7.46 – 7.39 (m, 2H, Ar-H), 6.03 (d, J = 3.8 Hz, 1H, H-1), 5.57 (ddd, J = 3.9, 1.1, 0.5 
Hz, 1H, H-3), 4.71 (dd, J = 3.8, 1.1 Hz, 1H, H-2), 4.65 (dd, J = 4.7, 3.9 Hz, 1H, H-4), 4.51 (d, J = 4.7 
Hz, 1H, H-5), 3.73 (s, 3H, CH3COO), 1.52 (d, J = 1.2 Hz, 3H, CH3), 1.33 (s, 3H, CH3); 13C NMR (101 
MHz, CDCl3) δ 172.08 (C=O), 165.59 (C=O), 133.52 (Ar), 129.85 (Ar), 129.45 (Ar), 128.57 (Ar), 
112.97 (C), 104.97 (C-1), 84.17 (C-2), 79.77 (C-4), 77.24 (C-3), 69.63 (C-5), 53.00 (CH3COO), 
27.09 (CH3), 26.64 (CH3). Yields of 3.8A and 3.8B calculated by taking the unreacted SM into 
account.   
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NMR Experiment with 5-O-benzoyl-1,2-O-isopropylidene-β-L-idurono-3,6-lactone (3.1):  
The 5-O-benzoyl-1,2-O-isopropylidene-β-L-idurono-3,6-lactone (3.1) (44.2 mg, 0.16 mmol, 1 
eq.) was dissolved in dry CD3OD (0.06 mL, 1.55 mmol, 10 eq.) and dry CDCl3 (0.6 mL) (dried 
with freshly activated with 3Å molecular sieves (beads) under argon and added to a Wilmad 
pressure/vacuum valved NMR tube which had been evacuated and flushed with argon. 
Concentration of starting material = 74 mg/mL in CDCl3. To this the Et3N (0.11 mL, 0.78 mmol, 5 
eq.)(dried with freshly activated with 3Å molecular sieves (beads)) was added at r.t. and the 
first spectra recorded at 30°C  straight after the addition of Et3N. Spectra were then recorded 
every 20 minutes for 2 hours, at 4.5 hrs and 24 hrs after Et3N addition with shaking beforehand. 
The reaction mixture was left in the NMR at r.t. in between data collection. δ are in ppm and 
referenced with respect to TMS. 
 




The methyl 3-O-benzoyl-1,2-O-isopropylidene-β-L-idofuranuronate (3.8B) (68 mg, 0.19 mmol, 1 
eq.) was dissolved in 90% TFA (0.4 mL) at 0°C and vigorously stirred in a sealed round bottom 
flask for 15 mins, which after time TLC analysis revealed a single more polar product. The TFA 
was then removed under a stream of air and H2O removed azeotropically with toluene and 
purified using flash chromatography (1:1 hexane/EtOAc to 7:3 hexane/EtOAc) to yield 46 mg 
(78%) of a mixture of compounds as per NMR. Rf = 0.32 (100% EtOAc); 1H NMR (400 MHz, 
CD3OD) δ 8.15 – 8.01 (m, 10H, Ar-H), 7.66 – 7.56 (m, 5H, Ar-H), 7.53 – 7.44 (m, 10H, Ar-H), 5.55 
(t, J = 6.9 Hz, 1H, H-3 β-fur), 5.42 – 5.38 (m, 1H, H-3 α-fur, H-3 β-pyr), 5.37 (d, J = 4.8 Hz, 1H, H-1 
β-fur), 5.31 (t, J = 5.0 Hz, 1H, H-3 α-pyr), 5.29 (d, J = 3.4 Hz, 1H, H-1 α-pyr), 5.21 (d, J = 2.1 Hz, 1H, 
H-1 α-fur), 5.09 (d, J = 1.5 Hz, 1H, H-1 β-pyr), 4.89 (d, J = 3.3 Hz, 1H, H-5 α-pyr), 4.78 – 4.76 (m, 
1H, H-4 β-fur), 4.75 – 4.72 (m, 1H, H-4 α-fur), 4.64 (d, J = 2.1 Hz, 1H, H-5 β-pyr), 4.54 – 4.46 (m, 
1H, H-2 β-fur), 4.34 (d, J = 4.5 Hz, 1H, H-5, β-fur), 4.28 (dd, J = 3.8, 2.1 Hz, 1H, H-2 α-fur), 4.15 (d, 
J = 2.8 Hz, 1H, H-5 α-fur), 4.12 – 4.08 (m, 1H, H-4 α-pyr), 4.04 (ddd, J = 3.5, 2.1, 1.2 Hz, 1H, H-4 β-
pyr), 3.78 (s, 3H, CH3COO, β-pyr), 3.77 (s, 3H, CH3COO, α-pyr), 3.76 – 3.73 (m, 1H, H-2 β-pyr), 
3.69 (s, 3H, CH3COO, β-fur), 3.68 – 3.67 (m, 1H, H-2 α-pyr), 3.64 (s, 3H, CH3COO, α-fur); 13C NMR 
(101 MHz, Methanol-d4) δ 173.94 (C=O), 173.62 (C=O), 172.03 (C=O), 171.20 (C=O), 134.73 
(Ar), 134.57 (Ar), 134.37 (Ar), 134.14 (Ar), 134.10 (Ar), 131.28 (Ar), 130.80 (4 x Ar), 130.73 
(Ar), 129.74 (Ar), 129.61 (2 x Ar), 129.51 (Ar), 129.42 (Ar), 103.77 (C-1 α-fur), 96.60 (C-1 β-
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fur), 96.41 (C-1 α-pyr), 94.73 (C-1 β-pyr), 81.64 (C-4 α-fur), 81.23 (C-2 α-fur), 79.90 (C-3 α-fur), 
79.47 (C-3 β-fur), 78.18 (C-4 β-fur), 75.55 (C-5 β-pyr), 75.47 (C-2 β-fur), 73.32 (C-3 α-pyr), 
73.00 (C-3 β-pyr), 71.52 (C-5 β-fur), 71.21 (C-5 α-pyr), 71.03 (C-5 α-fur), 70.14 (C-2 α-pyr), 
69.43 (C-2 β-pyr), 69.18 (C-4 α-pyr), 68.47 (C-4 β-pyr), 52.69 (CH3COO), 52.61 (2 x CH3COO), 
52.55 (CH3COO); HRMS (ESI-TOF): [M+NH4]+ Calcd for C14H20NO8: 330.1189 found: 330.1185, 
[M+Na]+ Calcd for C14H16NaO8: 335.0743 found: 335.0742.  
 
Second attempt:40,44 
The methyl 3-O-benzoyl-1,2-O-isopropylidene-β-L-idofuranuronate (3.8B) (89 mg, 0.25 mmol, 1 
eq.) was dissolved in 90% TFA (0.5 mL) at r.t. and vigorously stirred in a sealed round bottom 
flask for 3 hrs, which after TLC analysis revealed a single more polar product. The TFA was then 
removed under a stream of air and H2O removed azeotropically with toluene and purified using 
flash chromatography (1:1 hexane/EtOAc to 7:3 hexane/EtOAc) to yield 36 mg (45%) of a 
mixture of compounds as per NMR and as characterised above. 
 
NMR experiment with methyl 3-O-benzoyl-1,2-O-isopropylidene-β-L-idofuranuronate 
(3.8B):  
The methyl 3-O-benzoyl-1,2-O-isopropylidene-β-L-idofuranuronate (3.8B) (60 mg) was 
dissolved in 90% TFA (1 mL) at r.t. in a round bottom flask, immediately transferred to an NMR 
tube, sealed and the spectrum recorded. The spectra were then recorded at 10 mins, 30 mins, 1 
hr, 1 hr 30 mins and 2 hrs after the initial run. δ are in ppm and referenced with respect to 





A solution of phenyl 2-amino-2-N,3-O-carbonyl-2,6-dideoxy-6-iodo-1-thio-β-D-glucopyranoside 
(2.55) (0.23 g, 0.57 mmol, 1 eq.) in dry DMF (5 mL) was stirred under argon and cooled to 0°C. 
To this benzyl bromide (75 μL, 0.63 mmol, 1.1 eq.) was added, followed by the slow addition of 
NaH (60% dispersion in mineral oil) (68 mg, 1.71 mmol, 3 eq.) The reaction mixture was stirred 
at 0°C for 30 mins and then at r.t. for 1.5 hrs. The reaction mixture was cooled down to 0°C, 
quenched with MeOH, concentrated and washed with brine (40 mL) and EtOAc (4 x 15 mL). The 
combined organic fractions were dried over Na2SO4, concentrated and purified using flash 
chromatography (100% hexane to 8:2 hexane/EtOAc) to yield 0.24 g (90%) of 3.14 as a white 
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solid. Rf  = 0.60 (6:4 hexane/EtOAc); mp 119-121°C; 1H NMR (400 MHz, CDCl3) δ 7.44 – 7.26 (m, 
15H, Ar-H), 5.15 (d, J = 9.7 Hz, 1H, H-1), 4.99 (t, J = 1.5 Hz 1H, H-6), 4.90 (t, J = 1.0 Hz, 1H, H-6’), 
4.78 (AB q, J = 15.24, 11.92 Hz, 2H, CH2), 4.77 (AB d, J = 15.6 Hz, 1H, CH2OPh), 4.62 (AB d, J = 
15.6 Hz, 1H, CH2OPh), 4.32 (dd, J = 11.4, 8.9 Hz, 1H, H-3), 4.26 (dt, J = 8.9, 0.9 Hz, 1H, H-4), 3.39 
(dd, J = 11.4, 9.7 Hz, 1H, H-2); 13C NMR (101 MHz, CDCl3) δ 159.18 (C=O), 137.28 (Ar), 136.34 
(Ar), 132.50 (Ar), 132.17(Ar), 129.28 (Ar), 128.85 (Ar), 128.67(Ar), 128.59 (Ar), 128.30 (Ar), 
128.11 (Ar), 127.99 (Ar), 127.88 (Ar), 103.71 (C-6), 88.50 (C-1), 79.84 (C-3), 76.08 (C-4), 71.60 
(CH2OPh), 59.79 (C-2), 47.99 (CH2OPh); HRMS (ESI-TOF): [M+H]+ Calcd for C27H26NO4S: 
460.1583 found: 460.1583; [M+NH4]+ Calcd for C27H29N2O4S: 477.1848 found: 477.1855. Crystal 






A solution of phenyl N-benzyl-4-O-benzyl-2-N,3-O-carbonyl-2,6-dideoxy-1-thio-β-D-xylo-hex-5-
enopyranoside (3.14) (64 mg, 0.14 mmol, 1 eq.) in dry THF (2 mL) and freshly activated with 
3Å powdered molecular sieves was stirred under argon and cooled to -10°C. To this 0.5M 9-BBN 
in THF (0.7 mL, 0.36 mmol, 2.6 eq.) was added and stirred at this temperature for 10 minutes 
and r.t. for 2 hrs. Another 7.4 eq. of 9-BBN was then added and stirred for a further 4 hrs.   
 
Using BH3.THF:49 
A solution of phenyl 2-N-benzyl-4-O-benzyl-2-N,3-O-carbonyl-2,6-dideoxy-1-thio-β-D-xylo-hex-
5-enopyranoside (3.14) (90 mg, 0.24 mmol, 1 eq.) in dry THF (3.5 mL) and freshly activated 
with 3Å powdered molecular sieves was stirred under argon and cooled to 0°C. To this 1M 
BH3.THF (2.44 mL, 2.44 mmol, 10 eq.) was added and stirred at this temperature for 1.5 hrs. The 
reaction mixture was then filtered through celite with cold THF (30 mL), cooled to 0°C and to 
this was added 30% aq. H2O2 (3.48 mL) followed by 2N NaOH (3.48 mL). This was left to slowly 
warm to r.t. over 1 hr. The reaction mixture was then diluted with EtOAc, transferred to a 
separating funnel and washed with EtOAc (4 x 35 mL) and NH4Cl (30 mL). The combined 
organic fractions were dried over Na2SO4, concentrated and purified using flash 
chromatography (1:1 hexane/EtOAc) to yield 62 mg (52%) of 3.16 as a white solid. Rf  = 0.42 
(100% EtOAc); mp 145-147°C; 1H NMR (400 MHz, CDCl3) δ 7.50 – 7.26 (m, 13H, Ar-H), 7.08 – 
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6.93 (m, 2H, Ar-H), 5.14 (AM d, J = 16.1 Hz, 1H, CH2OPh), 4.86 (ddd, J = 9.9, 4.5, 1.3 Hz, 1H, H-5), 
4.85 (AB d, J = 11.66 Hz, 1H, CH2OPh), 4.55 (AB d, J = 11.8 Hz, 1H, CH2OPh), 4.44 (m, 1H, H-3), 
4.43 (d, J = 6.5 Hz, 1H, H-1), 4.37 (AM d, J = 16.0 Hz, 1H, CH2OPh), 4.25 – 4.20 (m, 1H, H-2), 4.13 
(m, 1H, H-4), 3.77 (ddd, J = 12.6, 5.9, 4.4 Hz, 1H, H-6), 3.76 – 3.65 (m, 1H, H-6’), 2.08 (dd, J = 9.0, 
4.4 Hz, 1H, 6-OH); 13C NMR (101 MHz, CDCl3) δ  159.11 (C=O), 131.41 (Ar), 131.26 (Ar), 129.48 
(Ar), 129.04 (Ar), 128.83 (Ar), 128.78 (Ar), 128.43 (Ar), 128.28 (2 x Ar), 127.92 (Ar), 124.32 
(Ar), 90.92 (C-2), 80.39 (C-1),  79.27 (C-5), 76.67 (C-4), 72.07 (CH2OPh), 61.55 (CH2OPh), 55.20 
(C-3), 48.90 (CH2OPh); HRMS (ESI-TOF): [M+H]+ Calcd for C27H28NO6S: 494.1637 found: 





A solution of phenyl 2-amino-2-N,3-O-carbonyl-2-deoxy-1-thio-β-D-glucopyranoside (2.47) 
(3.79 g, 12.75 mmol, 1 eq.) was dissolved in dry DCM under argon and cooled to 0°C. To this the 
DIPEA (13.3 mL, 76.50 mmol, 6 eq.), followed by freshly distilled AcCl (5.3 mL, 76.5 mmol, 6 eq.) 
was added and stirred for 45 mins at this temperature. The reaction mixture was diluted with 
DCM, transferred to a separating funnel and washed with 5% HCl solution (100 mL) and  DCM 
(3 x 60 mL) and combined organic fractions were dried over Na2SO4, concentrated and purified 
using flash chromatography (1:1 hexane/DCM) to yield 5.27 g (96%) of 3.18 as a yellow oil. Rf  = 
0.67 (3:1 DCM/EtOAc); 1H NMR (400 MHz, CDCl3) δ 7.53 – 7.46 (m, 2H, Ar-H), 7.31 – 7.25 (m, 
3H, Ar-H), 5.27 (dd, J = 9.8, 8.8 Hz, 1H, H-4), 4.90 (d, J = 8.3 Hz, 1H, H-1), 4.23 (dd, J = 11.4, 9.8 
Hz, 1H, H-3), 4.19 (dd, J = 6.1, 1.0 Hz, 2H, H-6’s), 4.16 (dd, J = 11.7, 8.6 Hz, 1H, H-2), 3.72 (ddd, J = 
8.7, 5.2, 3.3 Hz, 1H, H-5), 2.54 (s, 3H, CH3CO), 2.09 (s, 3H, CH3CO), 2.03 (s, 3H, CH3CO).  
 
Phenyl 2-N-acetyl-4,6-di-O-acetyl-2-amino-2-N,3-O-carbonyl-2-deoxy-1-thio-α-D-
glucopyranoside (3.19).  
 
First attempt:34 
A solution of phenyl N-acetyl-2-amino-4,6-di-O-acetyl-2-N,3-O-carbonyl-2-deoxy-1-thio-β-D-
glucopyranoside (3.18) (47 mg, 0.11 mmol, 1 eq.) and activated 4Å molecular sieves in mL of 
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dry DCM (5 mL) was stirred under argon for 10 minutes. To this silver 
trifluoromethanesulfonate (AgOTf) (5.7 mg, 0.2 mmol, 0.2 eq.) was added and stirred at r.t. for 
20 hours. The reaction mixture was filtered through celite, diluted with DCM and transferred to 
a separating funnel and washed with brine and DCM (3 x 20 mL). Combined organic fractions 
were dried over Na2SO4, concentrated and purified using flash chromatography (7.5:2.5 
hexane/EtOAc to 6:4 hexane/EtOAc) to yield 36.2 mg (77%, 9:1 α/β from NMR) of a mixture of 
3.18 and 3.19 as a yellow oil. Rf  = 0.67 (3:1 DCM/EtOAc). Crude NMR revealed un-anomerized 
product still present. 
 
Second attempt:37 
A solution of phenyl N-acetyl-2-amino-4,6-di-O-acetyl-2-N,3-O-carbonyl-2-deoxy-1-thio-β-D-
glucopyranoside (3.18) (3.29 g, 7.73 mmol, 1 eq.) and activated 3Å powdered molecular sieves 
in dry DCM (20 mL) was stirred under argon for 10 minutes. To this SnCl4 (2.3 mL, 19.32 mmol, 
2.5 eq.) was added and stirred at r.t. for 25 hours. The reaction mixture was filtered through 
celite, diluted with DCM and transferred to a separating funnel and washed with brine and DCM 
(3 x 20 mL). Combined organic fractions were dried over Na2SO4, concentrated and purified 
using flash chromatography (7.5:2.5 hexane/EtOAc to 6:4 hexane/EtOAc) to yield 2.94 g (89%) 
of 3.19 as a yellow oil. Rf  = 0.67 (3:1 DCM/EtOAc); 1H NMR (400 MHz,CDCl3) δ 7.49 – 7.43 (m, 
2H, Ar), 7.35 – 7.28 (m, 3H, Ar), 6.19 (d, J = 4.6 Hz, 1H, H-1), 5.30 (dd, J = 10.1, 9.3 Hz, 1H, H-4), 
4.47 (dd, J = 12.1, 10.1 Hz, 1H, H-3), 4.38 (dddd, J = 9.2, 5.1, 2.2, 0.7 Hz, 1H, H-5), 4.31 (dd, J = 
12.3, 5.1 Hz, 1H, H-6), 4.18 (ddd, J = 12.3, 6.4, 3.4 Hz, 2H, H-2, H-6’), 2.53 (s, 3H, CH3CO), 2.14 (s, 
3H, CH3 CO), 2.06 (s, 3H, CH3 CO); 13C NMR (101 MHz, CDCl3) δ 171.12 (C=O), 170.55 (C=O), 
169.22 (C=O), 152.55 (C=O), 132.82 (C-Ar), 131.99 (C), 129.40 (C-Ar), 128.59 (C), 86.29 (C-1), 
76.00 (C-3), 70.52 (C-5), 68.18 (C-4), 61.81 (C-6), 60.03 (C-2), 23.83 (CH3CO), 20.72 (CH3CO), 
20.72 (CH3CO). NMR values agree with the published values.50 HRMS (ESI-TOF): [M+H]+ Calcd 
for C19H22NO8S: 424.1066 found 424.1056, [M+NH4]+ Calcd for C19H25N2O8S: 441.1332 found: 














Table 3.1, Entry 1: 
 
Phenyl 2-N-acetyl-2-amino-4,6-di-O-acetyl-2-N,3-O-carbonyl-2-deoxy-1-thio-α-D-
glucopyranoside (3.19) (55 mg, 0.13 mmol, 1 eq.) in MeOH (2 mL) was cooled to 0°C and to this 
2 drops of 4.62 M NaOMe was added. This was then taken up to r.t. and left to stir for 30 mins 
after which time Amberlite IR-120 (H+ form) was added and stirred for 15 mins. The reaction 
mixture was filtered and purified using flash chromatography (3:1 DCM/EtOAc) to yield 27 mg 
(55%) of 3.21 as a white solid. Rf = 0.67 (13:7 DCM/EtOAc); 1H NMR (400 MHz, CDCl3) δ 7.52 – 
7.47 (m, 2H, Ar-H), 7.37 – 7.30 (m, 3H, Ar-H), 5.68 (d, J = 4.89 Hz, 1H, H-1), 5.34 (dd, J = 10.1, 9.3 
Hz, 1H, H-4), 5.29 (bs, 1H, NH), 4.57 (dd, J = 11.8, 10.1 Hz, 1H, H-3), 4.39 (dddd, J = 9.3, 5.4, 2.2, 
0.6 Hz, 1H, H-5), 4.32 (dd, J = 12.24, 5.37 Hz, 1H, H-6), 4.17 (dd, J = 12.3, 2.1 Hz, 1H, H-6’), 4.07 
(ddd, J = 11.7, 4.8, 1.3 Hz, 1H, H-2), 2.14 (s, 3H, CH3CO), 2.07 (s, 3H, CH3CO); 13C NMR (101 MHz, 
CDCl3) δ 170.60 (C=O), 169.37 (C=O), 157.97 (Ar), 132.25 (Ar), 129.48 (Ar), 128.45 (Ar), 85.28 
(C-1), 78.26 (C-3), 70.59 (C-5), 68.38 (C-4), 62.00 (C-6), 58.68 C-2), 20.80 (d, 2 X CH3CO). 
 
Table 3.2, Entry 2: 
 
Phenyl 2-N-acetyl-2-amino-4,6-di-O-acetyl-2-N,3-O-carbonyl-2-deoxy-1-thio-α-D-
glucopyranoside (3.19) (68 mg, 0.16 mmol, 1 eq.) in MeOH (2 mL) was cooled to 0°C and to this 
4.62 M NaOMe (14 μL, 0.07 mmol, 0,4 eq.) was added. This was then taken up to r.t. and left to 
stir for 30 mins after which time Amberlite IR-120 (H+ form) was added and stirred for 10 mins. 
The reaction mixture was filtered and purified using flash chromatography (19:1 DCM/MeOH) 
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HRMS (ESI-TOF):  
3.22: [M+H]+ Calcd for C13H16NO5S: 298.0749 found: 298.0750 
3.23: [M+H]+ Calcd for C14H20NO6S: 330.1011 found: 330.1013, [M+Na]+ Calcd for C14H19NNaO6S: 
352.0831 found: 352.0833 
3.24: [M+H]+ Calcd for C19H21NO5S2: 407.0861 found: 408.0943 
 
Table 3.1, Entry 3:51 
Phenyl 2-N-acetyl-2-amino-4,6-di-O-acetyl-2-N,3-O-carbonyl-2-deoxy-1-thio-α-D-
glucopyranoside (3.19) (0.10 g, 0.24 mmol, 1 eq.) was dissolved in MeOH/H2O (7.5 mL) (2:1) 
and to this K2CO3 (0.23 g, 1.65 mmol, 7 eq.) was added and stirred at r.t. for 10 mins after which 
time Amberlite IR-120 (H+ form) was added and stirred for a further 10 mins. The reaction 
mixture was filtered and purified using flash chromatography (19:1 DCM/MeOH) to yield 36 mg 
of a mixture of compounds as seen by 1H NMR. Rf = 0.12 (19:1 DCM/MeOH). Characterization as 
above.  
 
Table 3.1, Entry 4:52 
Phenyl 2-N-acetyl-2-amino-4,6-di-O-acetyl-2-N,3-O-carbonyl-2-deoxy-1-thio-α-D-
glucopyranoside (3.19) (53 mg, 0.13 mmol, 1 eq.) in THF (2 mL) was cooled to 0°C and to this 
was added LiOH.H2O (16 mg, 0.38 mmol, 3 eq.) and 30% aq. H2O2 (0.19 mL) and stirred at this 
temperature for 2 hrs after which time TLC indicated that the starting material had degraded.  
 
Table 3.1, Entry 5:36 
Phenyl 2-N-acetyl-2-amino-4,6-di-O-acetyl-2-N,3-O-carbonyl-2-deoxy-1-thio-α-D-
glucopyranoside (3.19) (59 mg, 0.14 mmol, 1 eq.) in THF/H2O (5.6 mL) (3:1) was cooled to -
40°C and to this was added 2 drops of 30% aq. H2O2 followed by LiOH.H2O (12 mg, 0.0.28 mmol, 
2 eq.) and stirred at this temperature for 5 mins, brought to r.t. and immediately quenched with 
sat. aq. Na2SO3 (2 mL). The reaction mixture was diluted with EtOAc (10 mL) and brine (10 mL) 
and the aq. layer washed with EtOAc (3 x 20 mL). The combined organic fractions were dried 
over Na2SO4, concentrated and TLC checked to reveal a mixture of compounds which was not 
worth purifying since no dominant product could be seen.  
 
Table 3.1, Entry 6:  
Phenyl 2-N-acetyl-2-amino-4,6-di-O-acetyl-2-N,3-O-carbonyl-2-deoxy-1-thio-α-D-
glucopyranoside (3.19) (17 mg, 0.04 mmol, 1 eq.) in THF (2 mL) was cooled to 0°C and to this 
was added 2N NaOH (60 μL) and stirred at this temperature for 2 hrs after which time TLC 
indicated that the starting material had degraded.  
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Table 3.1, Entry 7: 
 
Phenyl 2-N-acetyl-2-amino-4,6-di-O-acetyl-2-N,3-O-carbonyl-2-deoxy-1-thio-α-D-
glucopyranoside (3.19) (0.95 g, 2.22 mmol, 1 eq.) was dissolved in acetone/H2O (39 mL) (2:1) 
and to this 10.2M HCl (5.6 mL) was added and stirred at 65°C for 4.5 hrs and then at r.t. for 18 
hrs. The reaction mixture was neutralized with sat. aq. NaHCO3 (50 mL), acetone removed, 
diluted with EtOAc, transferred to a separating funnel and the aqueous layer washed with EtOAc 
(3 x 40 mL). The combined organic fractions were dried over Na2SO4, concentrated and purified 
using flash chromatography (7:3 hexane/EtOAc) to yield 0.22 g (29%) of 3.20 as a white solid. 
Rf = 0.29 (7:3 hexane/EtOAc); mp 191-193°C; 1H NMR (400 MHz, CO(CD3)2) δ 7.56 – 7.52 (m, 
2H, Ar), 7.39 – 7.32 (m, 3H, Ar), 6.11 (dd, J = 4.4, 0.6 Hz, 1H, H-1), 5.12 (d, J = 5.5 Hz, 1H, OH-4), 
4.37 (dd, J = 12.1, 9.6 Hz, 1H, H-3), 4.23 (dd, J = 12.1, 4.4 Hz, 1H, H-2), 4.10 (ddd, J = 9.6, 8.8, 5.4 
Hz, 1H, H-4), 4.03 – 3.94 (m, 1H, H-5), 3.87 (dd, J = 3.4, 2.1 Hz, 1H, H-6), 3.85 (d, J = 3.4 Hz, 1H, 
OH-6), 3.78 (dd, J = 7.2, 5.3 Hz, 1H, H-6’), 2.44 (s, 3H, CH3CO); 13C NMR (101 MHz, Acetone-d6) δ 
171.83 (C=O), 154.21 (C=O), 134.57 (Ar), 133.23 (Ar), 130.06 (Ar), 128.79 (Ar), 87.55 (C-1), 
79.76 (C-3), 77.05 (C-5), 68.93 (C-4), 61.33 (C-6), 60.57 (C-2), 23.79 (CH3CO); HRMS (ESI-TOF): 
[M+H]+ Calcd for C15H18NO6S: 340.0855 found: 340.0848, [M+Na]+ Calcd for C15H17NNaO6S: 
362.0674 found: 362.0669.  
 
Table 3.1, Entry 8: 
Phenyl 2-N-acetyl-2-amino-4,6-di-O-acetyl-2-N,3-O-carbonyl-2-deoxy-1-thio-α-D-
glucopyranoside (3.19) (0.47 g, 2.22 mmol, 1 eq.) was dissolved in acetone/H2O (19.5 mL) (2:1) 
and to this 10.2M HCl (1.6 mL) was added and stirred at 65°C for 4 hrs. The reaction mixture 
was neutralized with sat. aq. NaHCO3 (50 mL), acetone removed, diluted with EtOAc, transferred 
to a separating funnel and the aqueous layer washed with EtOAc (3 x 40 mL). The combined 
organic fractions were dried over Na2SO4, concentrated and purified using flash 
chromatography (7:3 hexane/EtOAc) to yield 0.22 g (29%) of 3.20 as a white solid. Rf = 0.29 
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Phenyl 2-amino-2-N,3-O-carbonyl-2-deoxy-1-thio-α-D-glucopyranoside (3.32).37 
 
A solution of phenyl 2-amino-2-N,3-O-carbonyl-2-deoxy-1-thio-β-D-glucopyranoside (2.47) 
(44.9 mg, 0.15 mmol, 1 eq.) was dissolved in dry DCM/THF (5 mL) (4:1) and activated 3Å 
molecular sieves under argon. To this 1M SnCl4 (0.04 mL, 0.38 mmol, 2.5 eq.) was added and 





A solution of phenyl 2-N-acetyl-2-amino-2-N,3-O-carbonyl-2-deoxy-1-thio-α-D-glucopyranoside 
(3.20) (0.35 g, 1.02 mmol, 1 eq.) and activated 3Å molecular sieves in dry pyridine (10 mL) was 
stirred under argon and cooled to 0°C. To this freshly recrystallized p-toluenesulfonyl chloride 
(0.23 g, 1.22 mmol, 1.2 eq.) was added and stirred for 3 hours at this temperature and then at 
r.t. for 1.5 hours. The reaction mixture was filtered through celite, transferred to a separating 
funnel and washed with 5% HCl solution (40 mL). The aqueous layer was washed with DCM (4 x 
30 mL) and combined organic fractions were dried over Na2SO4, concentrated and purified 
using flash chromatography (9.5:0.5 Hexane/EtOAc to 7:3 hexane/EtOAc) to yield 0.39 g (77%) 
of 3.25 as an off white solid. Rf = 0.51 (1:1 hexane:EtOAc), mp 165-167°C; 1H NMR (400 MHz, 
CDCl3) δ 7.79 – 7.73 (m, 2H, Ar-H), 7.43 – 7.36 (m, 2H, Ar-H), 7.33 – 7.27 (m, 5H, Ar), 6.02 (d, J = 
4.5 Hz, 1H, H-1), 4.51 (dd, J = 11.5, 3.4 Hz, 1H, H-6), 4.34 (dd, J = 12.1, 9.2 Hz, 1H, H-3), 4.26 (dd, J 
= 11.5, 1.8 Hz, 1H, H-6’), 4.18 – 4.06 (m, 2H, H-5, H-4), 3.97 (dd, J = 12.1, 4.5 Hz, 1H, H-2), 3.19 (s, 
1H, OH-4), 2.52 (s, 3H, CH3), 2.43 (s, 3H, CH3CO); 13C NMR (101 MHz, CDCl3) δ 171.28 (C=O), 
153.10 (C=O), 145.38 (Ar), 132.78 (Ar), 132.63 (Ar), 132.33 (Ar), 130.03 (Ar), 129.36 (Ar), 
128.40 (Ar), 128.14 (Ar), 86.37 (C-1), 78.15 (C-3), 72.54 (C-5), 68.12 (C-4), 67.78 (C-6), 59.72 
(C-2), 23.88 (CH3CO), 21.78 (CH3); HRMS (ESI-TOF) [M+H]+ Calcd for C22H24NO8S2: 494.0943 











(3.25) (0.100 g, 0.21 mmol, 1 eq.) and NaI (70 mg, 0.46 mmol, 2.2 eq.) were dried using a 
Schlenk line. To this dry butanone (3 mL) was added under argon and refluxed for 17 hrs. The 
reaction mixture was then concentrated and purified using flash chromatography (8:2 
hexane/DCM to 100% DCM) to yield 63 mg (67%) of 3.26 as a white solid. Rf  = 0.56 (18.5:1.5 
DCM:EtOAc); 1H NMR (400 MHz, CDCl3) δ 7.54 – 7.49 (m, 2H, Ar-H), 7.36 – 7.30 (m, 3H, Ar-H), 
6.18 (dd, J = 4.5, 0.6 Hz, 1H, H-1), 4.43 (dd, J = 12.1, 9.6 Hz, 1H, H-3), 4.08 (dd, J = 12.1, 4.5 Hz, 
1H, H-2), 3.97 (dd, J = 9.6, 8.5 Hz, 1H, H-4), 3.86 – 3.77 (m, 1H, H-5), 3.58 (dd, J = 11.0, 3.0 Hz, 1H, 
H-6), 3.54 (dd, J = 11.0, 4.9 Hz, 1H, H-6’), 2.55 (s, 3H, CH3CO); 13C NMR (101 MHz, CDCl3) δ 
171.31 (C=O), 153.16 (C=O), 132.97 (Ar), 132.31 (Ar), 129.40(Ar), 128.50 (Ar), 86.61 (C-1), 
78.10 (C-3), 72.75 (C-5), 72.71 (C-4), 59.98 (C-2), 23.93 (CH3CO), 5.87 (C-6); HRMS (ESI-TOF) 
[M+H]+ Calcd for C15H17INO5S: 449.9872 found: 449.9860, [M+Na]+ Calcd for C15H16INNaO5S: 







A solution of phenyl 2-N-acetyl-2-amino-2-N,3-O-carbonyl-2,6-dideoxy-6-iodo-1-thio-α-D-
glucopyranoside (3.26) (43 mg, 0.10 mmol, 1 eq.) in dry DMF (2 mL) and 3Å powdered 
molecular sieves was stirred under argon and cooled to 0°C. To this benzyl bromide (14 μL, 0.12 
mmol, 1.2 eq.) was added, followed by the slow addition of NaH (60% dispersion in mineral oil) 
(11.6 mg, 0.30 mmol, 3 eq.) The reaction mixture was stirred at 0°C for 10 mins and then at r.t. 
for 6 hrs. The reaction mixture was cooled down to 0°C, quenched with MeOH, concentrated, 
and washed with brine (15 mL) and EtOAc (4 x 15 mL). The combined organic fractions were 
dried over Na2SO4, concentrated, remaining DMF azeotropically removed with toluene and 
purified using flash chromatography (100% hexane to 4:6 hexane/EtOAc) to yield 24.5 mg 
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(65%) of 3.28 as an opaque oil, which upon recrystallization (DCM/hexane) gave a white solid. 
Rf  = 0.22 (9:11 hexane/EtOAc); mp 134-136°C; 1H NMR (400 MHz, CO(CD3)2) δ 7.57 – 7.48 (m, 
4H, Ar-H), 7.43 (tt, J = 6.6, 0.9 Hz, 2H, Ar-H), 7.39 – 7.28 (m, 3H, Ar-H), 7.27 – 7.21 (m, 1H, Ar-H), 
7.06 (bd, J = 10.5 Hz, 1H, NH), 5.72 (d, J = 4.1 Hz, 1H, H-1), 4.89 (AB d, J = 11.3 Hz, 1H, CH2OPh), 
4.69 (AB d, J = 11.4 Hz, 1H, CH2OPh), 4.65 (t, J = 2.9 Hz, 1H, H-5), 4.47 (dtt, J = 10.4, 4.2, 0.9 Hz, 
1H, H-2), 4.34 (d, J = 10.9 Hz, 1H, H-6), 4.19 – 4.16 (m, 1H, H-3),‡ 4.13 (ddd, J = 5.5, 2.6, 0.9 Hz, 
1H, H-4), 4.01 (dd, J = 10.9, 3.0 Hz, 1H, H-6’), 1.75 (s, 3H, CH3CO); 13C NMR (101 MHz, CO(CD3)2) 
δ 169.13 (C=O), 138.86 (Ar), 136.38 (Ar), 130.99 (Ar), 129.77 (Ar), 129.45 (Ar), 128.88 (Ar), 
128.61 (Ar), 127.55 (Ar), 83.31 (C-1), 78.71 (C-4), 74.77 (C-5), 72.92 (C-3), 72.72 (CH2OPh), 
69.42 (C-6), 52.23 (C-2), 23.03 (CH3CO); HRMS (ESI-TOF) [M+H]+ Calcd for C21H24NO4S: 
386.1426 found: 386.1428; [M+Na]+ Calcd for C21H23NNaO4S: 408.1245 found: 408.1240.  
 
Second attempt: 
A solution of phenyl 2-N-acetyl-2-amino-2-N,3-O-carbonyl-2,6-dideoxy-6-iodo-1-thio-α-D-
glucopyranoside (3.26) (34 mg, 0.07 mmol, 1 eq.) in dry DMF (2 mL) and 3Å powdered 
molecular sieves was stirred under argon and cooled to 0°C. To this benzyl bromide (10 μL, 0.08 
mmol, 1.1 eq.) was added, followed by the slow addition of NaH (60% dispersion in mineral oil) 
(9 mg, 0.37 mmol, 5 eq.) The reaction mixture was stirred at 0°C for 2 hrs and then at room 
temperature for 6 hrs. The reaction mixture was cooled down to 0°C, quenched with MeOH, 
concentrated, and washed with brine (15 mL) and EtOAc (4 x 15 mL). The combined organic 
fractions were dried over Na2SO4, concentrated, remaining DMF azeotropically removed with 
toluene and purified using flash chromatography (100% hexane to 4:6 hexane/EtOAc) to yield 
14.3 mg (49%) of 3.28 as an opaque oil, which upon recrystallization (DCM/hexane) gave a 
white solid. Characterised as above. 
                                                          
‡
 Assigned as a multiplet, but appears to be a dd.  
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Chapter 6: Nuclear Magnetic Resonance (NMR) spectral analysis of  




6.1  NMR spectroscopy 
Nuclear magnetic resonance (NMR) spectroscopy is a powerful tool used for the structural 
elucidation of molecules. It is a robust, non-destructive method of analysis, requiring easy 
sample preparation (no derivatisation of the molecule is necessary) and gives an indication of 
the structural integrity and purity of a compound.1 NMR is an important analytical tool used by 
pharmacopoeia, the WHO and U.S. Food and Drug Administration (FDA) for regulation and 
approval of drugs and vaccines.2 
 
6.1.1  NMR spectroscopy for glycoconjugate analysis  
In the case of glycoconjugate vaccines, NMR analysis provides a fingerprint spectrum which is 
characteristic of the antigen. Because of this it can be used to monitor the polysaccharide 
component of the vaccine at intermediate steps throughout the manufacturing process, making 
it an ideal tool for the analysis, regulation and licensure of glycoconjugate vaccines.  
 
The number of monosaccharides in the repeating unit can be determined from the anomeric 
region (1H: δ 4.4 - 5.5 ppm) in the 1H NMR spectrum and the anomeric configuration of these 
sugars can be identified from the chemical shifts and coupling constants.3 However, line 
broadening is often seen in glycoconjugate samples due to the slow tumbling of the conjugate as 
a result of the large hydrodynamic size, and so determining coupling constants of the attached 
polysaccharide is not always possible.3,4 In addition, other functional groups such as methyl 
groups belonging to N-acetyl and O-acetyl groups (2.2 - 2.0 ppm) as well as methyl groups 
belonging to 6-deoxy sugars (1.35 - 1.5 ppm) can easily be identified. Since it is a sensitive tool, 
changes to inter-sugar linkages or O-acetylation patterns of the antigen can also be detected 
simply from inspecting the 1D 1H NMR spectrum.5 Furthermore, it may be possible to identify 
terminal residues of short chains, and since NMR spectroscopy is a quantitative tool, this can 
sometimes be used to determine the saccharide chain length. 
 
In addition to the 1D 1H NMR experiment, more advanced 1D and 2D homo- and heteronuclear 
experiments can be used to elucidate the structure of the repeating unit to gain further 
structural information. The 2D homonuclear (1H-1H) correlation experiment (COSY) reveals 
correlations between vicinal protons, and by tracing the signals from the anomeric region, the 
neighboring proton (H-1 to H-2 and H-2 to H-3 and so on) for each constituent monosaccharide 




 within the same spin system (e.g. H-1 to H-6). This however depends on signal overlap and the 
magnitude of coupling constants.6 The heteronuclear correlation experiment (HSQC) identifies 
1H-13C correlations and gives the 2D proton-carbon fingerprint. The HMBC and NOESY 
experiments allow for the determination of inter-sugar linkages and the 3D structure of the 
saccharide through 3J heteronuclear multiple bond couplings and through-space effects 
respectively.7,8 From the above experiments it is possible to fully characterize the structure of 
the polysaccharide component of glycoconjugate vaccines.  
 
6.2 The structure S. flexneri 2a serotype 
S. flexneri 2a is one of 17 serotypes in the S. flexneri serogroup9 and accounts for the majority of 
infections in the developing world.10–12 All S. flexneri serotypes, except type 6 and 6a are 
composed of the basic linear tetrasaccharide repeating unit (Figure 6.1), to which α-D-
glucopyranose and/or O-acetyl groups are attached at different positions. It is this varying 




                               (Rha III)                 (Rha II)                   (Rha I)             
 
Figure 6.1: The basic tetrasaccharide repeating unit found in all S. flexneri serotypes except type 6 & 6a.13  
 
 
The S. flexneri 2a repeating unit was found to be 100% glucosylated at the RhaI position (α-1→4 
linked) with O-acetylation quantified,13,16 but the position and degree of O-acetylation was only 
recently determined by Kubler-Kielb et al.,17 with later reports by Perepelov et al.18 giving 
evidence for further minor O-acetylation at the 4-position of RhaIII (Figure 6.2). In other 
bacteria, the observed pattern of O-acetylation may vary with the specific strain used, the 







Figure 6.2: The repeating unit of S. flexneri 2a.17,18 
 
 
6.3 GlycoVaxyn S. flexneri 2a sample analysis 
Glycoconjugate vaccines made using traditional methods require the separate culturing of the 
bacterial pathogen and protein carrier (Figure 6.3). In order to obtain the polysaccharide 
component, it needs to be chemically cleaved from the lipid A, after which, further 
derivatisation for chemical linkage to the protein may be needed. Each step requires the 
purification and rigorous analysis of the desired component using various techniques. The step-
by-step analysis of the polysaccharide using several assays confirms composition and structure 
early on in the process and therefore only a subset of assays are required for the final 
glycoconjugate analysis. On the other hand, by virtue of the GlycoVaxyn method, only one 
purification step is required to obtain the glycoconjugate and all analysis is carried out at this 
stage. The use of NMR spectroscopy in characterizing the antigen is therefore essential for this 
























Figure 6.3: Traditional vs. GlycoVaxyn methods for glycoconjugate preparation.20 
 
 
GlycoVaxyn is preparing for Phase I clinical trials of the S. flexneri 2a serotype glycoconjugate 
vaccine and this chapter deals with the analysis of the glycoconjugate and glycopeptide samples 
from development to the GMP test lots for the clinical trial.  
 
6.4  Experimental methods  
Samples were received from GlycoVaxyn. Each sample contained between 1 – 2 mg of O-antigen 
and as a result no 13C NMR experiments could be conducted.  The vial contents was dissolved in 
D2O and transferred to a pear shaped flask and freeze-dried. After a further exchange with D2O 
(0.7 mL), the sample was dissolved in 0.7 mL D2O and transferred to a NMR tube (Wilmad) for 
analysis. NMR experiments on the glycoconjugate and glycopeptide development lot samples 
were conducted using a Bruker 400 MHz NMR spectrometer with the probe temperature set at 
303K or 313K, whereas the glycoconjugate and glycopeptide GMP test lot samples were 
analysed using a Bruker Avance III 600 MHz NMR spectrometer equipped with a BBO Prodigy 
cryoprobe and the probe temperature was set at 303K or 313K. 1H and 13C spectra were 
referenced with respect to H-1 and   C-1 of the Glc residue (5.20/98.9 ppm). 2D NMR spectra 
were obtained using standard Bruker software, and MesReNova 8.1 was used to process the 
NMR data. 1D TOCSY (selmlgp) experiments were conducted with mixing times = 250 ms (400 




MHz); HSQC-TOCSY (hsqcdietgpsisp), mixing time = 120 ms (600 MHz); 2D NOESY (noesyphpr), 
mixing time = 300 ms (600 MHz). 
 
6.5 Analysis of the glycoconjugate development lot sample 
Analysis of the 1D 1H NMR spectrum of the glycoconjugate development lot sample identified 
various key signals (Figure 6.4). This showed the presence of broad rEPA signals together with 
sharper peaks assignable to the S. flexneri 2a antigen. The 5 anomeric signals at 5.20 ppm (Glc), 
5.13 ppm (RhaIII), 5.02 ppm (RhaII), 4.84 ppm (RhaI) and 4.73 ppm (GlcNAc), the CH3 peaks 
from C-6 of the rhamnose units at 1.35 and 1.29 ppm, and the N-acetyl group at 2.07 ppm are all 
easily identified. No additional O-acetyl peaks in the region of 2.0 - 2.2 ppm can be seen 
(although free acetate at 1.91 ppm is present) and this together with the anomeric shifts agree 
































Figure 6.4: 1D 1H NMR spectrum of the glycoconjugate development lot sample with pre-saturation of 
the HOD peak at 313K.  
 
 
The spin systems for the five monosaccharide residues were investigated using proton-proton 
1D TOCSY experiments. Generally, for TOCSY experiments (1D and 2D) transfer of 
magnetization from H-1 to all the other protons in the spin system requires large vicinal J-
couplings between the protons.6 With Glc and GlcNAc residues it is often possible for 
magnetisation to be transferred to all protons in the spin system due to the axial-axial couplings 




while signals beyond H-2 are not usually observed for L-rhamnose. However, irradiating an 
alternative proton first, such as H-6 of the Rha residue overcomes this. In this instance the 1D 
TOCSY experiments were performed by irradiating H-6 of RhaI and H-2 of RhaII and RhaIII and 
this allowed for the identification of all protons in the respective spin systems (Figure 6.5), 
which were in agreement with published data.18 The 2D COSY and TOCSY experiments further 






































Figure 6.5: 1D TOCSY spectra of each monosaccharide from the glycoconjugate development lot sample. 
 
 
Next, carbon assignments were confirmed with the aid of the HSQC experiment. The HSQC 
spectrum (Figures 6.6) constitutes a 2D proton-carbon fingerprint of the S. flexneri 2a antigen. 
The area highlighted by the red oval indicates where O-acetyl crosspeaks should appear, 
confirming that this sample contains no O-acetylation. Closer inspection of the ring region made 
the proton-carbon assignments possible for all residues with the aid of literature (Figure 6.7).  
The 13C chemical shifts of C-5 (70.4-70.9 ppm) of all Rha units indicate they are α-linked.15 While 
the downfield shifts between 5.91-9.70 ppm of C-2 for RhaIII and RhaII, and C-3 of RhaI and 










Figure 6.6: HSQC experiment of the glycoconjugate development lot sample. This provides the proton-
carbon fingerprint of the antigen. The area highlighted by the red oval indicates where O-acetyl 





























Figure 6.7: HSQC spectrum of the ring region with assignments for the glycoconjugate development lot 
sample. Crosspeaks are assigned based on the proton assignments made from COSY and TOCSY and 





Likewise, analysis of the anomeric region made proton-carbon assignments for the five residues 
possible (Figure 6.8). Interestingly, two additional small crosspeaks were seen, one at 
4.97/103.99 ppm and another at 5.07/99.56 ppm. From the crosspeak at 4.97/1013.99 ppm in 
the TOCSY spectrum (Figure 6.9) a corresponding proton and carbon at 4.08/71.56 ppm in 
HSQC spectrum can be identified. These peaks were assigned to the non-reducing end terminal 
RhaIII unit (tRhaIII), with H-1 appearing at 4.97 ppm and H-2 at 4.08 ppm. This is in close 






1H:  4.97 ppm 
13C: 103.99 ppm





Figure 6.8: HSQC spectra of the anomeric region of the development lot  glycoconjugate sample. The 
crosspeak 4.97/103.99 ppm was assigned to H-1 of tRhaIII, while it was not possible to assign the 
















Figure 6.9: TOCSY and HSQC spectra of the glycoconjugate development lot sample indicating the 




The 1H and 13C chemical shifts of tRhaIII-1 and tRhaIII-2 are also consistent with CASPER 
predictions (Computer-Assisted Spectrum Evaluation of Regular polysaccharides, 
http://www.casper.organ.su.se/casper/).23 CASPER calculates the chemical shifts of various 
oligo- or polysaccharides based on the constituent monosaccharides and the glycosylation shifts 
from the substituents, and can be used to predict chemical shifts of unknown structures. 
Predictions for tRhaIII can be seen in Figure 6.10 and gives further evidence that supports the 







Figure 6.10: CASPER predicted chemical shifts for the tRhaIII and Glc residues. 
 
 
With the assignment of the terminal non-reducing end rhamnose (tRhaIII), it was possible to 
estimate the average number of repeating units in the polysaccharide. From the integration of 
the RhaIII signal vs. tRhaIII in Figure 6.11 the antigen is made up of approximately 5 repeats. 
However, the integration is at best a rough approximation due to various factors which need to 
be considered: Firstly, the baseline is ‘noisy’ and the signals are broad. Secondly, there are two 
sites of glycosylation on the protein (see Ch 1.7 for details) and integration will represent an 
average of the repeating units for these two. Lastly, the intensity of the signals for the antigen 
component may not include the internal residues (those closer to the protein component), 
leading to an under estimation of chain length. This means that the approximation of the O-













Figure 6.11: 1H NMR spectrum of the anomeric region with integration of the glycoconjugate 
development lot sample. *The intensity of this peak (5.07 ppm) is due to overlapping signals.  
 
 
The small crosspeak at 5.07 ppm could possibly be assigned to the terminal Glc residue (tGlc) or 
RhaII residue (tRhaII) found on the non-reducing end of the antigen.# Although crosspeaks from 
this proton could be seen in the TOCSY and HSQC spectra (Figure 6.9), the chemical shifts were 
too high for it to belong to a sugar residue, and therefore it could potentially belong to a 
contaminant.‡ 
 
6.6 Analysis of the non-O-acetylated and O-acetylated glycopeptide development lot 
samples   
In order to obtain more information about the antigen by diminishing signal overlap from 
amino acids, two additional glycoconjugate development lot samples were treated with pronase 
by GlycoVaxyn to give the glycopeptide sample. The remaining amino acid and antigen signals 
are much sharper in contrast to the glycoconjugate development lot sample (Figure 6.12), but 
are similar in profile showing that pronase treatment had no impact on the attached antigen 
structure.  
 
                                                 
# If the unknown crosspeak at 5.07/99.56 ppm was Glc then correlations beyond H-2 would be seen in the 
TOCSY. 













Figure 6.12: Comparison of the 1H NMR spectra of glycoconjugate and glycopeptide development lot 
samples. *Additional OAc signals. 
 
 
Since the signals in these spectra are sharper, the baseline is less noisy and protein component 
is shorter (peptide), integration of the RhaIII vs. the tRhaIII unit gives a better indication of the 
repeating unit length (Figure 6.13). Integration indicates that the polysaccharide is 








Figure 6.13: 1H NMR spectrum of the anomeric region with integration of the glycopeptide development 




The residual amino acids in both glycopeptide samples were identified from the COSY, TOCSY 
and HSQC experiments and were consistent with literature chemical shifts for the free amino 
acids.25 From the aromatic region tryptophan, tyrosine and phenylalanine were identified, while 
traces from the alkane region identified threonine, leucine, alanine and isoleucine. Proline, 
arginine and serine could also be identified from the above experiments for both samples. The 
two prominent distorted doublet of doublets at 3.24 and 3.09 ppm were assigned to asparagine 
(Figure 6.14). This is slightly deshielded compared to the free asparagine reference spectrum 
(2.94 and 2.85 ppm)26 indicating a different chemical environment and giving evidence that it is 









Figure 6.14: Comparison between the 1H NMR spectra of the glycopeptide development lot samples and 
free asparagine reference spectra.  
 
 
In order to assess whether the antigen component remained linked to the Asn residue, a  
diffusion ordered spectroscopy (DOSY) experiment was used. The DOSY experiment is based on 
the random translational motion of a molecule and can be quantitatively characterized by its 
diffusion coefficient (D). This is generally related to the size and shape of a molecule, and so this 
experiment can be used to separate out and identify different compounds in a complex mixture. 
DOSY is a pseudo 2D experiment where the horizontal axis represents the chemical shift (ppm) 
and the vertical axis represents the diffusion coefficient in milliseconds (ms).27 As seen in 
Figure 6.15, the antigen component diffuses at a different rate to the amino acids and 
particularly, to the Asn residue (3.24 and 3.09 ppm, highlighted), indicating that the antigen and 
                                                 
‡




peptide are unconjugated. In this instance, the observed chemical shift of Asn compared to the 
free Asn residue indicates that it remains attached to the peptide and is not linked to the 
saccharide. The intensity of the antigen signals are small compared to those of the peptide 
signals, which is not expected if the Asn was attached to the O-antigen, again confirming that the 































Figure 6.15: DOSY spectrum of the glycopeptide development lot (non-OAc). This shows that the amino 




The glycopeptide development lot (OAc) was obtained from wild-type S. flexneri and contained 
partial non-stoichiometric O-acetylation as seen from the intensity of the O-acetyl peaks 
between 2.22 and 2.17 ppm in the 1H NMR spectrum; with the position and degree of 
acetylation unknown. Acetylation of a hydroxyl group results in a deshielded environment, with 
the α-hydrogen of the OAc carbon shifting significantly downfield in the 1H NMR spectrum and 
the α-carbon less so in the 13C NMR spectrum. Often the proton of the O-acetylated carbon is 
visible in the proton anomeric region (4.4-5.5 ppm), while the carbon will appear at lower field 
resonances, and can therefore easily be identified in the HSQC spectrum.3,28 The β-carbon 
experiences an upfield shift, while the effects on the γ- and δ-carbons is much less.28 In fact, the 
effect of partial O-acetylation at various positions of the S. flexneri 2a repeating unit is felt across 
the rest of the repeating unit  and can be seen when comparing the anomeric chemical shifts of 




broader peak at 5.15 ppm and additional lower intensity peaks at 5.09, 5.07 and 4.90 ppm in 
anomeric region. Closer inspection of the HSQC spectrum (Figure 6.16) revealed a small 
crosspeak at 5.09/73.88 ppm. Based on the more shielded 13C shift and literature, this was 
assigned to RhaIII-3 (3OAc). Further evidence for O-acetylation of the 3-position of RhaIII is 
seen from the broad peak at 5.15 ppm which correlates to H-1 of RhaIII(OAc) and the more 
shielded C-2 and C-4 signals as a result of the β-effect of O-acetylation.28 While the crosspeak at 
5.07/102.48 ppm and 4.90/102.04 ppm was assigned to RhaII-1 and RhaI-1 respectively of the 
acetylated polysaccharide. If the RhaIII residue was O-acetylated at C-4, then the key crosspeak 
at 4.80/75.8 ppm should be visible, but it was not observed.18 Chemical shifts for Glc and GlcNAc 
remained unchanged, and in the latter residue this is highly indicative of no acetylation at the 6-
position of GlcNAc. The lack of a crosspeak in the region of 4.54/103.7 ppm confirms this. From 
the TOCSY (Figure 6.17), crosspeaks from 5.07/4.12 ppm and 5.07/3.88 ppm can be assigned 
to H-1/H-2 and H-1/H-3 of RhaII(OAc) respectively. A crosspeak at 5.09/3.52 can be assigned to 
H-3/H-4 of RhaIII(OAc) while a large crosspeak at 4.90/3.96 can be seen and assigned to H-1/H-
2 and H-3 of RhaI(OAc).   
RhaIII-3 (OAc)
1H:  5.09 ppm 
13C: 73.88 ppm
RhaI-1 (OAc)
1H:  4.90 ppm 
13C: 101.99 ppm
RhaII-1 (OAc)
















































Figure 6.16: The 2D HSQC spectrum of the glycopeptide development lot (OAc) sample. This shows the 
RhaIII-3 (OAc) crosspeak (highlighted in blue), while the red circles indicate where crosspeaks should be 



























































Figure 6.17: TOCSY spectrum of the development lot  glycopeptide (OAc) sample showing distinct 




Attempts to determine the degree of O-acetylation were made by deconvolution of the 1H NMR 
spectrum. However, since the starting point of the deconvolution is arbitrary, this method was 
abandoned. On the other hand, integration of the NAc peak of GlcNAc vs. the O-acetyl of RhaIII at 
2.22 ppm suggested that the antigen is approximately 20% acetylated (Figure 6.18). 
Alternatively, integration of the signals in the anomeric region could yield this result, however, 
there is signal overlap between 5.20 ppm to 4.95 ppm, but integration of  RhaI-1(OAc) vs. the 










Figure 6.18: Integration of OAc at 2.22 ppm vs. GlcNAc NAc suggests the antigen is approximately 20% 
acetylated at the 3-position of RhaIII.  
 
 
Alternatively, assays to determine the amount of O-acetylation could have been used,29,30 
however, from this point onwards GlycoVaxyn decided to synthesis the non-O-acetylated 
antigen. The degree and position of O-acetylation is known to influence immunogenicity,31–38 
however GlycoVaxyn’s findings, as well as recent reports, suggest that the lack of non-
stoichiometric O-acetylation of the S. flexneri 2a antigen does not significantly affect 
immunogenicity.15,39   
 
6.7 Analysis of the glycoconjugate GMP test lot sample 
These samples were analysed using a Bruker 600 MHz equipped with a cryoprobe which 
resulted in better quality spectra and permitted additional experiments such as HSQC-TOCSY 
and NOESY to be recorded with 1 – 2 mgs of saccharide.  
 
The anomeric and ring proton-carbon pairs in the glycoconjugate GMP test lot sample could be 
assigned from the HSQC spectrum (Figure 6.19). The additional crosspeak at 5.06/103.11 ppm 
was assigned to the H-1 of the terminal non-reducing end RhaII unit (tRhaII-1), which agrees 
with literature.22,‡  
 
 
                                                 
‡ In the previous glycoconjugate sample this crosspeak was diminished, but is now distinctly seen here, 



































Figure 6.19: HSQC spectrum of the anomeric and ring regions with assignments of the Glycoconjugate 
GMP test lot sample. Crosspeaks are assigned based on the proton assignments made from COSY and 
TOCSY experiments and agree with published data.18 Here the tRhaII-1 is clearly seen, highlighted by the 
blue oval.  
 
 
The average number of repeating units can again be determined from comparison of the 
integration of the tRhaIII and the RhaIII (Figure 6.20). In this instance, the polysaccharide was 









































Figure 6.20: 1D 1H NMR spectrum of the glycoconjugate GMP test lot sample with pre-saturation of the 
HOD peak at 313K. Integration of the anomeric protons is highlighted in the blue box. 
 
 
6.8 Analysis of the glycopeptide GMP test lot sample 
This sample was derived from the above glycoconjugate sample and further structural 
information was obtained. The coupling constants of the Glc and GlcNAc residues could be 
determined (Figure 6.21) and were found to 3.86 Hz and 8.55 Hz, which is consistent with the 
corresponding α- and β-configurations respectively.3 Here, integration of the RhaIII vs. the 
tRhaIII unit shows the polysaccharide to be approximately 7 repeating units long.#  
                                                 
# There is a slight shoulder on the RhaIII arising die to signal overlap. However, integration of this signal 




































Figure 6.21: 1D 1H NMR spectrum of the Glycopeptide GMP test lot sample at 313K. Integration of the 
anomeric protons is highlighted in the blue box. 
 
 
In this case, the 1D TOCSY experiments (Figure 6.22) were again performed and all protons 
from H-1 to H-6 in the Rha residues were seen when irradiating H-1 first. As a result the H-3 to 
H-6 signals are of a lower intensity. Interestingly, NOEs could also be detected (negative peaks 
highlighted in blue) as a result of magnetisation transfer through space, instead of through the 






































Figure 6.22: 1D TOCSY spectra of each monosaccharide from test GMP glycopeptide sample (600 MHz). 
The negative peaks highlighted in blue indicate NOEs. 
 
 
With the 2D NOEs the inter-sugar linkages can be elucidated (Figure 2.23) This had previously 
been assumed based on literature and the downfield shifts of the linked carbons.18 The 
detectable crosspeaks are reported in Table 6.1, and this gives confirmation that the linkage 
connections are consistent with literature. For example, the key NOE between H-1 of Glc and H-
4 of RhaI indicates the 1→4 linkage, while the NOE between H-1 of RhaIII and H-2 of RhaII 















































Figure 6.23: NOESY spectrum of the test GMP glycopeptide sample (600 MHz). Distinct crosspeaks from 
the anomeric region for each residue to neighbouring protons in the ring region can be seen. 
 
 
Table 6.1: Chemical shifts of NOEs confirming inter-sugar linkages. 
From H-1 NOE (ppm) Assignment 
 




RhaII & RhaIII 


















   
3.77 RhaI-4 
 







   
GlcNAc 4.16 RhaI-5 
 
   
 
 
The HSQC-TOCSY experiment provides additional dispersion as the TOCSY correlations are 
obtained along the attached carbons. As a result a much more comprehensive proton-carbon 




anomeric region, but was used to confirm the chemical shifts of all antigen signals through the 
respective intra-residue correlations. In addition, it made the detection of H-2 of the tRhaIII 
much easier than before, with the distinct tRhaIII-2 crosspeak at 4.08/71.56 ppm visible. For 








































Figure 6.24: HSQC-TOCSY spectrum of the test GMP glycopeptide sample (600 MHz). Identification of the 
tRhaIII H-2/C-2 crosspeak is much easier (highlighted in purple). For simplicity the crosspeaks between 
H-1/C-1 to H-1/C-6 and C-6/H-1 to C-6/H6 are highlighted in blue. 
 
 
Closer inspection of the anomeric region of the HSQC of the glycopeptide GMP test lot sample 
revealed additional crosspeaks. With the glycopeptide development lot samples it had not been 
possible to identify any GlcNAc-Asn residue. However, the appearance of an unusual crosspeak 
at 5.12/79.13 ppm (Figure 6.25) was assigned to H-1 of the GlcNAc linked to Asn (rGlcNAc) 
based on literature precedent.42,43 No rGlcNAc to Asn-NH crosspeaks in the in the COSY, TOCSY 
or NOESY spectra were detectable. Additional crosspeaks (highlighted in red) are due to partial 
hydrolysis of some glycosidic linkages, as a result of prolonged experiments performed at 313K. 



































Figure 6.25: HSQC spectrum of the anomeric region of the test GMP glycopeptide sample (600 MHz). 
Additional crosspeaks (highlighted in red) arose after extensive NMR experiments at 303K and 
313K which caused partial hydrolysis of some glycosidic linkages giving rise to free α/β-L-

















Lastly, a comparison of the 1H NMR spectra of all samples (Figure 6.26) from development to 








GMP test lot glycoconjugate
GMP test lot glycopeptide
 
 
Figure 6.26: Comparison of the 1H NMR spectra of all samples.  
 
 
6.9 Summary and Conclusion 
Analysis of the development and glycoconjugate GMP test lot vaccine using various 1D and 2D 
experiments confirmed the structure of the repeating unit, which is in agreement with 
literature.17,18   
 
 
The smaller peak at 4.97/103.99 ppm was assigned to the terminal RhaIII unit from non-
reducing end (tRhaIII), which is in agreement with literature.22 Integration of this peak can be 
estimated and indicated that the antigen was approximately 5-6 repeats long, but this is 




The position and degree of O-acetylation could be determined from the O-acetylated 
development glycopeptide lot, Here, only the 3-O-position of RhaIII was found to be 
approximately 20-30% acetylated. Additional information was also obtained through spin 
system correlations and NOESY experiments, which proved the inter-sugar linkages. In addition, 
the GlcNAc residue on reducing end attached to Asn was identified from the unusual position of 
the crosspeak at 5.12/79.13 ppm.42,43  
 
More detailed analysis of development and glycopeptide GMP test lot samples produced spectra 
with less overlap, sharper lines and better correlations. This again confirmed the structure of 
repeating unit, with integration indicating a slightly longer polysaccharide, estimated to be 
approximately 7 repeats long. In addition, H-1 of the reducing end GlcNAc (rGlcNAc) linked to 
asparagine could be identified.  
 
In conclusion, NMR spectroscopy has been an invaluable tool for the analysis of the 
glycoconjugate and glycopeptide development and GMP test lot samples. This has shown 
consistency between batches and has definitively confirmed antigen structure, identity and 
integrity.  
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2.1 Chapter 2 NMR spectra 






















































Cyclohexyl 2-acetamido-3-O-benzoyl-2,6-dideoxy-1-thio-α-D-glucopyranoside (2.20).  
 
 









Cyclohexyl 2-acetamido-4,6-O-benzylidene-2-deoxy-1-thio-α-D-glucopyranoside (2.23). 











































































































Cyclohexyl 2-acetamido-3-O-benzyl-2,6-dideoxy-1-thio-α-D-glucopyranoside (2.22). 



















































































































































































































































































































































































































































































































































































































































































































































Single-crystal X-ray diffraction data were collected on a Bruker KAPPA APEX II DUO 
diffractometer using graphite-monochromated Mo-K radiation ( = 0.71073 Å). Data collection 
was carried out at 173(2)K. Temperature was controlled by an Oxford Cryostream cooling 
system (Oxford Cryostat). Cell refinement and data reduction were performed using the 
program SAINT.1 The data were scaled and absorption correction performed using SADABS2.  
 
The structure was solved by direct methods using SHELXS-972 and refined by full-matrix least-
squares methods based on F2 using SHELXL-972 and using the graphics interface program X-
Seed3. The programs X-Seed3 and POV-Ray4 were both used to prepare molecular graphic 
images. All non-hydrogen atoms were refined anisotropically. All hydrogen atoms were placed 
in idealised positions and refined in riding models with Uiso assigned the values to be 1.2 times 
those of their parent atoms and the constraint distances of C-H ranging from 0.95 Å to 1.00 Å. 







Appendix 3, Table 1: Data collection and refinement parameters for 3.14 
Formula: C27H25NO4S 
Formula Weight 459.55   
Crystal System Orthorhombic 
Space Group P212121      (No. 19)   
Unit cell constants 
a (Å) 5.4082(8)   
b (Å) 11.4356(15)     
c (Å) 37.712(5)   
α (°) 90 
β (°) 90 
γ (°) 90 
Volume ((Å3) 2332.3(6)   
Z 4 
Densitycalc (g.cm-3) 1.309   
F (000) 968 
Temperature of Data collection (K) 173 
Crystal size (mm) 0.15 x  0.19 x  0.27   
μ (mm-1) 0.173 
Range scanned ϴ (°) 1.9 - 28.2   
Index ranges h: -7:  7 k: -13: 15  l; -50: 42   
Total no. reflections collected 20881 
Unique reflections 5724 
R (int) 0.036 
No. of reflections with l ˃ 2σ (l) 4885 
No. of parameters 298 
S 1.02 
R1 [l  ˃ 2σ (l)] 0.0374 
wR2 0.0851 
Max. and Av. Shift/Error 0.00, 0.00 
Min and Max. Resd. Dens. [e/Å3] -0.22, 0.24 
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